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Abstract
Dysregulated wound healing contributes to most currently unanswered ophthalmological
morbidity. Opacification and structure altering contractures compromise the delicate
ocular anatomy upon which ocular function and healthy vision are reliant. Glaucoma
filtration surgery, corneal stromal injury, proliferative vitreoretinopathy and age-related
macular degeneration are major contributors to ocular morbidity – all with myofibroblast
transdifferentiation and pathognomonic scarring activity at their core.
This thesis aims to revaluate the means by which dysregulated ocular wound healing is
combated with evidence describing a novel strategy to mitigate its effects. A translational
approach was used. An initial retrospective analysis of over ten thousand glaucoma
surgeries found that perioperative NSAID exposure was significantly associated with
surgical success. The current standard of care, corticosteroids, showed no such
association. This was surprising and provided impetus to evaluate these clinical findings
within the basic science lab.
The subsequent project examined the relative effects of NSAIDs to that of corticosteroids
on the in vitro wound healing activity of ocular fibroblasts. Relative to steroids, NSAID
exposure resulted in more ordered extracellular matrix remodelling, less cell-mediated
collagen contraction and greater impairment of myofibroblast associated protein
expression.
We hypothesized that these differences were due to NSAIDs more specific targeting of
COX enzyme activity. By sparing lipoxygenase activity, competitive NSAIDs leave intact
the biosynthetic machinery responsible for signaling the endogenous resolution of
inflammation. This system involves the collective effects of the pro-resolving superfamily
of lipid mediators and promotes the active resolution of inflammatory processes.
To assess the anti-fibrotic potential of inducing resolution within inflammation-induced
ocular fibroblasts, two COX2 Ser516 acetylating molecules were utilized to modify the
COX2 enzyme such that it: 1) ceases prostaglandin production, and 2) gains the capacity
i

to produce pro-resolving lipid mediators. When applied to inflammation-induced ocular
fibroblasts, a reduction in in vitro wound healing phenomena was observed with a
corresponding shift in pro-/anti-fibrogenic transcription factor expression and
downregulation of myofibroblast associated proteins.
Together these findings suggest that the resolution of inflammation and the resolution of
fibroproliferation may be controlled by a common signaling system, and that
interventions promoting the production of resolving lipid mediators could have significant
anti-cicatrizing properties.

Keywords: wound healing, inflammation, fibrosis, scarring, ophthalmology, ocular,
myofibroblast, fibroblast, transdifferentiation, immuno-suppression, immunoresolution
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Chapter 1

1

Introduction

1.1 Ocular Wound Healing
The mechanisms of wound healing within the anterior segment of the eye,
specifically the subconjunctival tissues, are similar to most non-nervous tissues
within the body.1–4 After hemostasis, tissues undergo repair in three stages: 1)
inflammation / resolution, 2) proliferation and 3) remodeling. These stages are
partially overlapping sequential events, controlled through the integration of
information from several dynamic signaling networks. These signaling networks
incorporate several diverse classes of signaling molecules, several cell types and
physical cues from the extracellular matrix (ECM) and external environment. For
healthy wound healing to occur, as opposed to an anatomically impairing
fibroproliferative response, orderly and efficient transitions between each phase
are required. A non-anatomically disruptive wound healing response after ocular
insult is critical to maintaining vision, as the slightest contracture, thickening or
opacification of delicate ocular anatomical structures can have dire
consequences to a patient’s refractive status and/or ocular physiology.

1

1.1.1

Inflammation and Resolution in Wound Healing

Inflammation and its resolution are an endogenously controlled biological
algorithm coding the intentional deviation and subsequent return to homeostasis
that is required to overcome infection or trauma.5,6 The magnitude of tissue
damage (fibrosis/scarring) that results from an inflammatory insult is directly
proportional to the intensity and duration of the inflammatory reaction the body
levies in response to that insult (Figure 1-1). In the eye, it is especially critical to
ensure inflammatory responses are kept to a minimum – as the anatomy upon
which healthy vision is dependent can easily be disrupted by inflammation and
fibrosis induced changes to tissue architecture, often with permanent
consequences.

Figure 1-1 Diagram illustrating the risk of local tissue damage during
inflammation-induced deviations from homeostasis. Immunosuppressive
interventions aim to block the molecular signals contributing to the original,
inflammation-induced deviation from homeostasis. Immuno-resolvent
interventions aim to reduce the risk of tissue damage by both dampening the
inflammatory deviation from homeostasis and hastening the subsequent
endogenously controlled return.

Inflammation is involved in both normal wound healing and the development of
fibrosis. Tissue damage caused by infectious, ischemic, autoimmune, traumatic
or surgical insults causes localized cell death. The intracellular components of

2

these necrotic cells are released into the interstitum. Surviving cells within the
area express danger associated molecular pattern (DAMP) receptors, which can
sense intracellular components such as DNA, RNA, histones, mitochondrial DNA
and ATP among others within the interstitum.7–9 Once activated, DAMP receptors
bind their ligands and initiate an intracellular signaling cascade culminating in
secretion of IL-1β and the canonical commencement of inflammatory signaling.7,8
The cardinal signs of inflammation have long been tied to the increased
production of the prostaglandin (PG) and leukotriene (LT) classes of lipid derived
signaling molecules. The secretion of these lipid mediators requires the actions of
intracellular phospholipases (PL), such as PLA2, acting on membrane
phospholipids to generate arachidonic acid (AA), eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA).10 These precursors are then oxygenated by
cyclooxygenase 2 (COX2) to produce the prostaglandins and leukotrienes.11 The
expression of both COX2 and PLA2 is induced by IL-1β.12 Due to their extremely
potent chemokine and vasoactive properties, PGs and LTs function in wound
healing mainly to perpetuate the inflammatory state, increase vascular
permeability and increase platelet aggregation. Vascular permeability and platelet
aggregation increase the relative numbers of local inflammatory cells, fibroblasts,
pro-inflammatory growth factors and wound healing associated cytokines.
Due to the difficulty of measuring lipid derived signaling molecules (LMs),
relatively little is known about their role in wound healing. Recent developments
in liquid chromatography tandem mass spectrometry (LC-MS/MS) have enabled
more in depth study. Mice with impaired AA lipid metabolism exhibit delayed
3

wound closure,13 the PGF2α receptor has been shown to facilitate the
development of pulmonary fibrosis,14 and the long term use of PG analogs was
shown to induce ECM contraction, upregulate pro-fibrotic cytokine release and
collagen expression in human eyes15 – thus it can be inferred that the AA derived
LMs facilitate certain aspects of the wound healing process.

Figure 1-2: Diagram of pro-inflammatory and pro-resolving lipid mediator
synthesis pathways. COX2 is responsible for utilizing n3 and n6
polyunsaturated fatty acid precursors to create PGs. The LOX enzymes
cooperate to give rise to many different AA, EPA and DHA derived RMs.
PLA2: phospholipase A2; AA: arachidonic acid; EPA: eicosapentaenoic acid;
DHA: docosahexaenoic acid; PUFAs: polyunsaturated fatty acids; COX2:
cyclooxygenase 2; LOX: lipoxygenase.
4

Over the past twenty years, our understanding of how inflammation undergoes
spontaneous resolution has evolved. Previously, resolution was thought to occur
through the passive diffusion and dilution of inflammatory mediators. However, it
is now understood to be an active process; tightly controlled by a novel
superfamily of lipid derived signaling molecules – the specialized pro-resolving
mediators (RMs).5,16–18 RM synthesis is triggered (after a slight delay) by proinflammatory mediators. They are generated in relatively large quantities and are
extremely bioactive (nanomolar level). Grossly, they are derived from the actions
of the lipoxygenase enzymes (as opposed to COX2) on AA, EPA and DHA
(Figure 1-2).6,19,20
In the eye, SPMs signal for the active termination of inflammatory processes such
as inflammatory cell trafficking, activation and vascular permeability.21 At a
cellular level, there are cell surface and nuclear receptors for SPMs,22–25 the
activation of which downregulates PG production,21,26 vascular cell adhesion
molecules, monocyte chemotactic protein 1, IL-8, IL-1β and TNFα signaling.21
Their effects also stimulate resolution-associated processes such as
macrophage-mediated phagocytosis of wound debris, inflammatory cell
clearance and efferocytosis.6,27 Overall, SPMs function to protect tissues from an
over exuberant inflammatory response via several cellular and organ-level
mechanisms, facilitating an ordered return to homeostasis after inflammatory
insult.28,29
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1.1.1.1

Fibroblasts as inflammatory cells

Fibroblasts can be conceptualized as sentinels of the immune system.30 They
express functional toll-like receptors,31 DAMP receptors, and normally exhibit little
cellular activity. However, fibroblasts are often the first cell type to encounter an
inflammatory stimulus. Indeed, when activated by DAMPs9 and pathogen
associated molecular patterns (PAMPs),30 fibroblasts begin to secrete their own
inflammatory cytokines and chemokines such as TGFβ1, IL-1β, IL-6, IL-13 and
IL-33 as well as exhibit strong induction of COX2.26,32 These protein based
mediators act in a paracrine manner to activate nearby fibroblasts, vascular
endothelial cells and recruit circulating inflammatory cells. They can also act in an
autocrine manner to illicit transdifferentiation of fibroblasts into myofibroblasts –
the main cellular drivers of fibrosis and scarring.1,33,34
The effects of RMs on fibroblasts within an inflammatory and wound healing
microenvironment are starting to be elucidated. The experimental overexpression
of LOX enzymes was found to impair the scarring observed in a mouse model of
pulmonary fibrosis and was attributed to increased LOX-mediated RM
generation.35 Exogenous application of individual RMs has impaired the
development of experimental renal fibrosis in an obstructed kidney model through
the inhibition of fibroblast proliferation and a mitigation of the inflammatory
response.36 Further studies have demonstrated that RMs have the capacity to
interfere with TGFβ1-induced collagen production and fibroproliferation.37 These
data would seem to suggest that RMs may function to attenuate fibroblastmediated tissue fibrosis and wound healing phenomena.
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1.1.2

Proliferative Stage of Wound Healing

The proliferative stage spans the end of the inflammatory and beginning of the
resolution stages. Inflammation induces the secretion of growth factors which
stimulate the proliferation of local fibroblasts and inflammatory cells. These cells
deposit ECM molecules and generate new granulation tissue to fill lesions and
restore barriers to the external environment.38 Contraction of the ECM is elicited
by inflammation-induced myofibroblast transdifferentiation,39 with the novel
expression of the contractile protein alpha smooth muscle actin (αSMA).40 As it is
governed by growth factors secreted during the inflammatory stage, the duration
and magnitude of the proliferative stage is determined by the duration and
intensity of the inflammatory phase. Thus, the amount of collagen deposited
within the wound, and the degree to which myofibroblast-mediated tissue
contraction occurs can be reduced by attenuating the inflammatory stage of
wound healing.
In humans, attenuation of the inflammatory phase has been accomplished for
over 100 years using an immuno-suppressive strategy. For example,
corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), among
others, are modalities of inflammation control that disrupt the generation of proinflammatory mediators. This strategy ignores the fact that the resolution of
inflammation is initiated by several of these very “pro-inflammatory” mediators
that are suppressed.27 The result is a dampening of clinical inflammatory signs
due to a lack of pro-inflammatory stimuli, however it may also induce a state of
“frustrated resolution” – defined as the absence RM signaling after inflammation,
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which hinders the ordered return to homeostasis.28 The discovery of RMs has
brought to the forefront a novel strategy in which to shorten the duration and
temper the intensity of inflammatory responses.17 Finding therapeutic means to
stimulate the body’s own endogenous mechanisms of resolution will be the first of
the immuno-resolvent interventions and have the potential to mitigate
inflammation by working synergistically with human physiology as opposed to
against it.

1.1.3

Remodeling Stage of Wound Healing

The remodeling stage usually begins about two to three weeks after the initial
insult. Local inflammatory cell infiltrates are greatly reduced and eventually return
to baseline levels.38 The remodeling stage begins during the resolution of
inflammation and it can span for months to years after injury. During this phase
fibroblasts and myofibroblasts respond to autocrine, paracrine and physical ECM
cues to reorganize the extracellular matrix in an attempt to recover normal tissue
architecture.41–44 Tension gradients within the matrix dictate the balance of matrix
metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) eliciting
degradation and re-synthesis of the ECM such that the stiffness and density of
collagen fibers is increased.44 The degree of stiffening and increased density is
directly proportional to the amount of cellular infiltrates as well as the duration
and intensity of the preceding inflammatory and proliferative stages.45,46 Indeed, a
novel class of RM termed resolvin conjugates in tissue regeneration (RCTRs)
have been shown to improve regenerative wound healing by decreasing the
duration and magnitude of inflammatory signaling during the inflammatory
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phase.22 Overall, the impact of RMs appear to be beneficial at all stages of the
normal wound healing response, and their absence appears to lead to a state of
frustrated resolution with less than optimal wound healing outcomes.

1.2 Glaucoma and Glaucoma Surgery
Glaucoma is the leading cause of irreversible blindness worldwide, with the
global burden expected to rise to 111.8 million people by the year 2040.47
Unfortunately, no definitive treatment for glaucoma exists. Currently, the only
therapy known to slow the disease's progression is the lowering of intra-ocular
pressure (IOP). Traditionally, first line therapy has been pharmacotherapy 48,
despite a significant number of well documented challenges. Non-compliance,49–
52

difficulty with administration,53,54 local irritation of the ocular surface,55,56 as well

as significant systemic side effects57,58 are well known barriers to successful
medical management. Surgical interventions are often undertaken once medical
management and laser-based procedures have failed to control IOP or are no
longer tolerated by the patient (Figure 1-3).
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Figure 1-3: Schematic representing the treatment algorithm for patients with
glaucoma. Patients usually initiate therapy medically then progress to more
invasive methods of IOP management. The final treatment modality is IOP
lowering surgical intervention. Surgical failure rates with use of the current
wound modulatory adjuvants are indicated. Failure rates were obtained from
previous work65,66 and extrapolated to estimate the percentage of overall
patients who require 1st, 2nd and 3rd revision surgeries.
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Glaucoma filtration surgery (GFS) functions to lower IOP through the creation of
a fistula from the anterior chamber of the eye into a surgically created drainage
space. A microshunt can be implanted at the time of surgery to guard the fistula
that connects to the anterior chamber to the drainage structure. If draining into
the subconjunctival space, these drainage structures are termed filtration blebs
(Figure 1-4A). If draining into the potential space between the ciliary body and the
sclera, they are termed superciliary lakes (Figure 1-4B).59 It is through these
novel anatomic structures that aqueous exits the anterior chamber, collects within
the surgically created space, diffuses through the interstitum and is removed from
the eye by the venous and lymphatic systems – thus lowering a patient’s IOP.60,61
Therefore, successful GFS depends on the incomplete healing of the surgical
wound and establishment of a controlled, chronic wound within the
subconjunctival or superciliary tissues.3,4 Maintaining the functional anatomy of
this novel outflow pathway long-term in the face of acute surgical/chronic
inflammation and aqueous humor driven wound healing, is a major challenge.

A)
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B)

Figure 1-4: A) sub-conjunctival filtration bleb, modified from Gardiner et al.
(2010).59 B) superciliary lake, shown with the Cypass aqueous shunt implanted
within, modified from Alcon Canada, Inc.

1.3 Consequences of Dysregulated Wound Healing in
Glaucoma Surgery
The overwhelming majority of surgical failures occur through an inflammatory and
fibroproliferative mechanism within the tissues surrounding the surgically created
drainage pathway. Clinically, the events preceding failure are characterized as an
overactive wound healing response.2,62 The consequence is a fibroproliferative or
contracture mediated obstruction of the surgical outflow tract - thereby hindering
aqueous humor egress and ultimately the magnitude of IOP reduction achieved
(Figure 1-5).3,4,63 Glaucoma surgeries performed without current anti-fibrotic
adjuvants fail at a lifetime rate approaching 100%.64 Using current anti-fibrotic
adjuvants, the lifetime surgical failure rate is approximately 30-50%.65,66
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A

Figure 1-5: A) Depicts an anterior segment optical coherence tomography (ASOCT) image of a functional subconjunctival filtering bleb superimposed over an
anatomic diagram of the eye. B) Depicts a failing filtering bleb. Note the
increased reflectance surrounding the fistula connecting the bleb to the anterior
chamber, the tissue contracture, and the hypertrophic walls of the bleb. The
patient subsequently underwent revision surgery. Modified from Shin 2010.63

Failure occurs most frequently within the first three weeks of surgery, 67 at
approximately the same time as the inflammatory and proliferative phases of
post-operative wound healing are occurring.3,46 As the outflow tract loses patency
and the patient’s IOP begins to return to pre-surgical levels, the failure of GFS is
managed in a progressive manner. In the early postoperative period, digital
massage, scleral flap suture lysis and releasable suture removal can be
attempted in order to restore the flow of aqueous. Glaucoma medical therapy is
often subsequently reinstituted to control the patient's rising IOP. Tragically, these
drugs themselves can lead to increased inflammation at the surgical site and can
accelerate the deterioration of aqueous outflow capacity.68–72 In up to 30% of
glaucoma surgery patients, outflow capacity decreases sufficiently to require a
second glaucoma surgery.66,73 Subsequent surgeries experience even lower
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odds of success - approximately 50% of these patients do not achieve their target
IOP post-operatively.64 Repeated attempts at surgery, until success is achieved,
is the only remaining treatment path for these patients – who face blindness as
an alternative.
The complication rate associated with scarring after glaucoma surgery is not only
a burden to patients and surgeons but is also a major healthcare economic issue.
The 5-year total treatment cost for glaucoma patients is similar when treated
medically or surgically.74 The ongoing cost of drugs is the major contributor to
medical management costs, which average approximately $6500 USD over a 5year span. The surgical treatment of the same patient would cost an average of
approximately $6300 USD. Even with their increased expense and undesirable
side effect profile, medications are the first line therapy due to the high risk of
glaucoma surgery failure. This risk profile also contributes significantly to the
overall cost – with management of post-surgical complications accounting for
60% of surgical treatment costs.74 Reducing the risk of complications and/or
revision surgery will dramatically reduce the total cost of glaucoma surgical
interventions, and the reduced risks / costs could shift surgical interventions
earlier in the treatment paradigm and would free patients from the burden of daily
glaucoma medications – which would be a significant improvement to their quality
of life.75–77
To avoid function altering scarring, normal wound healing requires the ordered
and appropriate interaction of a complex molecular signaling network – those
involved in inflammation, its resolution, and proliferation / remodeling. In the
14

subconjunctival tissues of glaucoma surgery patients there exist several
mechanisms known to disrupt these signaling networks. Pre-existing chronic
inflammation due to a patient's topical glaucoma medication burden,55,78 comorbid inflammatory ocular disease,79 and/or the novel interaction of aqueous
humor growth factors (AHGFs) with the mesenchymal subconjunctival tissues of
the filtration bleb80–83 all contribute to the post-surgical scarring and fibrosis
observed (Figure 1-6). In particular, the contribution of AHGFs to the failure of
aqueous filtration cannot be ignored, as they include several iconic molecular
instigators of inflammation and fibroproliferation.84 TGFβ1, TGFβ2, VEGF, CCN2,
IL-1β, TNFα and INFɣ are all found in the aqueous humor, and further, are
present at increased levels in glaucoma patients undergoing revision surgery
compared to patients undergoing their first glaucoma surgery83–88 – providing a
physiological explanation for the increased likelihood of failure in these patients.
Therefore, wound healing phenomena within the filtration structure's
microenvironment must be modulated pharmacologically for both the short- and
long-term success of GFS.
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Figure 1-6: Many factors potentiate scarring within the subconjunctival tissues of glaucoma surgery
patients. Pre-existing ocular inflammation or disease, surgical trauma / inflammation and the novel
interaction of AHGFs with the subconjunctival tissues all promote myofibroblast transdifferentiation,
fibroproliferation, contracture and ultimately surgical failure. COX2: cyclooxygenase 2; PLA2:
phospholipase A2

1.4 Current Glaucoma Surgery Adjuvants
Currently, the strategy used to mitigate post-operative scarring involves the intraoperative application of cytotoxic agents, with or without the application of perioperative anti-inflammatory drops (Figure 1-7).89–91 Cytotoxic agents, such as
mitomycin C (MMC) or 5-fluorouracil are dosed empirically, exerting their efficacy
through the destruction of local fibroblasts through DNA intercalation. Thus,
mitigating the post-operative wound healing response elicited by this cellular
population within the surgical site. Due to the cytotoxic mechanism of action,
these drugs are associated with complications that can be sight threatening.92

Figure 1-7: Mitomycin C intercalates DNA and is lethal to all cell types. It
functions as an anti-scarring adjuvant through its cytotoxic actions on the local
subconjunctival population. Corticosteroids prevent transcription of PLA2,
which is responsible for generating the substrates for all lipid mediators of
inflammation and resolution. By dampening the inflammatory response, fewer
inflammatory cells are recruited to the subconjunctiva to activate local
fibroblasts. Further, corticosteroids have been shown to directly act on
fibroblasts to inhibit their activity.
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To illustrate the variability inherent to the application of MMC, one need only
reference the therapeutic range that is currently employed: 0.2-0.4mg/ml is
applied by an MMC soaked sponge intra-operatively on the freshly dissected
conjunctiva, for one to four minutes (at surgeon discretion), at the start of
surgery.93 Over application can lead to tissue necrosis, wound leak, corneal
decompensation, hypotony and blindness. Under application results in loss of
efficacy and causes the post-operative failure rate to approach 100%.64,94
Anti-inflammatory drops such as corticosteroids are used post-operatively to
attenuate the inflammatory phase of wound healing and provide the clinician with
a titratable means to control subconjunctival wound healing phenomena over a
patient’s post-operative course. Corticosteroids function indirectly to mitigate
inflammation-induced activation of sub-conjunctival fibroblasts by preventing local
inflammatory cell activation and recruitment.65 They have also been shown to
exert direct anti-proliferative actions on sub-conjunctival fibroblasts, as well as
illicit a decrease in fibroblast wound healing associated biomarkers.95 However,
steroids are associated with adverse events such as cataract development,
elevation of intraocular pressure (IOP) and increased infection risk.96–103 These
risks add to the unpredictability of post-operative wound healing and fuel the
search for viable alternatives to control post-operative inflammation and scarring.
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1.5 Therapeutic modulation of ocular wound healing:
current evidence and contemporary strategies
The suppression of vascular endothelial growth factor (VEGF) signaling has
become recently widespread in ophthalmology.104 Anti-VEGF therapy as an antifibrotic intervention appears to be theoretically based on suppressing the
proliferative stage of wound healing by blocking angiogenesis as well as
interfering with VEGF’s direct stimulatory effects on fibroblasts.105 Several studies
have evaluated subconjunctival injections of anti-VEGF antibodies as anti-fibrotic
GFS adjuvants.105–107 The results from initial animal investigations demonstrated
improvements in wound healing related outcomes after GFS and several small
human trials were subsequently undertaken. A recently published meta-analysis
of their results indicated uncertainty as to the efficacy of anti-VEGF adjuvant
therapy in human GFS patients.108 Anti-VEGF therapy’s lack of anti-scarring
efficacy fits well with findings from its official use in another ocular disease. Up to
45% of patients receiving regular anti-VEGF injections for age related macular
degeneration will experience progressive sub-retinal scarring, despite
therapy.109,110
Transforming growth factor beta (TGFβ) isoforms are perhaps the most canonical
proteins associated with wound healing and fibroproliferation.111–114 Histological
studies demonstrate significant elevation of TGFβ isoforms within the
subconjunctival tissues of GFS patients post-operatively.115–117 In animal studies,
exogenous TGFβ was found to significantly increase IOP and the failure rate of
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GFS.118 Significant resources were spent at the in vitro, animal119,120 and human
level121,122 to assess an anti-TGFβ2 antibody known as CAT-152 as an adjuvant
for GFS. Ultimately the intervention failed, possibly attributable to the specificity
of the CAT-152 antibody for the TGFβ2 isoform only. Interventions that
incorporate a more broad blockade of both TGFβ1 and TGFβ2 isoforms, or the
receptor that is shared by both are underway and have seen some success at
pre-clinical stages.118,123
Matrix metalloproteinases and their inhibitors (TIMPs) are fundamental to the
remodeling stage of wound healing. In the subconjunctiva of GFS patients, the
expression of these molecules is upregulated and contributes to scar
formation.124 In vitro, an MMP inhibitor (ilomastat), was found to inhibit fibroblastmediated collagen contraction by subconjunctival fibroblasts.125 In two different
animal models, ilomastat improved wound healing after GFS, prolonging bleb
survival, lowering intraocular pressure, and reducing the amount of
subconjunctival scar tissue to a similar degree as MMC.126,127 This appears to be
one of the more promising avenues of wound modulation research at the current
time.
Ultimately, scarring and fibrosis appear to have redundant mechanisms for
bypassing interventions targeting a single pathway. Suppressive strategies
against specific mediators that each individually contribute to a redundant
process is destined for difficulty. Such difficulties may be quite familiar to the
cancer biologist, as similarly aberrant tumor growth is often fueled by multiple
redundant intracellular signaling pathways.128 This can potentially explain the
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current position of nonspecific anti-proliferative drugs and steroidal antiinflammatory agents as the gold standard adjuvants for GFS. More specific
inhibitors of TGFβ signaling, MMP inhibitors, Nuclear Factor-κB signaling
inhibitors, anti-oxidants and PPARγ agonists have all demonstrated promising
wound modulating effects at various levels of in vitro, pre-clinical and clinical
development.4 However, none of these applications have thus far been translated
into clinical use. Ideally, a point of biochemical intervention that has multiple
downstream effects and counters many of the redundant pathways involved in
scarring and fibrosis could be identified.

1.6 Thesis Overview
Sixty years ago, Dr. Epstein first noticed what he then coined: the fibrosing
response to aqueous.84 Since then dramatic improvements have been made in
surgical success due to wound modulatory adjuvants. The aim of this thesis was
to investigates potential means of improving these success rates still further –
ideally in a more efficacious and/or safer manner than current standards of care.
The investigative work begins in Chapter 2, with a retrospective cohort study.
This was the first study of its kind that was adequately powered to assess
perioperative risk factors associated with revision GFS – as opposed to the
failure of IOP control. We uncovered the surprising finding that perioperative
NSAID exposure was more strongly associated with surgical success than
corticosteroids, the current standard of care. These results inspired the
subsequent in vitro investigation in Chapter 3, which found that these drugs exert
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differential effects on wound healing phenomena elicited by subconjunctival
fibroblasts. Data from both chapters were used to write a successfully funded
grant for a randomized controlled trial assessing the merits of NSAID use in
human GFS patients (Appendix I). The results of this trial are outside the scope
of this thesis, however it felt appropriate to “close the translational loop” and do
what was within reach to bring the knowledge attained from our retrospective and
in vitro work – back to human patients.
While investigating the differences between NSAIDs and corticosteroids, a
second manner in which to end this thesis presented itself. Based on the theory
that corticosteroids more completely inhibit the endogenous generation of RMs
than is observed with NSAIDs, I hypothesized that modulating the production of
lipid mediators to resolve inflammation – rather than suppress it – is a better
means to mitigate post-operative scarring. Such an approach works more
synergistically with the body’s endogenous systems of inflammation and
resolution, rather than against them. The following two chapters, Chapter 4 and
Chapter 5, pursue this hypothesis and present data to support a novel
therapeutic strategy which resolves inflammation and mitigates wound healing
phenomena in vitro.
Taken together, these investigations highlight novel strategies to combat scarring
after glaucoma surgery. The first suggests a shift in the utilization of currently
used ophthalmic drugs to improve patient outcomes. The subsequent strategies
would require more lengthy safety approvals – however they demonstrate even
more promising efficacy in vitro. The knowledge gained from this thesis is
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uniquely powerful, as it should enjoy rapid translation to human patients at the
same time as significantly advancing our understanding of how LMs and more
specifically RMs influence wound healing phenomena.
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Chapter 2

2

Risk Factors for Secondary Surgical Intervention after
Primary Glaucoma Filtration Surgery1

This study focused on surveying the current contributors to GFS failure risk in
order to establish theoretical grounds for future in vitro work. We examined
patient factors, surgical history, the type of GFS performed, and most importantly,
we investigated various perioperative drugs exposures for association with GFS
failure rates. This study consisted of the following:
1. Defining a cohort of filtration surgery patients within Ontario medical
records spanning 2003 to 2015
2. Following this cohort for 1-year after GFS
3. Investigating candidate baseline / exposure variables for association with
subsequent revisions procedures

1

Parts of this chapter have been published: Armstrong, J.J., Welk, B.K., Reid, J.N.S., Kansal, V., Hutnik,
C.M.L. Secondary surgical intervention after primary glaucoma filtration surgery: an Ontario populationbased study. Canadian Journal of Ophthalmology. 2018; 54(2): 212-222; DOI:
https://doi.org/10.1016/j.jcjo.2018. 04.004.
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2.1 Introduction
The failure of glaucoma filtration surgery is managed in a progressive manner. In
the early postoperative period, digital massage, scleral flap suture lysis and
releasable suture removal can be attempted. Medical therapy is often
subsequently reinstituted, which itself may lead to increased inflammation at the
surgical site and accelerate deterioration of aqueous outflow capacity.68,70–72,129
Some of these patients are refractory to medical treatment and a secondary
surgical intervention is the only remaining option.
Several studies have reported rates of secondary surgical intervention after
primary glaucoma filtration surgery.130–133 The Tube Versus Trabeculectomy
study reported secondary surgical intervention rates of 2.8%130 within the first
post-operative year and Cankaya et al. reported a rate of 8.5% in a randomized
controlled trial of 59 patients.131 However, the event rate within these samples
was too low to investigate factors associated with increased rates of secondary
surgical intervention. Young age,134–138 previous intraocular surgery,135,139 chronic
exposure to topical medications,68,70–72,129 and comorbid systemic disease136,138
have all been previously associated with failure of intra-ocular pressure (IOP)
control. However, few studies have reported on patient factors associated with
increased rates of secondary surgical intervention.
Such information is critical to establishing individualized patient treatment plans,
as patients at high risk for secondary surgical intervention may be advised to
delay surgery, to elect for any of the available less invasive surgical options
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and/or to have modified perioperative adjunctive medical therapies. Further, even
recent reports of secondary surgical intervention rates may not be representative
of current surgical practices. The rapidly evolving surgical techniques, adjuvants
and their place in the glaucoma treatment paradigm may confer different risks
than those of past practice.140,141 To address these issues, our objective was to
determine the rate of secondary surgical intervention after primary filtration
surgery within the first post-operative year in a large cohort of older adults
undergoing their first glaucoma filtration surgery. We hypothesized that patient
and surgical factors, pre-existing filtration surgery in the contralateral eye, as well
as exposure to peri-operative and anti-glaucoma medications, would influence
the rate of secondary surgical intervention.

2.2 Methods
2.2.1

Design and Setting

A retrospective, population-based cohort study was conducted using
administrative healthcare data from the province of Ontario, Canada. As
Canada’s most populated province, Ontario provides all citizens with universal
health coverage through a single health care system. In addition, individuals ≥65
years of age have universal access to a variety of prescription medications
approved for coverage by the Ontario Drug Benefit (ODB) Plan, including most
glaucoma medications. Individual patient level data were linked using a unique
encoded identifier and were analyzed at the Institute for Clinical Evaluative
Sciences (ICES) Western. Research approval is through the institutional review
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board at Sunnybrook Health Sciences Centre, Toronto, Ontario. Study reporting
followed the STROBE/RECORD checklist (Appendix A).142

2.2.2

Data Sources

Several linked population based administrative databases were used: the Ontario
Health Insurance Plan (OHIP) which captures greater than 95% of Ontario
physician services;143 the Registered Persons Database (RPDB), which captures
demographic data and vital statistics on all Ontario residents (approximately 13
million people);144 the Canadian Institute for Health Information (CIHI) Discharge
Abstract Database (DAD) and the Same Day Surgery (SDS) database, which
contains detailed diagnostic and procedural information regarding all surgical
procedures and hospital admissions;144 and finally the Ontario Drug Benefits plan
database (ODB), which accurately captures all prescriptions filled by outpatients
aged 65 and older.145 To identify certain systemic co-morbidities, we used
databases derived from validated case definitions: the Hypertension Database
(HYPER)146, the Ontario Diabetes Database (ODD)147 and the Ontario Asthma
(ASTHMA) dataset.148 All these databases provide accurate data on the
covariables assessed in this study and have been validated for many outcomes,
exposures and diagnoses.144,145,149 All codes used for assembly of cohorts, as
well as detection of covariables, are referenced in Appendix B-G.
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2.2.3

Cohort Assembly

Ontario residents who underwent a primary glaucoma filtration surgical procedure
(no previous incisional glaucoma surgery in both eyes) between April 1, 2003 to
March 30, 2015 were identified. A patient’s OHIP and CIHI records both had to
indicate a glaucoma filtration procedure to be included in this study. Excluding
any patients with conflicting records was a measure to reduce misclassification of
patients and to increase the specificity of the cohort. Full coding definitions for
cohort creation are referenced in Appendix B. In short: first, a physician billing
record for a filtration procedure was required (from the OHIP database): a single
OHIP surgeon fee code for “glaucoma filtration procedure” (E132) or “glaucoma
filtering procedure and cataract extraction (same eye)” (E214). Second, a
Canadian Classification of Health Interventions (CCI) procedural code for
“drainage, anterior chamber (of eye)” (1.CJ.52.LA, 1CJ.52.LA-SJ, 1.CJ.52.LA-QB
and 1.CJ.52.WJ) was required for the same patient in their CIHI-SDS/DAD
hospital records. The date of this procedure was considered the index date.
Notable patient exclusions were: patients less than 66 years of age and greater
than 105 years of age were excluded (n=7,072) to retain all patients with an ODB
database record (and therefore medication utilization information) at least 1 year
in length; patients with evidence of prior filtration surgery were excluded
(n=1,332) to remove revision filtration surgeries that may have been miss-coded
as primary surgeries; and finally, patients who had evidence of a revision surgery
on the same day as the primary filtration surgery were excluded (n=767) as these
were not considered to be secondary surgical interventions. If patients underwent
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additional filtration surgery on the contralateral eye during the 365-day follow-up
(n=2,510), they were then censored from the original cohort and placed into a
separate cohort. This sequential-bilateral surgery cohort was used to investigate
the possibility of a different outcome rate among these patients.

2.2.4

Outcome Measures

Patients were followed for one year after the date of primary filtration surgery, to
a maximum of March 30, 2016. Primary outcomes were (a) revision filtering
surgery and (b) any procedure (excluding needling) encompassing conjunctival
manipulation. Revision filtering surgery was defined by OHIP fee codes E983 or
E984 and CCI intervention codes 1.CJ.52.LA, 1CJ.52.LA-SJ, 1.CJ.52.LA-QB,
and 1.CJ.52.WJ (accompanied by the intervention attribute “revision”). OHIP fee
codes E212 and E213 and/or CCI intervention codes 1.CS.80, 1.CS.72, 1.CS.84,
1.CS.87, 1.CS.52, 1.CC.80, 1.CD.80 revision, 1.CJ.54, 1.CJ.55, 1.CJ.80,
1.CJ.87, and 1.CD.52.LA revision were used to identify patients who required
conjunctival manipulation (excluding needling). See Appendix B for complete
definition.

2.2.5

Covariables

Patient factors assessed included demographic data (age, sex, year of cohort
entry and income quintile), medical comorbidity, ophthalmic surgical history, eye
drop medication history and eye drop preservative exposure. Income quintile was
derived from Statistics Canada census data on the average income per single-
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person equivalent by postal code.150 Medical comorbidity was estimated using a
Charlson-Deyo comorbidity index with a 5-year review of CIHI-DAD.151,152
Patients with no CIHI-DAD record were assigned a score of 0 indicating
negligible comorbidity. Previously validated algorithms were used to identify
patients with diabetes,147 hypertension,146 asthma,148 stroke153 and sleep
apnea154 (Appendix C). Ophthalmic surgical history was determined through
OHIP billing codes (Appendix D) with a 5-year lookback window. Surgical
procedures were grouped for analysis based on anatomic location. Data for eye
drop prescription history were assessed for the 1-year period prior to the index
event for glaucoma medications (Appendix E) and 30 days prior to index event
for all other ocular medications (Appendix F) captured by the ODB.
Exposure to the ophthalmic eye drop preservative, benzalkonium chloride (BAK),
was assessed for a subset of the main cohort based on data availability. Drugs
with known BAK concentrations are listed in Appendix G. All patients who
received a prescription for an ophthalmic drug with unknown BAK concentration
were excluded from this portion of the analysis. One-year cumulative BAK
exposure was calculated as the volume of medication dispensed to a patient
during the 365 days before the index event, multiplied by each medication’s BAK
content (%vol). The resulting number was used to evaluate a patient’s 365-day
cumulative exposure to BAK.
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2.2.6

Statistical Analysis

Data are reported as means and standard deviations unless otherwise indicated.
Groups of patients <6 in size are not released in accordance with ICES privacy
regulations, so some results are reported as “approximately or ≤5”. Significant
differences between groups were initially assessed using Students t-test and chi
square. Significant variables were then included in a multivariable cox
proportional hazards model. Patients were censored on the date of a primary
outcome, death, enucleation, evisceration or exenteration. A second primary
filtration procedure on the contralateral eye within the observation window
qualified patients for inclusion in the sequential-bilateral surgery cohort for
separate analysis. Hazard ratios (HRs) and 95% confidence intervals (95% CIs)
were determined using a Cox proportional hazards model. The proportional
hazards assumption was evaluated using Schoenfeld residuals, interaction with
time covariables, and log-negative-log plots of the survival function.155 If the
proportional hazards assumption was violated, then the hazard ratio at day zero
of the 365 day follow up was reported along with their graphed functions.
Immortality bias was assessed through a competing risk analysis with death
during the follow-up period. Both the cause-specific and subdistribution hazard
ratios were calculated, where the cause-specific model is the equivalent of our
cox regression model (censoring death) for the primary outcome. All analyses
were performed with SAS enterprise guide version 7.12 (SAS Institute, Cary,
North Carolina) for UNIX.
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2.3 Results
A total of 10,097 primary filtration surgeries were identified after 12,787 patients
were excluded based on predetermined criteria (Figure 2-1). The yearly volume
of primary filtration surgeries varied over the study period, ranging from a
minimum of 1,335 cases for the year April 1, 2013 to March 31, 2014 to a
maximum of 1,916 between April 1, 2005 to March 31, 2006. The complete
cohort consisted of 4,287 male (42.46%) and 5,810 female (57.54%) patients
with a mean ± standard deviation (SD) age of 76.69 ± 6.45 years, and
interquartile range (IQR) 72-81 years (Table 2-1).
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Figure 2-1: Flow Diagram of Cohort Selection
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Table 2-1: Cohort Characteristics (Overall, Secondary Surgical Intervention and
No Outcome)*
Entire Cohort
n=10,097

Secondary Intervention
n=349

No Outcome
N=9,748

P
Value

76.7 ± 6.5
4,014 (39.8%)

75.8 ± 6.3
162 (46.4%)

76.7 ± 6.5
3,852 (39.5%)

0.01

6,083 (60.2%)

187 (53.6)

5,932 (60.4%)

4,287 (42.5%)

147 (42.1%)

4,140 (42.5%)

5,810 (57.5%)

202 (57.9%)

5,608 (57.5%)

1,604 (15.8%)

49 (14.0%)

1,555 (16.0%)

2005-2006

1,916 (19.0%)

74 (21.2%)

1,842 (18.9%)

2007-2008

1,666 (16.5%)

76 (21.8%)

1,590 (16.3%)

2009-2010

1,661 (16.5%)

52 (14.9%)

1,609 (16.5%)

2011-2012

1,732 (17.2%)

49 (14.0%)

1,683 (17.3%)

2013-2014

1,335 (13.2%)
183 (1.8%)

42 (12.0%)
7 (2.0%)

1,293 (13.3%)
176 (1.8%)

Variable
Demographics
Age
Mean ± SD
66-74
75-90+
Sex
Male (%)
Female (%)
Year of Primary Filtration Surgery
2003-2004

2015
Income
Quintile
1st (lowest)

2,024 (20.1%)

58 (16.6%)

1,966 (20.1%)

nd

2

2,061 (20.4%)

84 (24.1%)

1,977 (20.3%)

3rd

2,012 (19.9%)

69 (19.8%)

1,943 (19.9%)

4th

1,879 (18.6%)

71 (20.3%)

1,808 (18.6%)

5th (highest)

2,121 (21.0%)

67 (19.2%)

2,054 (21.1%)

Mean ± SD
0

0.6 ± 1.2
6,915 (68.5%)

0.7 ± 1.1
221 (63.3%)

0.6 ± 1.2
6,694 (68.6%)

1

1,372 (13.6%)

57 (16.3%)

1,315 (13.5%)

2

1,147 (11.4%)

47 (13.5%)

1,100 (11.3%)

≥3
Diabetes
Yes

663 (6.5%)

24 (6.9%)

639 (6.6%)

2,024 (20.0%)

66 (18.9%)

1,958 (20.1%)

8,073 (80.0%)

283 (21.1%)

7,790 (79.9%)

6,041 (59.8%)

211 (60.5%)

5,830 (59.8%)

4,056 (40.2%)

138 (39.5%)

3,918 (40.2%)

0.90

0.09

0.23

Charlson Comorbidity Index

No
Hypertension
Yes
No
Asthma
Yes

0.35
0.18

0.60

0.81

1,136 (11.3%)

44 (12.6%)

1,092 (11.2%)

8,961 (88.70%)

305 (87.4%)

8,656 (88.8%)

Stroke
Yes
No

704 (7.0%)
9,393 (93.0%)

31 (8.9%)
318 (91.1%)

673 (6.9%)
9,075 (93.1%)

0.15

Sleep Apnea
Yes
No

394 (3.9%)
9,703 (96.1%)

11 (3.1%)
338 (96.9%)

383 (3.9%)
9,365 (96.1%)

0.46

No

0.41

*Data are expressed as n (%) unless otherwise indicated. SD, standard deviation; IQR, inter-quartile range.
†
Institute for Clinical and Evaluative Sciences (ICES) privacy policies preclude the publication of data cells containing
fewer than 5 patients.
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Table 2-1. continued. Cohort Characteristics (Overall, Secondary Surgical Intervention and No
Outcome)*
Variable
Prior Ocular Surgery (5 years)
Yes
No
Prior Conjunctival Disrupting Surgery (5
years)
Yes
No
Scleral
†
Yes
†
No
Vitreous
Yes
No
Retinal
†
Yes
†
No
Conjunctival
†
Yes
†
No
Prior Conjunctival Sparing Surgery (5 years)
Yes
No
Lens
Yes
No

Entire Cohort
n=10,097

Secondary Intervention
n=349

No Outcome
N=9,748

P
Value
0.64

7,265 (72.0%)

255 (73.1%)

7,010 (72.0%)

2,832 (28.0%)

94 (26.9%)

2,738 (28.0%)

532 (5.3%)
9,565 (94.7%)

20 (5.7%)
329 (94.3%)

502 (5.3%)
9,236 (94.7%)

0.69

≤60 (0.6%)
≥10,037
(99.4%)

≤5 (1.4%)
≥344 (98.6%)

56 (0.6%)
9,629 (99.4%)

0.48

444 (4.4%)
9,653 (95.6%)

17 (4.4%)
332 (95.6%)

427 (4.4%)
9,321 (95.6%)

0.66

≤100 (1.0%)
≥9,097
(99.0%)

≤5 (1.4%)
≥344 (98.6%)

97 (1.0%)
9,651 (99.0%)

0.43

25 (0.3%)
10,072
(99.7%)

≤5 (1.4%)
≥344 (98.6%)

20 (0.2%)
9,728 (99.8%)

0.74

7,230 (71.6%)
2,867 (28.4%)

254 (72.8%)
95 (27.2%)

6,976 (71.6%)
2,772 (28.4%)

0.62

2,609 (25.8%)
7,488 (74.2%)

100 (28.6%)
249 (71.4%)

2,509 (25.7%)
7,239
(74.23%)

0.22

Corneal Transplant
Yes
109 (1.1%)
8 (2.3%)
101 (1.0%)
0.026
No
9,988 (98.9%)
341 (97.7%)
9,648 (99.0%)
Iris
Yes
1,517 (15.0%)
35 (10.0%)
1,482 (15.2%)
0.008
No
8,580 (85.0%)
314 (90.0%)
8,266 (84.8%)
Laser angle surgery
Yes
4,916 (48.7%)
182 (52.2%)
4,734 (48.6%)
0.19
No
5,181 (51.3%)
167 (47.8%)
5,014 (51.4%)
Photocoagulation
Yes
620 (6.1%)
13 (3.7%)
607 (6.2%)
0.06
No
9,477 (95.9%)
336 (94.3%)
9,141 (93.8%)
Interventions for retinal disease
Yes
497 (4.9%)
13 (3.7%)
484 (5.0%)
0.29
No
9,600 (95.1%)
336 (96.2%)
9,264 (95.0%)
*Data are expressed as n (%) unless otherwise indicated. SD, standard deviation; IQR, inter-quartile range; CAI,
carbonic anhydrase inhibitor; PGA, prostaglandin analogue; NSAIDs, non-steroidal anti-inflammatory drugs.
†
Institute for Clinical and Evaluative Sciences (ICES) privacy policies preclude the publication of data cells
containing fewer than 5 patients.
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Table 2-1 continued. Cohort Characteristics (Overall, Secondary Surgical Intervention and No
Outcome)*
Variable

Entire Cohort
n=10,097

Secondary
Intervention
n=349

No Outcome
N=9,748

P Value
Glaucoma Medication History (1 year)
Beta-Blocker
Yes
5,379 (53.3%)
191 (54.7%)
5,188 (53.2%)
0.58
No
4,718 (46.7%)
158 (43.3%)
4,560 (46.8%)
Mean ±SD days of meds/patient
136.3 ± 105.9
130.3 ± 108.2
136.5 ± 105.8
0.42
CAI
Yes
2,253 (22.3%)
74 (21.3%)
2,179 (22.4%)
0.61
No
7,844 (77.7%)
275 (78.7%)
7,569 (77.6%)
Mean ±SD days of meds/patient
124.4 ±111.6
117.0 ± 124.0
123.7 ± 111.1
0.65
Miotics
Yes
2,595 (25.7%)
90 (25.8%)
2,505 (25.7%)
0.97
No
7,502 (74.3%)
259 (74.2%)
7,243 (74.3%)
Mean days ±SD of meds/patient
108.0 ± 108.0
105.1 ± 113.4
108.1 ± 107.8
0.80
PGA
Yes
8,987 (89.0%)
323 (92.5%)
8,664 (88.9%)
0.03
No
1,110 (11.0%)
26 (7.5%)
1,084 (11.1%)
Mean ±SD days of medspatient
159.4 ± 107.3
153.4 ± 102.6
159.7 ± 107.5
0.32
Sympathomimetics
Yes
4,538 (44.9%)
172 (49.3%)
4,366 (44.8%)
0.14
No
5,559 (55.1%)
177 (50.7%)
5,382 (55.2%)
Mean ±SD days of meds/patient
131.6 ± 108.1
124.4 ± 93.0
131.8 ± 108.6
0.47
Other Ophthalmic Medications (30 days)
Antibiotic
Yes
851 (8.4%)
46 (13.2%)
805 (8.3%)
0.001
No
9,246 (91.6%)
303 (86.8%)
8,943 (91.7%)
Corticosteroid
Yes
4,519 (44.8%)
169 (48.4%)
4,350 (44.6%)
0.16
No
5,578 (55.2%)
180 (51.6%)
5,398 (55.4%)
Aminoglycoside
Yes
135 (1.3%)
15 (4.3%)
120 (1.2%)
<0.001
No
9,962 (98.7%)
334 (95.7%)
9,628 (98.8%)
Mydriatic
Yes
426 (4.2%)
33 (9.5%)
393 (4.0%)
<0.001
No
9,671 (95.8%)
316 (90.5%)
9,355 (96.0%)
NSAIDs
Yes
1,767 (17.5%)
36 (10.3%)
1,731 (17.8%)
<0.001
No
8,330 (82.5%)
313 (89.7%)
8,017 (82.2%)
*Data are expressed as n (%) unless otherwise indicated. SD, standard deviation; IQR, inter-quartile range; CAI,
carbonic anhydrase inhibitor; PGA, prostaglandin analogue; NSAIDs, non-steroidal anti-inflammatory drugs.
†
Institute for Clinical and Evaluative Sciences (ICES) privacy policies preclude the publication of data cells
containing fewer than 5 patients.
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2.3.1

Type of Primary Filtration Surgery

Most primary filtration surgeries were solo procedures, with 6,947 (68.80%)
patients undergoing primary filtration surgery without cataract extraction or
implantation of an indwelling drainage device (IDD). Filtration surgery was
combined with cataract extraction in 1,745 (17.28%) patients. An IDD was used
in approximately 860 (8.52%) cases, and approximately 550 (5.45%) cases were
combined with cataract extraction and implantation of an IDD. Of these initial
cases, 2,510 (25.8%) patients had their second eye undergo primary filtration
surgery. Of these, 1,698 (67.7%) were solo-procedures, 504 (20.1%) were
combined with cataract extraction, 134 (5.3%) involved an IDD and 174 (6.9%)
cases were combined with an IDD and cataract extraction.

2.3.2

Primary Outcome

Secondary surgical intervention was required for 349 patients (3.46%) a median
[IQR] of 21 [9-56] days following the initial filtering surgery. Life table is presented
in Table 2-2. For these patients, 303 conjunctival manipulations occurred,
approximately 5 implanted drainage devices were removed, and 72 revision
filtration surgeries were performed (certain patients experienced multiple
secondary surgical interventions within the 1-year follow-up period).

Table 2-2: Life table of primary outcome – unilateral cohort†
Time
Interval
(days)

Filtering
procedure
(solo-procedure)
N
Outcome

N at Risk

Filtering Surgery
+IDD
N
Outcome

N at Risk

Filtering Surgery
+cataract
extraction
N
Outcome

N at Risk

Filtering Surgery
+IDD, +cataract
extraction
N
Outcome

N at Risk

0-182
270
5427
20
740
27
1354
≤5
427
182-365
20
4825
≤5
681
≤5
1184
≤5
357
†Institute for Clinical and Evaluative Sciences (ICES) privacy policies preclude the publication of
data cells containing fewer than 5 patients
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Solo-filtration surgeries had a secondary surgical intervention rate of 1.43 per
10,000 person-days. With use of an IDD, the rate was approximately 1.00 per
10,000 person-days (vs solo-filtration, p = 0.0.035). When filtering surgery was
combined with cataract extraction the rate was 0.61 per 10,000 person-days (vs
solo-filtration, p < 0.0001). Patients who underwent filtration surgery combined
with cataract extraction and an IDD experienced secondary surgical interventions
at a rate of less than 0.25 per 10,000 patient-days (vs solo-filtration, p < 0.0001).
In the sequential-bilateral filtration surgery cohort, following patients for an
additional 365-days after primary intervention on the contralateral eye revealed
higher rates of secondary surgical intervention compared to patients with
monocular surgical interventions (Table 2-3). Secondary surgical intervention
was undertaken in 367 patients and had an incidence rate of 7.44 per 10,000
person-days, which was higher than that of the unilateral surgery cohort – 1.08
per 10,000 person-days (p < 0.0001). Considering a per-eye event rate equal to
half that observed in the sequential-bilateral cohort, there was additional risk
observed on a per-eye basis.
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Filtering surgery
+ cataract extraction
157,397

507,594

272,971

2,028,425

Unilateral Cohort
Person-days
of follow up

≤0.25

0.61

≤1.00

1.43

Event
Rate*

13

60

59

235

35,432

102,812

17,099

338,050

3.67

5.84

34.50

6.95

Sequential Bilateral Cohort
N
Person-days
Event
Outcomes
of follow up
Rate*

<0.0001

<0.0001

<0.0001

<0.0001

P value**

321
2,966,387
1.08
367
493,393
7.44
<0.0001
Total
*Event rate per 10,000 person-days; **p-value was derived using a poison regression model to compare incidence rates in
unilateral and bilateral groups; †Institute for Clinical and Evaluative Sciences (ICES) privacy policies preclude the publication
of data cells containing fewer than 5 patients

≤5

≤30

Filtering surgery
+ IDD†

Filtering surgery
+ cataract extraction
+ IDD†

290

Filtering procedure
(solo-procedure)

Type of Primary Surgery

N
Outcomes

Table 2-3: Primary outcome by cohort and type of filtration surgery

2.3.3

Covariables

Patient demographics, medical comorbidities, ophthalmic surgical history, eye
drop medication history and eye drop preservative exposure are listed in Table
2-1 for the complete cohort (n=10,097), those who required secondary surgical
intervention (n=349) and those who did not experience an outcome within the first
post-operative year (n=9,748).
Analysis of patients who underwent unilateral glaucoma filtration surgery
revealed that the initial type of filtration surgery was significantly associated with
secondary surgical intervention rates. Surgeries that included an IDD,
phacoemulsification, or both had decreased risks compared with solo-filtration
procedures without an IDD (HR=0.58 (p=0.013), HR=0.33 (p < 0.0001), and
HR=0.087 (p = 0.0001) respectively). In the adjusted multivariable Cox
proportional hazards model, several factors in a patient’s medical history were
identified to have a significant association with secondary surgical intervention
(Table 2-4). Patients under the age of 75 were more likely to undergo secondary
surgical intervention than those over 75 years of age (HR=1.35, p=0.005). A
history of iris surgery (laser iridotomy, iridectomy) was associated with a reduced
risk of secondary surgical intervention (HR=0.70, p=0.04). Filling a prescription
for aminoglycoside or mydriatic eye drops within the month preceding filtration
surgery was associated with an increased risk of secondary surgical intervention,
HR=3.19 (p < 0.0001) and HR=2.32 (p=0.0002) respectively. Hazard functions
that violated the proportionality assumption, and are variable over time, are
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*1.22 (0.46-3.22)
0.70 (0.49-0.99)
*1.18 (0.79-1.74)
3.19 (1.89-5.36)
*2.32 (1.49-3.61)
0.62 (0.44-0.88)

Prescriptions filled in the month before surgery
Topical antibiotics
Topical aminoglycosides
Topical mydriatics
Topical NSAIDs
0.42
< 0.0001
0.0002
0.007

0.70
0.04

0.005

P Value

0.85 (0.59-1.22)
*1.32 (0.52-3.35)
4.03 (3.02-5.37)
0.93 (0.71-1.22)

4.77 (2.58-8.83)
*0.86 (0.62-1.19)

0.92 (0.75-1.14)

Bilateral Cohort Hazard
Ratio (95% CI)

0.37
0.56
<0.0001
0.60

<0.0001
0.35

0.45

P Value

Type of primary filtration surgery
Filtering surgery w/IDD
*0.58 (0.37-0.89)
0.01
3.24 (2.42-4.35)
<0.0001
Combined w/cataract extraction only
*0.33 (0.21-0.52)
<0.0001
0.87 (0.65-1.15)
0.33
Combined w/cataract extraction and IDD
*0.09 (0.03-0.31)
0.0001
0.56 (0.32-0.97)
0.04
*Proportionality assumption violated and therefore the model was adjusted with an “interaction with time” covariate, and the HR at time
zero is reported. The hazard functions for covariates violating the proportionality assumption, and whose associated hazard varies over
the follow-up period are displayed in Figures 2 and 3.

1.35 (1.10-1.66)

Surgical History
Corneal transplant
Surgeries on the Iris

Unilateral Cohort Hazard
Ratio (95%CI)

Age (younger vs older than 75y)

Significant Covariates

Table 2-4: Multivariable Cox Proportional Hazards Model for Secondary Surgical Intervention –
Unilateral and Bilateral

displayed in Figure 2-2 for the unilateral cohort and in Figure 2-3 for the bi-lateral

cohort.

Figure 2-2 Hazard functions that violated the proportionality assumption are
displayed for the unilateral cohort. The proportional hazards assumption was
evaluated using Schoenfeld residuals, interaction with time covariables, and
log-negative-log plots of the survival function.

Figure 2-3: Hazard functions that violated the proportionality assumption are
displayed for the cohort of patients who had filtration surgery on both eyes. Iris:
prior surgeries on the iris.
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Within the sequential-bilateral surgery cohort, several covariables were
significantly associated with the rate of secondary surgical intervention (Table
2-4). Surgeries involving an IDD were associated with higher rates of secondary
surgical intervention (HR=3.24, p < 0.0001), whereas surgeries combined with
cataract extraction and an IDD were associated with reduced risk (HR=0.56, p <
0.04). History of corneal transplant was associated with more frequent secondary
surgical interventions (HR=4.77, p < 0.0001) as was perioperative exposure to
mydriatic eye drops (HR=4.03, p < 0.0001). Hazard functions that violated the
proportionality assumption (surgeries of the iris and aminoglycoside exposure),
and vary over time, are displayed in Figure 2-3.
The competing risk of death was considered not to have confounded results
(Appendix H), as the cause-specific hazard ratios were almost equivalent to the
subdistribution hazard ratios - due to the rarity of the competing risk event
(death).156 Further, the cumulative incidence function for death was not significant
(p=0.7403) across all types of initial filtration surgeries. Therefore, immortality
bias was not a major concern.
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2.3.4

Benzalkonium Chloride Exposure Cohort

Patient demographics, medical comorbidities, ophthalmic surgical history, eye
drop medication history and eye drop preservative exposure are listed in Table
2-5 for the BAK-cohort (n=8,676), those who required secondary surgical

intervention (n=315) and those who did not experience an outcome within the first
post-operative year (n=8,361). Within the BAK-cohort, only 48 patients were
exclusively prescribed preservative free medications within the 365 days prior to
surgery. None of these patients experienced an outcome within the follow-up
period. However, cumulative 365-day BAK exposure preceding surgery was not
associated with secondary surgical intervention, with patients requiring secondary
surgical intervention exposed to a median [IQR] of 11 [5-23] vs. 12 [5-26] ml for
patients who did not (p = 0.64).
Significant covariables were unchanged from the main study cohort except in the
case of PGA exposure. The group of patients who filled a prescription for PGA
eye drops within the year preceding primary filtration surgery experienced a postoperative secondary intervention rate of 3.6% (p=0.031). However, in the BAK
cohort a history of PGA had no significant association with secondary intervention
(p=0.066).
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Table 2-5: BAK Exposure Cohort Characteristics (Overall, Secondary Surgical
Intervention and No Outcome)*
Variable

BAK Cohort
n=8,676

Secondary
Intervention
n=315

No Outcome
N=8,361

P
value

Demographics
Age
Mean ± SD
76.7 ± 6.5
75.7 ± 6.4
76.7 ± 6.4
66-69.9
0.005
3,474 (40%)
150 (47.6%)
3,324 (39.8%)
70-74.9
5,202 (60%)
165 (52.4%)
5,037 (60.2%)
Sex
Male (%)
0.76
3,654 (42.1%)
130 (41.3%)
3,524 (42.2%)
Female (%)
5,022 (57.9%)
185 (58.7%)
4,837 (57.8%)
Year of Primary Filtration Surgery
2003-2004
0.14
1,202 (13.9%)
44 (14.0%)
1,158 (13.9%)
2005-2006
1,712 (19.7%)
67 (21.3%)
1,645 (19.7%)
2007-2008
1,601 (18.5%)
75 (23.8%)
1,526 (18.3%)
2009-2010
1,613 (18.6%)
52 (16.5%)
1,561 (18.7%)
2011-2012
1,449 (16.7%)
41 (13.0%)
1,408 (16.8%)
2013-2014
957 (11.0%)
30 (9.5%)
927 (11.1%)
2015
142 (1.6%)
6 (1.9%)
136 (1.6%)
Income Quintile
1st (lowest)
0.20
1,740 (20.1%)
50 (15.8%)
1,690 (20.2%)
2nd
1,772 (20.4%)
76 (24.1%)
1,696 (20.3%)
3rd
1,719 (19.8%)
67 (21.3%)
1,652 (19.8%)
4th
1,612 (18.6%)
61 (19.4%)
1,551 (18.6%)
5th (highest)
1,833 (21.1%)
61 (19.4%)
1,772 (21.1%)
Charlson Comorbidity Index
Mean ± SD
0.64 ± 1.2
0.58
0.68 ± 1.1
0.64 ± 1.2
0
0.54
5,940 (68.5%)
205 (65.0%)
5,735 (68.6%)
1
1,166 (13.4%)
46 (14.6%)
1,120 (13.4%)
2
1,001 (11.5%)
43 (13.7%)
958 (11.5%)
≥3
569 (6.6%)
21 (6.7%)
548 (6.5%)
Diabetes
Yes
1,713 (19.7%)
57 (18.1%)
1,656 (19.8%)
0.45
No
6,963 (80.3%)
258 (81.9%)
6,705 (80.2%)
Hypertension
Yes
5,173 (59.6%)
190 (60.3%)
4,983 (59.6%)
0.79
No
3,503 (40.4%)
125 (39.7%)
3,378 (40.4%)
Asthma
Yes
1,023 (11.8%)
43 (13.6%)
980 (11.7%)
0.29
No
7,653 (88.2%)
272 (86.4%)
7,381 (88.3%)
Stroke
Yes
612 (7.1%)
28 (8.9%)
584 (7.0%)
0.19
No
8,064 (92.9%)
287 (91.1%)
7,777 (93.0%)
Sleep Apnea
Yes
344 (3.9%)
8 (2.5%)
336 (4.0%)
0.19
No
8,332 (96.0%)
307 (97.5%)
8,025 (96.0%)
*Data are expressed as n (%) unless otherwise indicated. SD, standard deviation; IQR, inter-quartile range.
†Institute for Clinical and Evaluative Sciences (ICES) privacy policies preclude the publication of data cells
containing fewer than 5 patients.
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Table 2-5 continued. BAK Exposure Cohort Characteristics (Overall, Secondary Surgical Intervention and
No Outcome)*
BAK Cohort
Secondary
No Outcome
P
Variable
n=8,676
Intervention
N=8,361
value
n=315
Prior Ocular Surgery (5 years)
Yes
6,247 (72.0%)
226 (71.7%)
6,021 (72.0%)
0.92
No
2,429 (28.0%)
89 (28.3%)
2,340 (28.0%)
Prior Conjunctival Disrupting Surgery (5 years)
Yes
0.54
458 (5.3%)
19 (6.0%)
439 (5.3%)
No
8,218 (94.7%)
296 (94.0%)
7,922 (94.7%)
Scleral
†Yes
≤55
≤5
51 (0.6%)
0.51
†No
≥8,621
≥310
8,310 (99.4%)
Vitreous
Yes
383 (4.4%)
16 (5.1%)
367 (4.4%)
0.56
No
8,293 (95.6%)
299 (94.9%)
7,994 (95.6%)
Retinal
†Yes
≤85
≤5
82 (1.0%)
0.54
†No
≥8,591
≥310
8,279 (99.0%)
Conjunctival
†Yes
≤20
≤5
18 (0.2%)
0.70
†No
≥8,656
≥310
8,343 (99.8%)
Prior Conjunctival Sparing Surgery (5 years)
Yes
0.93
6,216 (71.7%)
225 (71.4%)
5,991 (71.7%)
No
2,460 (28.3%)
90 (28.6%)
2,370 (28.3%)
Lens
Yes
2,234 (25.8%)
87 (27.6%)
2,147 (25.7%)
0.44
No
6,442 (74.2%)
228 (72.4%)
6,214 (74.3%)
Corneal Transplant
Yes
97 (1.1%)
8 (2.5%)
89 (1.1%)
0.02
No
8,579 (98.9%)
307 (97.5%)
8,272 (98.9%)
Iris
Yes
1,318 (15.2%)
32 (10.2%)
1,286 (15.4%)
0.01
No
7,358 (84.8%)
283 (89.8%)
7,075 (84.6%)
Laser angle surgery
Yes
4,232 (48.8%)
163 (51.7%)
4,069 (48.7%)
0.28
No
4,444 (51.2%)
152 (48.3%)
4,292 (51.3%)
Photocoagulati
on
Yes
544 (6.3%)
12 (3.8%)
532 (6.4%)
0.07
No
8,132 (93.7%)
303 (96.2%)
7,829 (93.6%)
Interventions for retinal disease
Yes
427 (4.9%)
12 (3.8%)
415 (5.0%)
0.35
No
8,249 (95.1%)
303 (96.2%)
7,946 (95.0%)
*Data are expressed as n (%) unless otherwise indicated. SD, standard deviation; IQR, inter-quartile range;
CAI, carbonic anhydrase inhibitor; PGA, prostaglandin analogue; NSAIDs, non-steroidal anti-inflammatory
drugs; BAK, benzalkonium chloride.
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Table 2-5 continued. BAK Exposure Cohort Characteristics (Overall, Secondary Surgical Intervention and
No Outcome)*
BAK Cohort
Secondary
No Outcome
P
Variable
n=8,676
Intervention
N=8,361
value
n=315
Glaucoma Medication History (1 year)
Antibiotic
Yes
716 (8.23%)
38 (12.1%)
678 (8.1%)
0.01
No
7,960 (91.7%)
277 (87.9%)
7,683 (91.9%)
Corticosteroid
Yes
3,951 (45.5%)
154 (48.9%)
3,797 (45.4%)
0.22
No
4,725 (54.5%)
161 (51.1%)
4,564 (54.6%)
Aminoglycoside
Yes
119 (1.4%)
13 (4.1%)
106 (1.3%)
<
0.001
No
8,557 (98.6%)
302 (95.9%)
8,255 (98.7%)
Mydriatic
Yes
373 (4.3%)
30 (9.5%)
343 (4.1%)
<
0.001
No
8,303 (95.7%)
285 (90.5%)
8,018 (95.9%)
NSAIDs
Yes
1,580 (18.2%)
34 (10.8%)
1,546 (18.5%)
<
0.001
No
7,096 (81.8%)
281 (89.2%)
6,815 (81.5%)
BAK Exposure (1 year)
BAK Containing Drops
Yes
8,628 (99.5%)
315 (100%)
8,628 (99.5%)
0.02
No
48 (0.5%)
0 (0%)
48 (0.5%)
Cumulative BAK Load (percentile)
1st to 25th
2,166 (25.0%)
73 (23.2%)
2,093 (25.0%)
0.64
25th to 50th
1,956 (22.5%)
82 (26.0%)
1,874 (22.4%)
50th to 75th
2,042 (23.5%)
82 (26.0%)
1,960 (23.5%)
75th to 100th percentile
2,512 (29.0%)
78 (24.8%)
2,434 (29.1%)
*Data are expressed as n (%) unless otherwise indicated. SD, standard deviation; IQR, inter-quartile
range; CAI, carbonic anhydrase inhibitor; PGA, prostaglandin analogue; NSAIDs, non-steroidal antiinflammatory drugs; BAK, benzalkonium chloride.
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2.4 Discussion
This large administrative data study of more than 10,000 cases identified the
proportion of filtration surgery patients that required secondary surgical
intervention (3.46%) within the first year of follow-up. The rate was higher in solo
filtration surgery procedures, while combined surgeries (IDD, cataract extraction)
experienced reduced rates of secondary surgical intervention. The rate was
unchanged between men and women, however older age was associated with
reduced rates of secondary surgical intervention. No significant differences were
found in annual rates from 2003 to 2015 and there was no significant association
with socioeconomic status. Overall, prior intraocular surgery had minimal
association with secondary surgical intervention rates. Age, prior iris surgery as
well as perioperative aminoglycoside and mydriatic exposure were all significant
variables in the adjusted Cox multivariate model.
The sequential-bilateral cohort revealed a dramatically increased rate of
secondary surgical intervention, with several different covariables reaching
significance compared to the unilateral cohort. The difference in risk may be due
to patients requiring sequential-bilateral interventions having potentially more
advanced glaucoma, and thus placing them at a higher risk for secondary
surgical intervention – even when considered on a risk-per-eye basis.157
Analysis of the BAK-cohort revealed no major changes in significant covariables
from the main cohort. BAK exposure had no effect on secondary surgical
intervention rates. No trends were evident for any other types of prior ocular
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surgeries, any of the systemic comorbidities assessed nor any specific class of
glaucoma medication, save the prostaglandin analogs which showed a significant
association with secondary surgical intervention in the main study cohort.
This population-based analysis is strengthened by the nature of the public
healthcare system in Ontario. Filtration surgery, as well as all risk factors
discussed, are insured services and for physicians to be reimbursed for their
services, billing records must be submitted to the Ontario Health Insurance Plan.
Patient records are continuous, even patients who have switched surgeons within
Ontario are captured in our datasets. The number of patients that are lost to
follow-up is low. Only if a patient elects to pay out-of-pocket for surgery in another
province, country or in an independent surgical center would that data not be
captured. Finally, our analysis of BAK exposure as a risk factor used a
cumulative 365-day pre-operative exposure, which allowed us to model it as a
continuous outcome in order to maximize the chance of detecting a significant
effect on surgical failure rates. However, all data relies on the accuracy and
reliability of billing practices and medical records coding. Further, ODB only
tracks prescriptions filled by patients greater than 65 years old, necessitating
exclusion of patients under the age of 66 from our study in order to obtain and
analyze prescription information. Medically treated surgical failures were not
captured – only secondary surgical interventions. Further limitations to these data
should also be clarified. We could not determine the type of IDD used in
combined procedures, patient compliance with prescribed medications, receipt of
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non-recorded “sample” medications from physician offices, nor could we
determine any risk factors for IOP-related outcomes.
It is our understanding that, to date, this study is the largest to investigate rates of
secondary surgical intervention within the first post-operative year after glaucoma
filtration surgery, considering single eye interventions and sequential-bilateral
interventions separately. The observed rate within the present study’s unilateral
cohort was similar to those reported previously, ranging from three to eight
percent in unilateral interventions.131–133,158 Patients who underwent glaucoma
surgery in the contralateral eye were more than twice as likely to experience
secondary surgical interventions. In agreement with these data, Mietz and
colleagues previously analyzed 138 trabeculectomy patients and found that
additional interventions occurred more frequently in the second operated eye. 159
The work of Iwasaki et. al. further supports this trend and found that as the length
of time between surgery on the first and second eye increased, so did the risk of
failure.160
Our unilateral cohort showed significantly lower secondary surgical intervention
rates when undergoing glaucoma procedures combined with cataract extraction
and/or an IDD. This is in contrast to previous reports indicating similar safety
profiles for both filtration surgery and phaco-filtration surgery – however it is
possible that our larger sample size has allowed us to statistically elucidate this
association.161,162 As Ontario does not yet have device-specific billing codes, data
specifying the type of IDD used were unavailable. Thus, the IDD procedures
captured within this study were likely a heterogeneous mixture of various shunt
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devices including both traditional as well as micro-invasive glaucoma surgical
(MIGS) drainage devices. As MIGS devices are currently only indicated to be
combined with phacoemulsification, patients receiving these devices would likely
have been captured in the cataract extraction w/IDD group. However, this
precludes attributing any of the observed risk factors to a specific type of IDD.
Data must be interpreted within the context of its collection however, and the
included heterogeneity may allow for greater generalizability (i.e. what risk is
attributable to a foreign body in the eye vs no foreign body and is it associated
with secondary surgical intervention).
In patients who underwent glaucoma surgery on their second eye, combined
procedures were also protective, except for the insertion of an IDD alone. In this
IDD group, a much larger hazard was associated with IDDs than observed in the
unilateral cohort. The severity of glaucomatous disease is likely greater in
patients who had surgeries in both eyes, and perhaps these IDDs were more
likely to be traditional valves and shunts, not novel MIGS devices, which could
help to explain these findings. Nevertheless, care should be taken when inserting
any foreign body into an eye with advanced disease.
In the present study, older age significantly reduced the risk of secondary surgical
intervention in the unilateral cohort, however the significance was lost if patients
underwent sequential-bilateral procedures. Several studies have reported similar
results for unilateral procedures.134,139 Previous intraocular surgery has been well
explored as a risk factor for filtration failure.135,139 Broadway and Chang found
that fibroblast and inflammatory cell numbers were increased in the conjunctiva of
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patients with a positive history, providing a potential physiological mechanism for
this risk factor.71,72 However, data from the present study did not reveal any clear
association between prior ocular surgery and rates of secondary surgical
intervention in the real world setting. No significant effect was observed for prior
conjunctival disrupting surgeries, nor for conjunctival sparing surgeries, save for
the protective effect of prior surgery on the iris in the unilateral cohort and prior
corneal transplant in the sequential-bilateral cohort.
Exposure to topical antiglaucoma medications and the preservative
benzalkonium chloride (BAK) has been associated with filtration surgery
failure.68,70–72 Our results indicated that neither the type, save prostaglandin
analogs in the main study cohort, nor the amount of dispensed glaucoma
medications in the year prior to surgery were significantly associated with
secondary surgical intervention rates. Neither was cumulative BAK exposure.
Previous work has supported BAK exposure as a risk factor for early failure,
however it was also noted that significance was independent of the number of
BAK containing medications used.68 As just 48 patients received prescriptions for
exclusively preservative free medications during the study period, and none of
these patients experienced an outcome during the observation period, it remains
possible that the complete absence of BAK exposure does result in a lower risk
of secondary surgical intervention.
Prescriptions for certain topical ocular medications, filled within 30 days prior to
surgery, were significantly associated with secondary surgical intervention.
Topical NSAIDs were significantly associated with decreased rates of secondary
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surgical intervention in the unilateral cohort, however significance was lost within
the sequential-bilateral cohort. Interestingly, dexamethasone was not significantly
associated with intervention rates. Previously, a randomized clinical trial
investigated the potential benefit of pre-operative topical NSAIDs versus steroids
before trabeculectomy.163 Patients were treated with either drug 4 times daily for
one month before surgery and both drugs were found to significantly reduce
needling rates. These findings were also mirrored in a study involving Ahmed
glaucoma valves.90 These results together with the incidence of steroid induced
IOP spikes97 suggests NSAIDs could serve as preferential adjunctive medications
to these surgical procedures.
Filling a prescription for an antibiotic, particularly aminoglycosides, prior to
surgery was significantly associated with increased rates of secondary surgical
intervention in the unilateral cohort. One in nine patients who received a
prescription for aminoglycosides required a secondary surgical intervention.
Aminoglycosides are known to be toxic in the ear and induce toxicity and scarring
in the kidney.164,165 However, it is unclear if this study’s observation is a
consequence of these drugs acting on subconjunctival tissues, or if the infection
being treated by these medications may be negatively influencing surgical
outcomes. An ocular infection and accompanied inflammation just prior to
filtration surgery could prime the conjunctiva for aggressive post-surgical wound
healing. These novel findings warrant further investigation.
In conclusion, the rate of secondary surgical intervention within the first postoperative year after glaucoma filtering surgery is modest within the Ontario.
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Approximately a quarter of patients undergo sequential-bilateral filtering
procedures, and secondary surgical interventions occur much more frequently in
this group of patients – even on a per-eye basis. Surgeries involving IDDs,
combination with cataract surgery or both experienced fewer surgical
interventions in the unilateral cohort. Surgeries combined with both an IDD and
cataract extraction experienced fewer secondary surgical interventions in the
sequential-bilateral cohort, whereas surgeries with IDDs alone experienced
secondary surgical interventions more frequently. Further investigation into the
effects of mydriatic and aminoglycoside use prior to surgery should be
undertaken and caution may be warranted when patients undergoing filtration
surgery have experienced recent ocular infections. Exploring the potential
physiological basis of these associations could provide novel strategies for
perioperative wound management and guide the development of novel adjuvant
therapies. Results indicate that filtration surgery combined with an IDD and/or
phacoemulsification may be considered as a primary surgical intervention and
patients undergoing sequential-bilateral glaucoma procedures should be
counseled regarding their greatly increased surgical risk.
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Chapter 3

3

Differential Effects of Dexamethasone and
Indomethacin: Implications for Glaucoma Surgery2

In the previous chapter, surprisingly, perioperative exposure to NSAIDs was
found to be more strongly associated with GFS success than were
corticosteroids. Due to the favorable actions of RMs during wound healing, and
the fact that much of RM biosynthesis is abrogated by corticosteroids, we
hypothesized that NSAIDs may better impede post-operative wound healing
phenomena than corticosteroids.
In Chapter 3, these ideas are pursued in vitro, comparing the effects of steroidal
vs. NSAID anti-inflammatory exposure on wound healing phenomena elicited by
primary human subconjunctival fibroblasts within a 3D collagen culture system.

2

Parts of this chapter have been published: Armstrong, J.J., Denstedt, J., Trelford, C.B, Li, E. and Hutnik,
C.M.L. Differential effects of dexamethasone and indomethacin on Tenon’s capsule fibroblasts:
Implications for glaucoma surgery. Experimental Eye Research. 2019; 182(Jan); 65
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3.1 Introduction
Antimetabolites dramatically increase glaucoma surgery success rates, but may
be associated with complications relating to overly suppressed wound healing i.e. bleb leakage, blebitis, endophthalmitis, bleb dysesthesia and hypotony.92,166–
168

The use of perioperative, anti-inflammatory drops permits further control of

inflammation-driven wound healing. This strategy allows the surgeon to adjust
dosing in response to changing bleb morphology over the post-operative period,
a clinical luxury absent when relying on anti-metabolites as the sole modality of
wound modulation.169 To this end, topical corticosteroids are commonly used to
control inflammation-driven scarring after glaucoma surgery. Typically, they are
applied peri-operatively, oftentimes for several weeks or months, before89and/or
after glaucoma surgery.170 This includes trabeculectomy, phacotrabeculectomy,
traditional tube shunt or many of the novel micro-invasive glaucoma surgical
(MIGS) devices or procedures. However, steroids are associated with adverse
events such as cataract development, elevation of intraocular pressure (IOP) and
increased infection risk.96–103 These risks add to the unpredictability of postoperative wound healing and fuel the search for viable alternatives to control
post-operative inflammation and scarring.
Several clinical trials have compared topical NSAIDs to topical steroids for
perioperative inflammation control in glaucoma surgery.90,163,171–173 A recent
meta-analysis synthesized the results from several of these smaller trials and
determined that there was insufficient evidence to recommend one modality of
inflammation control over the other.174 When examining the individual studies of
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this meta-analysis, most found topical NSAIDs to produce equivalent IOP
outcomes to those attained with topical steroids.90,163,171,175 However, in a
randomized trial of 42 patients undergoing phacotrabeculectomy, patients
receiving post-operative topical diclofenac required fewer glaucoma medications
after surgery compared to those who received topical dexamethasone.175 Another
study reported a reduced likelihood of post-operative needling in a group of 54
patients who received topical ketorolac before trabeculectomy compared to the
group receiving topical fluorometholone.163 A further two studies found that
NSAIDs after Ahmed glaucoma valve insertion lead to significantly lower postoperative IOPs – albeit with a higher risk of wound healing related complications
such as hypotony and bleb leak.90,173 Finally, we recently conducted a
retrospective analysis of over 10,000 glaucoma surgery patients and found that
those who filled a prescription during the perioperative period for a topical NSAID
experienced significantly fewer interventions directed against bleb failure
compared to patients who did not fill a prescription for an NSAID during the
perioperative period.67 These clinical findings suggest that NSAIDs and steroids
exert differential effects on the quality of subconjunctival wound healing when
given perioperatively for glaucoma surgery.
Steroids mitigate inflammation by blocking transcription of phospholipase A2 176
as well as the activity of the cyclooxygenase and lipoxygenase biosynthetic
pathways, thereby suppressing the production of lipid-derived autacoids – of
which the prostaglandins and leukotrienes are the best known pro-inflammatory
examples.177,178 However, steroids also abrogate synthesis of another two
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classes of lipid-derived autacoids, synthesized by the lipoxygenase enzymes and
known to actively resolve inflammation – the specialized pro-resolving mediators
(SPMs) and the lipoxins.17,179 Non-steroidal anti-inflammatory drugs (NSAIDs) are
known to be very effective at reducing blood aqueous barrier breakdown and
preventing cystoid macular edema after cataract surgery through inhibition of
cyclooxygenase activity and prostaglandin synthesis.180–182 NSAIDs do not
significantly inhibit phospholipase A2 nor the lipoxygenase enzymes. This subtle
difference in mechanism of action leaves the endogenous enzymatic machinery
responsible for the resolution of inflammation intact – not the case after treatment
with steroidal anti-inflammatories.
NSAIDs are not in routine use after glaucoma filtration surgery, and their effects
relative to steroidal treatment on critical post-operative wound healing
phenomena remain unknown. Two dimensional monolayer cell culture
experiments have demonstrated the anti-proliferative effects of several NSAIDs
to be greater than that of dexamethasone on human ocular fibroblasts.95,183
However, their effects on ocular fibroblast mediated wound healing activity have
yet to be compared within a three-dimensional collagen-based culture system.
Such a culture system permits the study of cell-matrix interactions, allowing one
to study the influence of experimental treatment on cell-mediated tissue
contraction and matrix remodeling
Successful filtering surgery depends on the incomplete healing of the surgical
wound and establishment of a controlled, chronic wound within the
subconjunctival or superciliary tissues.3,4 Therefore, it is of critical importance to
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understand how these two classes of anti-inflammatory drug effect the wound
healing functions of human ocular fibroblasts. The purpose of this study was to
compare cell-mediated collagen contraction and remodeling in a threedimensional collagen-based culture system.184 Through macroscopic and
microscopic assessment of the human Tenon’s capsule fibroblast (HTCF)
containing collagen matrices that are produced by this culture method, we
present in vitro evidence, complementary to previous in vivo trials, for the
differential effects of these drugs on collagen remodeling and wound healing
phenomena orchestrated by HTCFs.

3.2 Methods
3.2.1

Isolation and Culture of HTCFs

This study followed the tenants of the Declaration of Helsinki and was approved
by the office of Human Research Ethics at Western University (REB# 106783).
Primary HTCF cell lines were derived from 2-4 mm3 surgically resected segments
of Tenon’s capsule. After the acquisition of informed consent, tissue specimens
were obtained from male and female glaucoma patients undergoing primary
trabeculectomy at St. Josephs Hospital, London, Canada. The samples were
obtained by ophthalmic surgeons who removed segments of Tenon’s capsule
and placed them into primary culture growth media containing Dulbecco modified
Eagle's minimal essential medium (DMEM), 10% Fetal Bovine Serum (FBS), 1%
penicillin/streptomycin, and 1% amphotericin, all from Sigma-Aldrich (Oakville,
Canada). After, specimens were placed in fibronectin (Sigma-Aldrich) coated 6well culture plates, submerged in primary culture media, and subcultured upon
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confluency for further use. Cell cultures were used for experimentation prior to
passage five. Table 3-1 provides a summary of donor characteristics for the
HTCF cell lines used in experiments.

Table 3-1: Donor information for the HTCF cell lines used for experimentation
Patient no.

Age/Sex

1
2
3
4*
5
6#,*

69/F
78/M
71/M
63/F
83/F
71/F

Glaucoma
Diagnosis
POAG
POAG
POAG
OAG
POAG
OAG

Surgery

Glaucoma Medications
(at time of surgery)

Trabeculectomy

Bimatoprost, Dorzolamide-timolol

Trabeculectomy

Brimonidine, Timolol, Latanoprost

Seton Implant

Bimatoprost, Brimonidine, Timolol

Seton Implant

Timolol, Metoprolol

Trabeculectomy

Bimatoprost, Dorzolamide-timolol

Trabeculectomy
Timolol, Metoprolol
processed sections not available for fluorescent microscopy experiments; *Protein
samples not available for western blot experiments; POAG: primary open-angle glaucoma; OAG:
open-angle glaucoma
#Histologically

3.2.2

Collagen Contraction Assay

The delayed release fibroblast populated collagen lattice model,185 based on the
model first proposed by Bell,186 was used to assess the effects of
dexamethasone and indomethacin on HTCF-mediated gel contraction. In brief,
HTCFs were mixed within an extracellular matrix (ECM) mixture containing 400μl
of type I collagen (1.8mg/ml; A1048301, Gibco), 80μl of neutralizing solution
(equal parts Waymouth media (Sigma-Aldrich) and 0.275M NaOH) and 20μl of
HTCF conditioned media (concentrated to 25x to obtain a 1x final concentration
within the 500μl construct volume) in order to achieve a final cell density of 2.5 x
105 cells/mL within the solution. Cell free collagen lattices were prepared
identically, albeit without the inclusion of HTCFs, as negative control. The
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solution was pipetted gently to ensure homogenous distribution of HTCFs while
avoiding the production of air bubbles, then 500μl were pipetted into each well of
a 24-well tray. Collagen constructs were allowed to polymerize at 37°C and 5%
CO2 for 45 minutes before adding low serum culture media containing DMEM,
2% Fetal Bovine Serum (FBS), 1% penicillin/streptomycin.
After incubation at 37°C and 5% CO2 for 72 hours, a sterile spatula was used to
detach each collagen construct from the edges of the culture well. Plates were
then immediately scanned on a flatbed laser scanner (Scanjet 8200, HewlettPackard) to record baseline area, and then every subsequent 24 hours for 7
days. The surface area of each collagen construct was measured using
ImageJ187 and standardized against the baseline surface area measurement to
express changes in area as a percentage of original surface area.

3.2.3

Anti-Inflammatory Treatment Protocol

After release of collagen constructs from the sides of the culture wells, the media
was removed twice daily (8am and 6pm) and replaced with one of the three
treatment solutions for a duration of 15 minutes. This schedule continued from
time of release for 7 days at which point the experiment concluded.
Dexamethasone (0.05, 0.1 and 0.2% wt/vol in DMEM with dimethyl sulfoxide
(DMSO: D2650, Sigma-Aldrich) 0.1% vol/vol), indomethacin (0.03, 0.1, 0.3
%wt/vol in DMEM with 0.1% DMSO) and vehicle control (DMSO, 0.1% vol/vol in
DMEM) treatment solutions were prepared from purified form (dexamethasone:
D4902; indomethacin: I8280, both from Sigma-Aldrich) and then filtered through a
0.2μm syringe filter to remove particulate and sterilize. These concentrations of
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indomethacin and dexamethasone were chosen to mirror doses in clinically
available topical preparations. After each treatment, the collagen constructs were
washed with PBS to remove any remaining treatment solution and fresh culture
media was added.

3.2.4

Extracellular Matrix Remodeling

Upon conclusion of the contraction assay, collagen constructs were fixed in 4%
paraformaldehyde overnight. After fixation, collagen constructs were dehydrated
in ethanol, embedded in paraffin blocks, sectioned (5µM) and mounted on glass
microscope slides using standard methods. For histological staining, sections
were deparaffinized and hydrated using standard protocols. Sections were
stained with picrosirius red. Briefly, a solution of 0.1% Sirius red (Sigma-Aldrich)
in saturated picric acid (Sigma-Aldrich) was applied for 60 min, followed by 2 x
0.5% acetic acid washes. Collagen birefringence, used to determine collagen
fibrillar hue,188 was assessed by circularly polarized light microscopy of picrosirius
red stained sections. Images were taken with an Abrio quantitative birefringence
imaging system (Hinds Instruments, Portland, Oregon) mounted on an Olympus
BX-51 microscope (Olympus Corporation, Tokyo, Japan). Specifically, a constant
light intensity, a fixed 45° angle to the polarizing filter, a 20x objective and the
same analyzer were used to facilitate consistent comparisons between each
sample.
When viewed under polarized light, the color of the collagen fibers stained with
picrosirius red depends upon fiber thickness and spatial orientation; with the color
changing from blue to yellow to orange to red as fiber thickness and density
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increase.189,190 This method has been used previously in rabbit experimental
filtration surgery to examine subconjunctival fibrosis, and red/orange staining was
associated with bleb dysfunction.105 Using ImageJ, this property was leveraged to
determine the relative proportions of different color fibers within the collagen
constructs. This quantitative method has been previously described by Rich and
Whittaker.191 In short, relative color content of the images is obtained by
separating the digital images into their hue, saturation and value components.
The hue component contains information on the color of each pixel within the
image. Every pixel can have one of 256 possible colors. To identify the red,
orange, yellow and blue pixels within a given image the following hue definitions
were used within ImageJ: red 2-9 and 230-256, orange 10-38, yellow 39-51 and
blue 52-128.191 The number of pixels within each hue range is calculated and
expressed as a proportion of the total number of pixels within each field
representing collagen. Ten random frames using a 20x objective were taken per
tissue section, with three tissue sections imaged per patient cell line and
treatment group.

3.2.5

Fluorescent Microscopy

Collagen constructs were cast with equal cell density, therefore there should be
equal variance in cell density between treatment groups after the 7-day
incubation period. This was assessed through fluorescent microscopy. Briefly,
deparaffinized and hydrated sections were permeabilized for 30 minutes with 1%
Triton X-100 (Sigma-Aldrich) in PBS (Sigma-Aldrich). Slides were then stained
with 4,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) for 10 minutes and
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imaged with a laser-scanning confocal microscope (A1R HD; Nikon Instruments
Inc., Tokyo, Japan). Relative cell density was determined by cell (nucleus) count
standardized to area of collagen autofluorescence (in pixels) within each section
and measured using ImageJ. Ten random frames were taken with the 40x
objective per tissue section, with three tissue sections imaged per patient cell line
and treatment group. The laser intensity settings were kept consistent between
slides to facilitate consistent comparison between replicates.
Expression of the contractile protein alpha smooth muscle actin (αSMA) by
HTCFs within collagen constructs was assessed through immunohistochemistry.
Deparaffinized and hydrated sections were permeabilized for 30 minutes with 1%
Triton X-100 in PBS. After blocking of nonspecific sites with 1% BSA in PBS,
sections were incubated for 40 minutes with Alexa Fluor 488–conjugated primary
antibody against αSMA (Abcam, ab202295). Finally, slides were stained with
DAPI for 10 minutes. For each tissue section, ImageJ was used to measure the
total area staining positive for αSMA. This value was then normalized to the total
number of nuclei counted within that same frame and compared between
treatment groups. Since fibroblasts and myofibroblasts are mononuclear this
approximates the αSMA expression per cell. Ten random frames were taken with
the 40x objective per tissue section, with three tissue sections imaged per patient
cell line and treatment group. The laser intensity settings were kept consistent
between slides to facilitate consistent comparison between replicates.
Thresholding of images to minimize background autofluorescence of the collagen
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matrix was accomplished using identical cut off values for each laser channel and
image analyzed prior to analysis.

3.2.6

Cell Culture and Western Blot

HTCFs were grown in 6-well culture plates in DMEM with 10% FBS at 37°C and
5% CO2 until 80-90% confluent. The cultures were then starved of serum for
24hrs, after which they were treated with vehicle (DMEM), TGFβ1 (2ng/ml,
Sigma-Aldrich) or TGFβ1 co-incubated with one of the experimental antiinflammatory treatment solutions. After 48hrs incubation, western blot was used
to assess relative protein expression between the experimental treatment groups.
Briefly, cells were lysed in lysis buffer (PhosphoSafe Extraction Reagent,
Novagen) containing a protease inhibitor cocktail (P2714, Sigma-Aldrich) and the
crude protein lysate (10μg) was resolved using a Novex WedgeWell 4-20% trisglycine gel (Invitrogen). Using an iBlot Gel Transfer Device (IB1001, Invitrogen),
the separated protein was transferred to a nitrocellulose membrane (IB301001,
iBlot Transfer Stack, Invitrogen) which was then blocked with 5% (w/v) bovine
serum albumin (Sigma- Aldrich) in Tris buffered saline (TBST) for 1 hour at room
temperature. The membranes were incubated overnight at 4°C with primary
antibody diluted in TBST containing 5% BSA (w/vol). Primary antibodies used
were as follows: collagen 1 (ab138492, Abcam), αSMA (ab5694, Abcam) and
GAPDH (Santa Cruz Biotechnology, Inc.). After incubation with primary
antibodies, the blots were washed and hybridized with 1:3000 (v/v) dilutions of
goat anti-rabbit IgG conjugated with horseradish peroxidase (Santa Cruz
Biotechnology, Inc.). Visualization was accomplished by applying WesternBright
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Quantum chemiluminescent reagent (Advansta, Inc.), with GAPDH used as a
protein loading control. Imaging and relative densiometric quantification was
accomplished using a ChemiDoc MP System (Bio-Rad Laboratories, Inc.)
connected to Image Lab (Version 6, Bio-Rad Laboratories, Inc.).

3.2.7

Statistical Analysis

All data are presented as means ± SEM. For reporting purposes, all experimental
replicates using multiple cell lines are denoted using ‘N = x’, and the number of
experimental repeats performed using each cell line will be denoted using ‘n = y’.
Collagen contraction assay data were subject to two-way analysis of variance
followed by, if necessary, the Tukey-Kramer test with use of statistical and
graphing software Prism 7 (Version 7.03, GraphPad Software Inc.). For collagen
remodelling assay data, the relative area of collagen stained blue, yellow, orange
or red, under different treatment conditions were assessed by one-way ANOVA
with Dunnett’s multiple comparisons post hoc test with a single pooled variance, if
necessary. The same methods were used for western blot and fluorescent
microscopy data. For all experiments, a P value of less than 0.05 was considered
statistically significant.

3.3 Results
3.3.1

Collagen Contraction Assay

An in vitro assay utilizing HTCFs seeded within delayed-release collagen
matrices was employed to measure the effects of drug exposures on HTCF
mediated collagen contraction. Compared to vehicle control, exposure to all
tested indomethacin and dexamethasone treatment solutions (except dex 0.05%
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at all timepoints) significantly inhibited collagen contraction over the seven-day
incubation period (Table 3-2). Tukey-Kramer multiple comparisons test indicated
that 0.3% wt/vol. indomethacin inhibited HTCF mediated collagen contraction to a
significantly greater degree than 0.05% wt/vol. dexamethasone at all timepoints
(Figure 3-1, N = 6, n = 6, p<0.05). Indomethacin 0.1% wt/vol. also inhibited
contraction to a significantly greater degree than 0.05% wt/vol. dexamethasone at
all timepoints (N = 6, n = 6, p<0.05) except on day six where the P value was
0.07.
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SD

Vehicle
Mean

0.0
12.3
12.7
13.2
14.4
14.6
16.1
15.8

SD

Dex 0.05%
Mean

100.0 0.0 100.0
55.1 13.4 62.8
50.0 13.8 59.8
46.1 14.8 55.4
43.5 14.2 54.0
40.8 14.1 52.8
38.8 14.5 52.8
37.1 13.8 51.7
*p < 0.05 vs. vehicle control

Day
0
1
2
3
4
5
6
7

100
67.3
65.8
*64.1
*62.9
*60.7
*60.1
*60.0

Mean

0
11.1
12.3
13.2
14.6
15.4
15.9
17.4

SD

Dex 0.1%

100
*73.0
*70.3
*68.7
*67.0
*63.8
*64.0
*64.6

Mean

0
13.3
15.1
13.8
15.3
15.6
16.2
17

SD

Dex 0.2%

100.0
69.4
*69.2
*68.0
*69.2
*68.0
*65.0
*63.3

Mean

0.0
11.2
11.6
12.2
13.0
13.3
14.1
14.9

SD

Indo 0.03%

100.0
*79.4
*76.2
*73.3
*70.5
*69.1
*67.9
*68.8

Mean

0.0
16.1
17.5
18.6
18.1
20.3
22.6
16.4

SD

Indo 0.1%

100.0
*82.7
*80.8
*77.2
*75.3
*73.7
*72.1
*70.2

Mean

0.0
14.0
14.7
14.0
15.3
15.6
15.9
22.6

SD

Indo 0.3%

Table 3-2: Fibroblast-mediated collagen contraction (% baseline area, mean and SD, N = 6, n = 6)

Figure 3-1: Scan of HTCF-collagen matrices at experiment conclusion and graph
illustrating the effects of indomethacin (blue lines: 0.03, 0.1, 0.3% w/vol.) or
dexamethasone (red lines: 0.05, 0.1, 0.2% w/vol.) on the contraction of HTCFpopulated collagen lattices compared to vehicle treated (black line). A TukeyKramer multiple comparisons test demonstrated that indomethacin dosed at 0.3%
and 0.1% had a significantly greater inhibitory effect on contraction than 0.05%
dexamethasone at the indicated time points. Data shown are mean ± SEM (N =
6, n=6, #indicates significance level for Indo 0.3% vs. Dex 0.05%, ^indicates
significance level for Indo 0.1% vs. Dex 0.05%).

3.3.2

Extracellular Matrix Remodeling

Picrosirius red staining was used in combination with circularly polarized light as
a highly sensitive means to visualize collagen fibers. Fibrillar hue was used to
assess structural changes induced by HTCFs in the collagen matrix compared to
cell free matrices (Figure 3-2). Cell free matrices, incubated for seven days under
identical experimental conditions, contained significantly greater proportions of
blue staining compared to constructs containing HTCFs, which revealed a
predominance of densely packed, mature red/orange staining collagen fibers
(Figure 3-2). These changes are inferred to be cell mediated, structural changes
to the collagen matrix.
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Figure 3-2: Picrosirius red and polarized light microscopy enabled assessment of
cell-mediated collagen remodeling. Collagen matrices were prepared with and
without HTCFs then cultured under normal conditions for two weeks, fixed,
sectioned and stained with picrosirius red. HTCF remodeling activity on the
collagen matrix is revealed by comparing cell free matrices, which stain uniformly
blue, to those cultured with HTCFs. Those cultured with HTCFs exhibit regions
staining yellow, orange and red where cell-mediated matrix modifications are selfevident. This remodeling activity was semi-quantitatively assessed in the
presence of steroidal (dexamethasone) and non-steroidal (indomethacin) antiinflammatory drugs by comparing the mean relative color content of each image
within a treatment group and using one-way ANOVA with Dunnett’s Multiple
comparisons test (N = 6, n = 3, five random high powered frames at 20x
magnification imaged per tissue section; **p<0.03, ***p<0.01, ****p<0.001 vs.
HTCF+VC experimental group).
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The effects of anti-inflammatory exposure on this remodeling activity was
assessed (Figure 3-2). Sections of dexamethasone treated constructs displayed a
similar fibrillar hue composition at all treatment doses compared to vehicle
treated sections (N = 6, n = 3, p>0.05). Indomethacin treated sections exhibited
significantly reduced red staining compared to vehicle treated sections and
sections treated with any dose of dexamethasone. Indomethacin treated sections
exhibited significantly greater areas of blue/yellow staining collagen fibrils
compared to vehicle and dexamethasone treated sections.

3.3.3

Fluorescent Microscopy

The number of DAPI stained nuclei per unit area of collagen matrix was
calculated to evaluate the final number of HTCFs within the collagen constructs
after seven days of experimental conditions. The effects of anti-inflammatory
treatment on final cell number are illustrated in Figure 3-3. Dexamethasone had
no significant effect compared to vehicle control on the density of HTCFs within
the collagen matrix at any concentration. The two highest concentrations of
indomethacin (0.1 and 0.3%) significantly reduced the number of HTCFs per unit
area of matrix after seven days of experimental conditions compared to vehicle
control. Expression of αSMA by HTCFs within the collagen constructs was
assessed using immunohistochemistry. Those treated with 0.2% dexamethasone
as well as those incubated with 0.1 and 0.3% indomethacin showed significantly
reduced αSMA staining per nuclei compared to vehicle control (Figure 3-3).
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Figure 3-3 Representative confocal laser scanning microscope images for each
treatment group. Cellular density was calculated as the number of nuclei (blue)
standardized to collagen matrix area (background collagen autofluorescence –
isolated by thresholding) within each given frame. Only indomethacin significantly
affected cellular density relative to vehicle control (N = 5, n = 3, *p<0.05,
**p<0.01). αSMA expression (green) within HTCF collagen constructs was
calculated as the area of αSMA staining (green) standardized to the number of
nuclei stained with DAPI (blue) within each given frame. Dexamethasone 0.2%
and indomethacin 0.1 and 0.3% significantly reduced the area of αSMA staining
per nuclei compared to vehicle control (N = 5, n = 3, *p<0.05, **p<0.01,
****p<0.0001).
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3.3.4

Western Blot

Western blot analysis of crude protein lysate revealed that, after 48hrs of culture,
indomethacin significantly impaired TGFβ1-induced collagen 1 and αSMA
expression such that it resembled the expression level of TGFβ1 naïve cells at all
concentrations tested (Figure 3-4, N = 4, *p<0.05, **p<0.01). Dexamethasone
exhibited a dose dependent impairment of TGFβ1-induced collagen 1 expression,
however this trend only reached statistical significance relative to the TGFβ1
control group at the highest concentration tested. The inhibition of αSMA
observed with dexamethasone was statistically significant in the 0.1 and 0.2%
(w/vol) treatment groups (Figure 3-4, N = 4, *p<0.05, **p<0.01, ***p<0.001).

73

74

Figure 3-4 Effects of anti-inflammatory treatment on TGFβ1-induced expression of collagen 1 and αSMA.
HTCFs were cultured for 48hrs with one of: 1) vehicle control (DMEM with 0.1% DMSO), 2) TGFβ-1
(2ng/ml), 3) TGFβ-1 (2ng/ml) with dexamethasone (0.05, 0.1 and 0.2% (w/vol) in DMEM with 0.1%
DMSO) or indomethacin (0.03, 0.1 and 0.3% (w/vol) in DMEM with 0.1% DMSO). Representative
western blot with densiometric analysis of multiple cell lines reported as mean ± SEM (N = 4, *p<0.05,
**p<0.01, ***p<0.001).

3.4 Discussion
Tissues undergo repair in three stages: inflammation, proliferation and
remodeling. Normal tissue repair requires an orderly and efficient transition
between these stages and events that disrupt these transitions, such as preexisting chronic inflammation due to a patient’s medication burden or the novel
interaction of aqueous humor with soft tissues at the surgical site, can cause
scarring and fibrosis. This complication is responsible for the majority of
glaucoma filtration surgery failures. Pharmacologic suppression of the
inflammatory response and modulation of fibroblast activity are thus essential to
the success rate of glaucoma filtering surgery.
Myofibroblast mediated tissue contraction is believed to contribute to bleb
encapsulation and a loss of patency in the surgical fistula that connects the AC to
the drainage structure, both of which can limit the structure’s outflow
capacity.3,4,192 Histological specimens of Tenon’s capsule obtained from failed
trabeculectomy blebs have been compared to control specimens obtained from
patients in surgically naïve eyes undergoing filtration surgery, retinal
reattachment or cataract surgery.193 These control sections demonstrate loose
connective tissue with few cellular infiltrates, and few cells positive for αSMA. In
contrast, sections from failed filtration structures tend to demonstrate αSMA
positive cell-rich mesenchymal proliferations containing densely packed collagen
fibrils which stain predominantly red/orange with picrosirius red.105,115,117,192–194
The intent of the presented in vitro model was to mimic the in vivo exposure
patient subconjunctival tissues might experience after topical application of
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steroid (dexamethasone) or NSAID (indomethacin) post-operatively. Collagen
constructs were immersed in treatment solutions twice daily for 15 minutes after
detachment of collagen constructs from culture wells, similar to the topical
application of medications after surgical tissue manipulation. Both
dexamethasone and indomethacin significantly inhibited HTCF-mediated
collagen contraction compared to control, with indomethacin exhibiting
significantly greater inhibition than dexamethasone at the extremes of the doses
assessed. Expression of the myofibroblast marker and contractile protein, αSMA,
is necessary for cell mediated tissue contraction to occur.112,195
Immunohistochemical staining demonstrated that both drugs had an inhibitory
effect on the expression of αSMA, however this effect was again slightly greater
with higher doses of indomethacin compared to dexamethasone. The effects of
treatment solutions on TGFβ1-induced αSMA expression was also assessed
through western blot. These results were corroborative of the trends seen in the
immunohistochemical experiments. These findings suggest that both drugs may
function in vivo to prevent decreases in outflow capacity due to the contraction of
tissues at or around the filtration site, however at the level of the fibroblast,
NSAIDs may better impair collagen contraction and associated biomarkers.
Picrosirius red staining revealed that only indomethacin significantly mitigated
HTCF-mediated collagen remodeling. Western blot after monolayer cell culture
revealed significant inhibition of TGFβ1-induced collagen 1 expression at all
tested indomethacin concentrations and certain dexamethasone concentrations.
The observed trend in collagen 1 expression is supportive of the trend seen in the
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picrosirius collagen remodeling assay. Indomethacin’s effects on collagen
remodeling may further be explained by the observation that treatment with
indomethacin significantly reduced the number of cells within collagen constructs
at experimental conclusion leaving fewer to remodel the matrix relative to the
control and dexamethasone groups. These observations are further strengthened
by previous monolayer cell culture experiments comparing the antiproliferative
effects of NSAIDs to that of steroids. NSAIDs showed comparable, or better, antiproliferative effects on ocular fibroblasts than did steroids.95 Another possible
explanation comes from the work of Sakaki et al, who cultured human gingival
fibroblasts and found that indomethacin reduced expression of matrix
metalloproteinases (MMPs).196 MMPs play an important role in extracellular
matrix remodeling and tissue repair, and MMP inhibitors have previously reduced
scarring outcomes in an in vitro model similar to the one presented here.125
Further, dexamethasone was previously demonstrated to decrease
glycosaminoglycan synthesis in cultured fibroblasts.197,198 Glycosaminoglycans
increase the hydration capacity of collagen matrixes, permitting looser
arrangement of fibers,199 thus providing further explanation for the denser
matrices produced by HTCFs when exposed to dexamethasone above that
provided by our collagen 1 western blot results. Further work is necessary to
characterize the cellular mechanisms underpinning the significant differential
effect these anti-inflammatory modalities exert on HTCF-mediated collagen
remodeling.
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In the present study, the combined anti-contractile and anti-remodeling effects of
indomethacin, in addition to its effects on cellular density, collagen 1 and αSMA
expression, suggest a capacity to mitigate many of the histopathological findings
associated with failed filtration blebs. Several previous glaucoma surgical trials
have compared perioperative treatment with NSAIDs to steroids and assessed
the impact on surgical outcomes.90,163,173,175,200 Patients treated post-operatively
with NSAIDs exhibited a clinical tendency to do better than those treated with
steroidal anti-inflammatory modalities in terms of the number of post-operative
glaucoma medications required, final IOP and bleb morphology.175 Favorable
bleb morphology with NSAID treatment in a clinical setting may be analogous to
the in vitro effects NSAIDs exhibited on HTCF-mediated collagen contraction and
remodeling in the present study.
Two previous studies evaluated NSAID versus steroid treatment after Ahmed
valve implantation and found a more favorable post-op IOP reduction with NSAID
treatment.90,173 However, complications relating to inadequate healing (such as
wound leak, hypotony, conjunctival retractions, etc.) were observed at higher
rates in the NSAID arm of one study.90 These findings support the conclusion that
indomethacin may better impede collagen remodeling orchestrated by HTCFs.
Remodeling, however, is an essential aspect of healthy wound healing and
critical, to a degree, in order to prevent bleb leaks, infection and hypotony. This
highlights the importance of modulating the existing positive and negative wound
healing stimuli that may influence the activity of HTCFs and, ultimately, surgical
outcomes. The glaucoma surgeon and patient will benefit from the understanding
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that NSAIDs and steroids are both effective at mitigating wound healing during
the post-operative phase. However, understanding the subtle differences in
efficacy and cellular mechanisms of action will allow for greater control of the
maturing bleb in vivo, allowing for finer adjustments to bleb maturation in
response to post-operative clinical observations.
Most of our current understanding of cellular functions such as migration,
differentiation and reaction to extra-cellular forces has been derived from
studying cells in two-dimensional monolayer cultures.184 In vivo, wound healing
and pathological scarring processes are a complex interaction between cells and
the extracellular matrix – the outcome of which is largely dependent on the
immediate microenvironment. The presented 3D collagen-based culture model
enables assessment of cell-mediated changes in collagen architecture as well as
differences in markers of cellular phenotype.201 It also accounts for the threedimensional cell-matrix interactions and signal transduction pathways, present in
vivo, that are unaccounted for in two-dimensional monolayer culture models.184
Our conclusions are strengthened by the complementary nature of the
macroscopic collagen contraction assay and the microscopic assessment of
collagen architecture as well as cellular morphology and protein expression.
A limitation of this in vitro model is the absence of inflammatory cells and immune
system. The infiltration of immune cells is thought to contribute to the failure of
glaucoma filtration surgery.71 It is highly likely that the anti-inflammatory
properties of steroids and NSAIDs act to limit the effects of these cells in vivo as
well, which in turn might diminish any negative impact on local fibroblast activity.
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Future studies could be undertaken incorporating inflammatory cells within a coculture system to investigate the impact these drugs have on HTCF wound
healing activities in the presence of immune cells.

3.5 Conclusions
In conclusion, both steroidal and non-steroidal anti-inflammatory treatment can
influence HTCF-mediated collagen contraction and αSMA expression.
Indomethacin alone was observed to mitigate HTCF-mediated changes in
collagen remodeling. This may be the result of different intracellular secondary
messengers being stimulated by the two drugs or a difference in relative potency
at the clinically available concentrations tested. These findings support the use of
this in vitro model to help understand observations from clinical trials involving ab
externo glaucoma surgery. Further, this model may be useful to investigate the
effects of other wound modulating agents, as well as the influence of surgically
implanted minimally invasive glaucoma (MIGS) devices. Given the rapidity and
frequency by which MIGS devices are emerging, this may be useful in providing
evidence to help optimize the success rates of implanted devices and perioperative wound management practices.
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Chapter 4

4

Acetylsalicylic Acid Mitigates Cytokine Induced
Myofibroblast Transdifferentiation and Activity within
Human Ocular Fibroblasts

Given the significant inhibitory effects on wound healing phenomena that are
observed with competitive COX inhibition, acetylsalicylic acid (ASA) and its
unique covalent inhibition of COX enzymes and PG production struck me as
potentially more powerful than what could be achieved with competitive inhibition.
Delving deeper, I learned of the relatively recent finding that ASA-acetylated
COX2 remains functional in situ – with the acetyl-COX2 enzyme now capable of
producing RMs from PUFA precursors, but not PGs. The ability to quickly and
simply acetylate this enzymatic engine of inflammation propagation into an
engine of resolving mediator production has the potential to be an immunoresolvent intervention. Chapter 5 pursues this idea and examines the effects of
ASA on RM generation, and the effects these ASA-triggered RMs exert on the in
vitro wound healing phenomena of subconjunctival fibroblasts.
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4.1 Introduction
Glaucoma represents a group of conditions involving progressive damage to the
optic nerve and subsequent vision loss. Glaucoma is one of the leading causes of
irreversible blindness, affecting over 70 million people across the world.202 There
is currently no cure, and the only known modifiable risk factor is the reduction of
intraocular pressure (IOP). Patients are prescribed medications to control their
intraocular pressure. However, due to physiological tolerance to the medications,
as well as poor treatment compliance, patients may undergo trabeculectomy.203
Trabeculectomy, also known as filtration surgery, involves the creation of a
pocket under the conjunctiva called a filtering bleb. Excess aqueous humor
drains into this bleb, thus lowering the intraocular pressure. Filtration surgery may
be considered the gold standard surgical intervention for refractory glaucoma
patients.202 However, the surgical failure rate is high: with a 10% failure rate per
year and up to a 50% failure rate in 5 years. This rate may be due to a
fibroproliferative response in the trabecular meshwork, the fistula between the
anterior chamber and the bleb, and/or the Tenon’s capsule, leading to
subconjunctival scarring after surgery and increased resistance to aqueous
outflow.3,4
The Tenon’s capsule is a collagen rich layer of connective tissue that lies under
the conjunctiva. This region contains fibroblasts; cells that transdifferentiate into
myofibroblasts,1 which function in wound healing by producing extracellular
matrix and contractile force.32,204 Under normal physiological conditions, the
Tenon’s capsule does not encounter aqueous humor. However, after filtration
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surgery, there is an influx of aqueous humor to this region of the eye. Numerous
cytokines are present in the aqueous humor, such as transforming growth factor
beta 1 (TGFβ1) and TGFβ2,86,205 tumor necrosis factor-alpha (TNFα), interferongamma (IFN-γ), and interleukin-1b (IL-1β).85,206,207 These inflammatory and
wound healing molecules function at the level of the fibroblast to promote wound
healing process, both directly and vicariously through immune cell recruitment.
These processes are required to some degree to avoid bleb leaks. However, if
the inflammatory phase of the wound healing response fails to resolve and reestablish homeostasis in the eye, chronic inflammation ensues.16,20,202 The TGFβ
isoforms are well-established as one of the main drivers of scarring after
glaucoma surgery.208–210 Myofibroblasts within the subconjunctival and Tenon’s
capsule tissues of failing glaucoma surgeries display excess proliferation, wound
contraction, and extracellular matrix protein production.1,4,211 These cellular
processes ultimately result in subconjunctival scar formation, increased
resistance to aqueous outflow and failure of IOP control.
Within the pro-inflammatory microenvironment of the filtration bleb, phospholipids
in the plasma membrane of HTCFs are converted to arachidonic acid by
phospholipase.12 Cyclooxygenase (COX) enzymes convert arachidonic acid into
pro-inflammatory mediators such as prostaglandins, which can recruit
inflammatory cells and subsequently vicariously activate local fibroblasts such
that they express fibrosis associated proteins such as alpha-smooth muscle actin
(α-SMA) and matrix metalloproteinases (MMPs).33,34 α-SMA is a structural protein
involved in scar contraction during the wound healing process. MMPs encompass
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a group of enzymes that degrade extracellular matrix and are involved in collagen
remodeling in wound healing.212 Previous work has demonstrated the
involvement of MMP9 in fibrosis after glaucoma surgery125,127,213 and MMP9 is
also upregulated during inflammatory processes.214 A healthy wound healing
response involves the build-up of pro-inflammatory mediators within the
fibroblast,16,215 which triggers the activity of lipoxygenases (LOX).35,216 The LOX
enzymes are the group enzymes whose actions produce most pro-resolving lipid
mediators, which then function to ultimately resolve inflammatory
processes.17,20,22
Anti-scarring agents in current use after glaucoma surgery include mitomycin C
— an antimetabolite that inhibits cell proliferation 217 — and corticosteroids —
broad-acting anti-inflammatory agents.65,218,219 However, these options have had
limited success. Mitomycin C may increase patients’ risk of developing
cataracts220, infection and hypotony.100,221 It is dosed empirically and has a very
narrow therapeutic range. As well, the use of corticosteroids have many adverse
effects, such as, dramatically increasing intraocular pressure in a subset of
patients, infection and cataract.69,97,222 Therefore, the efficacy of other agents
needs to be explored.
As an alternative, nonsteroidal anti-inflammatory drugs (NSAIDs) have shown
promise in a large retrospective study,67 in vitro223 and in a recent meta-analysis
of several small clinical trials.174 Acetylsalicylic acid (ASA), is unique among all
NSAIDs in that it does not competitively inhibit the COX2 enzyme. Instead, it
acetylates COX2 at Ser516 and changes its function.224,225 The acetylated COX2
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enzyme no longer produces prostaglandins, but instead produces pro-resolving
lipid mediators akin to those produced by the LOX enzymes. Examples of ASAtriggered lipid mediators include: 5R-hydroxyeicosatetraenoic acid (HETE),
15(R)-HETE226–228, 18-hydroxyeicosapentaenoic acid (HEPE)229 and 17Rhydroxy docosahexaenoic acid (OHDHA).6,230–232 Thus, ASA facilitates the
transition within cells from the pro-inflammatory biolipid synthesis pathway to the
pro-resolving biolipid synthesis pathway by triggering the production of proresolving lipid mediators from COX2 at the same time as mitigating PG synthesis
from the same enzyme. The downstream effects of ASA on TGFβ1-induced
myofibroblastic changes in human Tenon’s capsule fibroblasts are unknown. In
this study, we hypothesize that ASA will decrease TGFβ1-induced cell metabolic
activity and protein expression in HTCFs through the induction of pro-resolving
lipid mediators.

4.2 Materials and Methods
4.2.1

Isolation and Culture of Human Tenon’s Capsule Fibroblasts

This study was approved by the Human Research Ethics board at Western
University (REB# 106783). Human Tenon’s capsule tissue, 2-4 mm3 in size, were
resected from patients at St. Joseph’s Hospital, London, Canada. Specimens
were placed in a 1.5 mL microtube containing Dulbecco’s Modified Eagle Medium
(DMEM) with 10% (v/v) Fetal Bovine Serum (FBS) and 1% (v/v) Penicillin and
Streptomycin (PS), then placed into culture plates coated with fibronectin (SigmaAldrich, USA) at 37℃, 5% CO2. Cells from outgrowth were passaged prior to
reaching 80% confluence and all experiments were conducted with cells that
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were passaged fewer than 5 times. Donor information for the cell lines used in
experimentation are listed in Table 3-1.
HTCFs were cultured in separate 75 cm2 flask in DMEM with 10% FBS and 1%
PS (Gibco, Thermo Fisher Scientific, Canada). For all experiments, cells were
seeded at 105 cells/mL in 10% FBS-1% PS DMEM for 24 h or until 80%
confluence was reached. Next, cells were serum-starved for 24h. Vehicle control
HTCFs were treated with 0% FBS-1% PS DMEM and positive control HTCFs
was treated with 2 ng/mL of TGFβ1 (Thermo Fisher Scientific, Canada) in 0%
FBS-1% PS DMEM. To assess the effects of ASA (Thermo Fisher Scientific,
Canada) on HTCFs under non-inflammatory conditions, 3200 µg/mL ASA was
fully dissolved for 15 minutes in 0% FBS DMEM at 37℃, then serially diluted by a
factor of 2 to the lowest concentration of 100 µg/mL ASA, obtaining a total of
seven ASA concentrations. To assess the effects of ASA on TGFβ1-induced
HTCFs, cells were treated with the same set of ASA concentrations co-incubated
with 2 ng/mL of TGFβ1. Plates were incubated for 48 h at 37℃ and 5% CO2 prior
to conducting MTT/LDH assays, western blot, and immunohistochemistry.

4.2.2

Lipid Mediator Secretion Assay

Relative quantification of secreted pro-inflammatory and pro-resolving lipid
mediators was achieved using liquid chromatography tandem mass spectrometry
(LC-MS/MS). Specifically, we focused our analyses on the COX2 derived lipid
mediators, kPGF1a and PGE2; as well as the acetyl-COX2 derived mediators, 5HETE, 15-HETE, 17-OHDHA and 18-HEPE; and their PUFA precursors, AA,
DHA and EPA. Known quantities of deuterated internal standards of the analyzed
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the lipid mediators were added to each sample to enable relative quantification
between samples (Item Numbers: #10007737, #320110, #314010, #11182,
#315210, #319030, #390030, #10006410, #10006199, #334230, and
#10008040, Cayman Chemical). This is a well-established method to determine
the relative activity of lipid biosynthetic pathways 233,234. In brief, the ratios of the
integrated areas of the chromatographic peaks corresponding to each analyte
and the integrated areas of the peaks corresponding to each analyte’s internal
standard (with known absolute quantity) are used to determine the relative
quantity of each analyte in a given sample. After supernatant sample collection,
250μl of methanol containing 100pg of each deuterated internal standard was
added. Samples were then vigorously vortexed and centrifuged at 10,000g for
10min before loading onto solid-phase extraction cartridges (Strata-X 33um
Polymeric Reversed Phase, 10mg, Phenomenex 8B-S100-AAK), that were
previously activated with 2ml methanol and rinsed with 2ml water. Samples were
diluted upon loading so that the final concentration of methanol was between 10
and 15% of total volume. After washing with 5ml water, extracts were eluted with
1ml methanol. Solvent was then evaporated under vacuum in a SpeedVac
centrifuge, and the extract was resuspended in 100μl acetonitrile/water 60:40
(v/v). An aliquot of 20μl was injected into the LC-MS/MS system for analysis. A
Sciex ExionLC Integrated System was used with a 0.3ml/min flow rate, initial
mobile phase of 10% water / 0.1% formic acid followed by 100% acetonitrile /
0.1% formic acid on a Kinetex 2.6um C18 100 Å 100x2.1mm, Phenomax column
(OOD-4462-AN). A Sciex Triple Quad 6500+ mass spectrometer with multiple
reaction monitoring was used in negative ion mode. The chromatographic profile
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of the ion count for each m/z transition was monitored, and the area under the
peaks (ion intensity vs elution time) was integrated using commercial software
(MultiQuant, Sciex). Total cellular protein concentration was used for
normalization of the supernatant samples.

4.2.3

Collagen Contraction Assay

The delayed release fibroblast populated collagen lattice model,185 based on the
model first proposed by Bell,186 was used to assess the effects of experimental
treatments on cell-mediated gel contraction. In brief, HTCFs were mixed within an
extracellular matrix (ECM) mixture containing 80% type I collagen (1.8mg/ml;
A1048301, Gibco), 16% neutralizing solution (equal parts Waymouth media
(Sigma-Aldrich) and 0.275M NaOH) and 20μl of ocular fibroblast conditioned
media (concentrated to 25x to obtain a 1x final concentration within the 500μl
construct volume) in order to achieve a final cell density of 2.5 x 10 5 cells/mL
within the solution. Cell free collagen lattices were prepared identically, albeit
without the inclusion of ocular fibroblasts, as negative control. The solution was
pipetted gently to ensure homogenous distribution of ocular fibroblasts while
avoiding the production of air bubbles, then 500μl were pipetted into each well of
a 24-well tray. Collagen constructs were allowed to polymerize at 37°C and 5%
CO2 for 45 minutes before adding low serum culture media containing DMEM,
2% Fetal Bovine Serum (FBS), 1% penicillin/streptomycin.
After incubation at 37°C and 5% CO2 for 72 hours, a sterile spatula was used to
detach each collagen construct from the edges of the culture well. Plates were
then immediately scanned on a flat bed laser scanner (Scanjet 8200, Hewlett88

Packard) to record baseline area, and then periodically for the duration of the
experiment. The surface area of each collagen construct was measured using
ImageJ187 and standardized against the baseline surface area measurement to
express changes in area as a percentage of original surface area.

4.2.4

Collagen Remodeling Assay

Upon conclusion of the contraction assay, collagen constructs were fixed in 4%
paraformaldehyde overnight. After fixation, collagen constructs were dehydrated
in ethanol, embedded in paraffin blocks, sectioned (5µM) and mounted on glass
microscope slides using standard methods. For histological staining, sections
were deparaffinized and hydrated using standard protocols. Sections were
stained with picrosirius red. Briefly, a solution of 0.1% Sirius red (Sigma-Aldrich)
in saturated picric acid (Sigma-Aldrich) was applied for 60 min, followed by 2 x
0.5% acetic acid washes. Collagen birefringence, used to determine collagen
fibrillar hue,188 was assessed by circularly polarized light microscopy of picrosirius
red stained sections. Images were taken with an Abrio quantitative birefringence
imaging system (Hinds Instruments, Portland, Oregon) mounted on an Olympus
BX-51 microscope (Olympus Corporation, Tokyo, Japan). Specifically, a constant
light intensity, a fixed 45° angle to the polarizing filter, a 20x objective and the
same analyzer were used to facilitate consistent comparisons between each
sample.
When viewed under polarized light, the color of the collagen fibers stained with
picrosirius red depends upon fiber thickness and spatial orientation; with the color
changing from blue to yellow to orange to red as fiber thickness and density
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increase.189,190 This method has been used previously in rabbit experimental
filtration surgery to examine subconjunctival fibrosis, and red/orange staining was
associated with bleb dysfunction.105 Using ImageJ, this property was leveraged to
determine the relative proportions of different color fibers within the collagen
constructs. This quantitative method has been previously described by Rich and
Whittaker.191 In short, relative color content of the images is obtained by
separating the digital images into their hue, saturation and value components.
The hue component contains information on the color of each pixel within the
image. Every pixel can have one of 256 possible colors. To identify the red,
orange, yellow and blue pixels within a given image the following hue definitions
were used within ImageJ: red 2-9 and 230-256, orange 10-38, yellow 39-51 and
blue 52-128.191 The number of pixels within each hue range is calculated and
expressed as a proportion of the total number of pixels within each field
representing collagen. Ten random frames using a 20x objective were taken per
tissue section, with three tissue sections imaged per patient cell line and
treatment group.

4.2.5

Cellular Metabolic Activity Assay

To determine the effects of ASA on HTCF cell metabolic activity, MTT assays
(Sigma-Aldrich, USA) were conducted in 24-well plates. Supernatant from each
well was collected in individual microtubes for the LDH assay. Then, 0.5 mg/mL
MTT working solution in 0% FBS-1% PS DMEM was added per well, followed by
incubation for 3 h at 37℃, 5% CO2. Afterwards, the MTT solution was removed
and 500 µL of dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Canada) was added to
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each well. Plates were mixed for 30s on an orbital shaker, then analyzed using a
spectrophotometer at 575 nm. Optical densities (ODs) were corrected for
background OD from the DMSO, outliers were removed, and the mean corrected
optical densities of triplicate values were calculated. Cell metabolic activity was
calculated using the following equation:

Metabolic activity (%) =

4.2.6

mean corrected OD570 of experimental condition
mean corrected OD 570 of negative control

x 100%

Cytotoxicity Assay

Cytotoxicity was assessed using a Pierce LDH Cytotoxicity Assay Kit
(ThermoFisher, Canada). For this colorimetric assay, DMEM culture media
without phenol red (Gibco, Thermo Fisher Scientific, Canada) was used. In
addition to the previously indicated experimental treatment groups, HTCFs were
treated with 10% (v/v) TritonX-100 (Sigma-Aldrich, USA) diluted in 0% FBS-1%
PS DMEM for 1 h and 48hr, as a positive necrotic cell death control. After
experimental conclusion, supernatants were collected and the samples
immediately centrifuged for 10 minutes at 1,800g and 4℃. Next, each sample
was plated in duplicate in a 96-well plate with LDH standards. Output was
measured by spectrophotometer at dual filter 490 nm and 655 nm. Optical
densities were corrected for background, and the mean corrected optical
densities of the sample duplicates were calculated. Percentage of cell death was
calculated using the following equation:

Cytotoxicity (%) =

mean corrected OD490/655 of experimental condition
mean corrected OD490/655 of negative control
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x 100%

4.2.7

Western Blot

Once the effects of acetylsalicylic acid on TGFβ1-induced cell metabolic activity
were determined, ASA concentration at 100 µg/mL, 400 µg/mL, 1600 µg/mL and
3200 µg/mL were selected to assess the effects of ASA on TGFβ1-induced
protein levels. HTCFs were seeded in 6 well-plates at 105 cells/mL, then cotreated with 2 ng/mL TGFβ1 and the selected ASA concentrations for 48 h at
37℃, 5% CO2. Afterwards, total protein was extracted with lysis buffer
(PhosphoSafe Extraction Reagent, Novagen) containing a protease inhibitor
cocktail (P2714, Sigma-Aldrich) and a cell scraper (Pierce, Thermo Fisher
Scientific, Canada). Crude protein lysate (10 µg), determined using a Micro BCA
Protein Assay Kit (Thermo Fisher Scientific, USA), was separated using a 10%
acrylamide gel, alongside a SeeBlue Pre-stained Protein Standard (Thermo
Fisher Scientific, Canada). After gel electrophoresis, proteins were transferred to
a nitrocellulose membrane using an iBlot Gel Transfer Device (IB1001,
Invitrogen). Membranes were blocked in 5% (w/v) bovine serum albumin (BSA)
(Sigma- Aldrich, USA) dissolved in 10% (v/v) tris buffered saline (TBST) (Thermo
Fisher Scientific, Canada) for 1 h at room temperature, then incubated in primary
antibody overnight at 4℃, followed by incubation in secondary antibody
conjugated with horseradish peroxidase for 1 h at room temperature on a
benchtop shaker. Membranes were washed three times, 5 minutes each, with
10% TBST before and after the addition of each antibody. For analysis of alphasmooth muscle actin (α-SMA) protein levels, membranes were incubated in 2
µL/mL rabbit anti-alpha smooth muscle actin antibody (ab5694, Abcam, Canada)
in 3% BSA solution, washed, then incubated in 0.66 µL/mL secondary goat anti92

rabbit antibody (Bio-Rad Laboratories, Canada) in 3% BSA. For analysis of
matrix metalloproteinase-9 (MMP-9) protein levels, the same procedure was
followed but using rabbit anti-MMP9 antibody (ab38898, Abcam, Canada). All
membranes were also incubated with 2 µL/mL mouse anti-glyceraldehyde 3phosphate dehydrogenase (GAPDH) antibody (ab8245, Abcam, Canada) in 3%
BSA, followed by incubated in 0.66 µL/mL secondary anti-mouse antibody (BioRad Laboratories, Canada) both for 1 h at room temperature on a benchtop
shaker. Membranes were visualized by applying WesternBright Quantum
chemiluminescent reagent (Advansta, Inc.), with GAPDH used as a protein
loading control. Imaging and relative densiometric quantification was
accomplished using a ChemiDoc MP System (Bio-Rad Laboratories, Inc.)
connected to Image Lab (Version 6, Bio-Rad Laboratories, Inc.).

4.2.8

Immunohistochemistry

In order to examine the effects of ASA on TGFβ1-induced myofibroblast
morphology and α-SMA levels, HTCFs were seeded in 24-well plates, each
containing a 13 mm glass coverslip. Cells were treated in duplicate and analyzed
after incubation for 48h in the same treatment conditions as indicated for the
western blot experiments. Cells were washed with PBS two times, fixed and
permeabilized with 4% formaldehyde for 15 minutes, then washed again with
PBS two times. Cells were then incubated in 5% BSA dissolved in PBS for 1 h at
room temperature, followed by incubation with rabbit anti-α-SMA antibody at a
1:200 (v/v) dilution in 5% BSA for 1 h at room temperature. Cells were washed 3
times with PBS, 5 minutes each, then incubated in secondary goat anti-rabbit IgG
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(Alexa Fluor 555 Dye, Abcam, Canada) for 1 h, F-actin Staining Kit in Blue
Fluorescence (ab112124, Abcam, Canada) for 30 minute, then stained with
Hoechst solution (Thermo Fisher Scientific, Canada) for 15 minutes. Cells were
washed with PBS two times and dH2O two times prior to imaging using
fluorescence microscopy at 60x objective. Images were analyzed using ImageJ
by comparing, within each treatment group, the total area of α-SMA to the
number of nuclei. Ten random frames were taken with the 40x objective per
replicate, with three replicates imaged per treatment group within each patient
cell line. The laser intensity settings were kept consistent between samples to
facilitate consistent comparisons.

4.2.9

Exogenous Lipid Mediator Assay

The pro-resolving capabilities of ASA-triggered lipid mediators on TGFβ1-induced
HTCFs were assessed by western blot. HTCFs were seeded in 6-well plates at
105 cells/ml, serum-starved for 24 h, then treated with 2ng/mL TGFβ1 alone or
co-incubated with one of: 5(R)-HETE, 11(R)-HETE, 15(R)-HETE, and 17(R)OHDHA (Cayman Chemicals, USA) at concentrations of 10, 100, and 1000
ng/ml. After 48 h incubation, total protein was collected, and samples were
analyzed by western blot using the procedure described above. To include a nonASA-triggered lipid mediator negative control, 11-HETE was used due to its
derivation from cytochrome P450 in vivo.

4.2.10

Statistical Analysis

Data from all experiments are presented as mean ± SD. Experimental replicates
are denoted as ‘N=x’ and technical replicates performed within each cell line are
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denoted as ‘n=y’. Data collected from multiple treatment groups over time were
assessed by two-way repeated measures ANOVA with Dunnett’s multiple
comparison post hoc test. Data from the exogenous lipid mediator western blot
were assessed by one-way ANOVA with Tukey’s multiple comparisons post hoc
test. A p-value of less than 0.05 was considered statistically significant.

4.3 Results
4.3.1

Acetylsalicylic acid reduces prostaglandin production and
induces resolving mediator production in HTCFs

First, we assessed the ability of ASA to illicit ASA-triggered lipid mediators within
inflammation activated ocular fibroblasts. Cells induced with growth factors found
within the aqueous humor (AHGFs - 1ng/ml each: TGFβ1, TNFα, INFɣ and IL-1β)
exhibited high levels of prostaglandin production. Any dose of ASA exposure
resulted in the near complete abrogation of PG production (Figure 4-1A and B).
The relative production of ASA-triggered mediators 5-HETE, 15-HETE and 18HEPE was significantly increased after ASA exposure in a dose dependent
manner, up to 48hrs after exposure Figure 4-1C-E). No 17-OHDHA was detected
in any sample analyzed.
Error! Reference source not found.F summarizes the relative biosynthetic activity
of COX2 vs. acetyl-COX2 enzymes. The mean relative production of COX2
products (PGE2 and kPGF1a) was calculated, and from this figure the mean
relative production of acetyl-COX2 products (5-HETE, 15-HETE and 18-HEPE)
was subtracted. This way a value of zero would indicate equal relative
biosynthetic activity between acetyl-COX2 and COX2 enzymes; positive values
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would indicate COX2 dominated biosynthesis of lipid mediators; and negative
values would indicate acetyl-COX2 dominated lipid mediator biosynthesis.
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Figure 4-1 Relative AHGF-induced LM secretion was determined by supernatant
sampling and LC-MS/MS analysis at the indicated timepoints after exposure of
AHGF-induced ocular fibroblasts to the indicated experimental treatment. A-B)
COX2 prostaglandin products: kPGF1a and PGE2. C-E) Acetyl-COX2 RM
products: 5-HETE, 15-HETE and 18-HEPE. F) Displays the differential mean
relative secretion between pro-inflammatory mediators (PGE2 and kPGF1a) and
pro-resolving mediators (5-HETE, 15-HETE, 18-HEPE). A value of zero indicates
equal relative biosynthetic activity between acetyl-COX2 and COX2; positive
values indicate COX2 dominated biosynthesis of lipid mediators; and negative
values indicate acetyl-COX2 dominated lipid mediator biosynthesis. A-F) Twoway ANOVA with Dunnett’s post hoc test: *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
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4.3.2

Acetylsalicylic acid inhibits HTCF-mediated collagen
contraction and remodeling

Cell-mediated collagen contraction was assessed in the presence of increasing
concentrations of ASA (Figure 4-2). Compared to vehicle treated replicates, ASA
elicited a significant and dose dependent inhibition of ocular fibroblast-mediated
contraction over a period of four days. Contraction was almost completely
inhibited at 1600μg/ml ASA.

A)
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Figure 4-2 A) Representative scans of the same four contracting HTCFpopulated collagen lattices with the indicated treatments, the first 96hrs after
detachment from culture wells. B) Graph illustrating the effects of ASA (400,
800 and 1600 µg/ml in DMEM) on the contraction of HTCF-populated collagen
lattices compared to vehicle treated. Data shown are mean ± SEM (N = 6, n=6).
Two-way ANOVA with Dunnett’s post hoc test: *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
Picrosirius red staining was used in combination with circularly polarized light as
a highly sensitive means to visualize collagen fiber morphology. Fibrillar hue was
used to assess structural changes induced by ocular fibroblasts in the collagen
matrix compared to cell free matrices (Figure 4-3). Cell free matrices, incubated
for seven days under identical experimental conditions, contained significantly
greater proportions of blue staining compared to constructs containing HTCFs,
which revealed a predominance of densely packed, mature red/orange staining
collagen fibers (Figure 4-3). These changes are inferred to be cell mediated,
structural changes to the collagen matrix. Exposure to 1600μg/ml ASA
significantly inhibited the observed cell-mediated remodeling activity of ocular
fibroblasts.
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Cell Free
Vehicle Control
ASA 1600ug/ml
Figure 4-3 Picrosirius red and polarized light microscopy enabled assessment
of cell-mediated collagen remodeling. Collagen matrices were prepared with
and without HTCFs then cultured under normal conditions for two weeks, fixed,
sectioned and stained with picrosirius red. HTCF remodeling activity on the
collagen matrix is revealed by comparing cell free matrices, which stain
uniformly blue, to those cultured with HTCFs. Those cultured with HTCFs
exhibit regions staining yellow, orange and red where cell-mediated matrix
modifications are self-evident. This remodeling activity was semi-quantitatively
assessed over 7 days in the presence of 1600μg/ml ASA in DMEM. One-way
ANOVA with Tukey’s post hoc test: N=3, n=3, frames=10; **p<0.01,
***p<0.001.
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4.3.3

Acetylsalicylic acid decreases TGFβ1 induced HTCF
metabolic activity without increasing necrotic cell death

High levels of PG production are often associated with increased cellular
metabolic activity. Thus, to better understand the mechanisms underlying ASA’s
effects on in vitro wound healing phenomena, we examined the effects of ASA on
TGFβ1-induced HTCF cell metabolic activity. TGFβ1 increased HTCF cell
metabolic activity compared to un-induced fibroblasts (Figure4-4A). TGFβ1induced fibroblasts, treated with increasing concentrations of ASA, exhibited a
dose-dependent decrease in metabolic activity. In contrast, ASA had minimal
effects on HTCF metabolic activity in the absence of TGFβ1. A notable exception
in both cases was ASA at 3200 µg/mL — where metabolic activity was lower than
all other samples for both groups. Potentially reflecting an interference with
COX1’s homeostatic functions. Importantly, ASA at 1600 µg/mL returned TGFβ1induced metabolic activity to that of the baseline, no-TGFβ1 control. Thus, ASA
produced a significant and dose-dependent decrease in TGFβ1-induced HTCF
metabolic activity.
Next, we assessed whether ASA was exerting its effects — in particular at higher
concentrations — through cytotoxic mechanisms. We conducted an LDH assay
using supernatant from HTCFs (N=4, n=3) treated with the same conditions as
the MTT assay. HTCFs were also treated with 10% TritonX-100 for 1 h and 48 h
as a positive cell death control. For HTCFs treated both in the presence and
absence of TGFβ1, there was no difference in cell death – even at the highest
dose assessed (Figure4-4B). When compared to cells treated with vehicle and
those treated with TritonX-100, ASA treatments caused no significant increase in
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cell death. These results suggest that ASA decreases TGFβ1-induced metabolic
activity in HTCFs through a non-cytotoxic mechanism.

A)

B)

Figure 4-4 ASA decreases, A) cell metabolic activity, without significantly
impacting, B) cell death. HTCFs were co-cultured in triplicate in 24-well plates at
1 x 105 cells/mL with TGFβ1 and ASA at 100-3200 µg/mL for 48 h at 37℃ in 5%
CO2. Cell metabolic activity (N=6, n=3) and cell death (N=4, n=3) were measured
by MTT and LDH assays, respectively. TritonX-100 at 10% concentration was
used to assess maximal cell death. Results are presented as mean ± SD. Mean
and SD values were obtained at OD595 for MTT and OD490/655 for LDH. Readings
were corrected for background optical density, outliers were removed, and
treatment group ODs were normalized to the vehicle control OD. ASA,
acetylsalicylic acid; OD, optical density; VC, vehicle control. One-way ANOVA
with Tuckey’s post hoc test are indicated *p < 0.05, ***p < 0.001, ****p < 0.0001
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4.3.4

Acetylsalicylic acid decreases TGFβ1-induced
fibroproliferation-associated proteins

We assessed the effects of ASA on downstream protein expression within
TGFβ1-induced HTCFs by western blot. HTCFs (N=3-4, n=1) were co-treated
with TGFβ1 and ASA at 100, 400 and 1600 µg/mL for 48h. Relative levels of
myofibroblast-associated proteins—αSMA and MMP9—were measured and
normalized to GAPDH. HTCFs treated with TGFβ1 displayed an increase in
αSMA and MMP9 protein levels compared with that of the no-TGFβ1 vehicle
control (Figure 4-5A and B). A reduction in the levels of both proteins was
observed after treatment with increasing concentrations of ASA, suggesting that
ASA decreases the levels of TGFβ1-induced myofibroblast-associated proteins.

A)
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Figure 4-5 ASA decreases TGFβ1-induced protein levels. HTCFs (N=4) were cocultured in 6-well plates at 105 cells/mL with TGFβ1 and ASA for 48 h at 37℃ in
5% CO2. Relative protein levels were measured by western blot. A) Results of
densiometric analysis are presented as mean ± SD normalized to GAPDH with
one-way ANOVA with Tuckey’s post hoc test are indicated *p < 0.05, ***p <
0.001, ****p < 0.0001. B) Images of representative blots for each protein. ASA,
acetylsalicylic acid; α-SMA, alpha-smooth muscle actin; GAPDH, glyceraldehyde
3-phosphate dehydrogenase; VC, vehicle control.

To supplement the western blot findings, we conducted immunohistochemistry to
examine the effects of ASA on cell morphology and α-SMA levels. HTCFs treated
with TGFβ1 exhibited an expanded cell shape with a noticeable increase in linear
actin filaments when compared to vehicle control (Figure4-6A). After treatment
with increasing concentrations of ASA, there was an observable reduction in this
expanded and linear cell morphology. Furthermore, semi-quantitative analysis of
α-SMA within this assay revealed increased expression after treatment with
TGFβ1 when compared to vehicle control (Figure4-6B). A significant and dose
dependent reduction in α-SMA expression was observed with ASA exposure.
These findings follow a similar trend with those of the western blots, suggesting
that ASA represses myofibroblast-associated proteins induced by TGFβ1.
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Figure 4-6 ASA decreases TGFβ1-induced myofibroblastic changes. HTCFs
(N=3, n=2) were co-cultured in 24-well plates at 105 cells/mL with TGFβ1 and
ASA for 48 h at 37℃ in 5% CO2. A) Area of α-SMA was obtained through
ImageJ analysis and normalized to nuclei number. α-SMA levels are
presented as mean ± SD. Results from a one-way ANOVA with Tukey’s post
hoc test are indicated: *p < 0.05, ***p < 0.001, ****p < 0.0001. B) α-SMA (red)
and F-actin (green) expression were assessed by immunohistochemistry ASA,
acetylsalicylic acid; α-SMA, alpha-smooth muscle actin; VC, vehicle control.
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4.3.5

Acetylsalicylic acid triggered lipid mediators decrease TGFβ1
induced alpha-smooth muscle actin expression

We assessed whether exogenous treatment of ASA-triggered lipid mediators
would yield the same effect as treatment with ASA on TGFβ1-induced HTCFs.
We conducted western blots to assess relative levels of the myofibroblastassociated protein, α-SMA, after lipid mediator treatment. HTCFs (N=7, n=1)
were co-treated for 48 h with TGFβ1 and lipid mediator 5(R)-HETE, 11(R)-HETE,
15(R)-HETE, and 17(R)-OHDHA at concentrations 10, 100, and 1000 ng/mL.
HTCFs treated with TGFβ1 alone displayed a significant increase in α-SMA level
compared to vehicle control (Figure 4-7). A significant reduction in α-SMA was
observed after treatment with 5(R)-HETE, 15(R)-HETE and 17(R)-OHDHA at 100
and 1000 ng/ml, however, no significant difference was observed after treatment
with 11(R)-HETE. These findings suggest that the downstream lipid mediators
triggered by ASA can, themselves, repress myofibroblast-associated proteins.
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Figure 4-7 Exogenous lipid mediators decrease TGFβ1-induced α-SMA levels.
HTCFs (N=6, n=2) were co-cultured in 6-well plates at 105 cells/mL with TGFβ1
and lipid mediators: 5R-hydroxyeicosatetraenoic acid (HETE), 11(R)-HETE,
15(R)-HETE and 17(R)-hydroxy docosahexaenoic acid (17-OHDHA) for 48 h at
the indicated concentrations (nM). α-SMA levels were measured by western blot.
Results are normalized to GAPDH and presented as mean ± SD. Dotted line
represents α-SMA densitometry after treatment with TGFβ1 alone. One-way
ANOVA with Tukey’s post hoc test *p < 0.05, ***p < 0.001, ****p < 0.0001.
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; VC, vehicle control.
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4.4 Discussion
We have demonstrated, for the first time, that inflammation and wound healing
cytokines found within the aqueous humor illicit high levels of PG production
within HTCFs. PG production and the associated heightened metabolic activity
can be mitigated by ASA exposure, at the same time as inducing the production
of ASA-triggered resolving mediators. Both ASA and the exogenous applications
of ASA-triggered lipid mediators were found to repress TGFβ1-induced cellular
metabolic activity and protein expression in human Tenon’s capsule fibroblasts,
suggesting that this signaling system is capable of impeding the propagation of
both inflammatory and fibroproliferative processes. Indeed, results from the cellmediated collagen contraction and remodeling assays demonstrate ASA’s ability
to impair cell mediated wound healing phenomena in vitro.
TGFβ1, as well as its other two isoforms, are present in aqueous humor235 and
are implicated in post-surgical scarring by inducing the transdifferentiation of
fibroblasts into myofibroblasts.1,4 Based on the MTT results, ASA seems to
reverse the effects of TGFβ1 in a dose-dependent manner by decreasing TGFβ1induced cell metabolic activity. This finding is most prominently observed at ASA
concentration 1600 µg/mL, where TGFβ1-induced metabolic activity returns to
the baseline control level. Previous studies have observed a similar decline in
metabolic activity either after treatment at a single ASA concentration on nonhuman fibroblasts,236,237 or after treatment at multiple concentrations of ASA on
non-fibroblast cell lines.238–241 Therefore, to our knowledge, our study is the first
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to elucidate a dose-response to ASA in TGFβ1-induced human Tenon’s capsule
fibroblasts.
Furthermore, in the LDH assay, no notable increase in necrotic cell death was
observed, even at increasing ASA concentrations. This finding indicates that the
ASA concentrations tested are not cytotoxic to the fibroblasts, which aligns with
work from other research groups that have demonstrated the protective effects of
ASA against inflammation induced cellular damage.242–244 Together, the MTT and
LDH results suggest that ASA may be inactivating—rather than killing—TGFβ1induced fibroblasts, which subsequently lowers their metabolic activity level to
that of the pre-inflammation-induced state. On theoretical grounds, these results
may translate to a desirable outcome in vivo by decreasing fibroblast scarring
activity after glaucoma filtration surgery without inducing lethal effects on healthy
tissues.
We have also examined the downstream effects of ASA on expression of TGFβ1induced proteins, such as α-SMA and MMP-9. Western blot analysis
demonstrates that ASA represses the levels of both scarring associated proteins,
suggesting that ASA may mitigate the scar-forming potential these TGFβ1induced fibroblasts. Immunohistochemistry imaging confirmed these findings and
further demonstrates the ability of ASA to resolve the linear actin contractile fibers
induced by TGFβ1. These results are strengthened by the work from other
research groups, which have found a similar reduction in fibrosis-associated
proteins expression after ASA treatment in human236 and mouse237 fibroblasts, as
well as in other cell types.238–241 ASA’s ability to represses TGFβ1-induced
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proteins that are implicated in fibrosis suggests that ASA may mitigate the ability
of these cells to form scar tissue in vivo after filtration surgery.
After exogenous treatment of ASA-triggered lipid mediators, we have observed a
decrease in α-SMA levels within TGFβ1-induced HTCFs. This suggests that
downstream lipid mediators generated by ASA may have a role in transducing
the intracellular effects of ASA exposure. These findings align with those of
previous studies, which have demonstrated the ability of 5(R)- and 15 (R)-HETE
to reduce fibrosis in mice,35 and 17(R)-OHDHA was also found to be involved in
resolution in humans.230,231,245 We observed no effect with treatment of 11(R)HETE across the three concentrations tested. This was encouraging as it is not
considered an ASA-triggered lipid mediator, but the oxygenation product of
cytochrome P450 enzymes acting upon arachidonic acid.6
A limitation in this study is that the effects of ASA were assessed on a single cell
type. The chronic inflammatory micro-environment implicated in scarring after
filtration surgery involves the interaction of many different cell types, such as
immune cells, which cannot be completely recreated with the exogenous
inflammatory cytokine application.70,71 Therefore, future research may explore the
lipid mediator modulating effects of ASA within a fibroblast-immune cell co-culture
system.
In conclusion, we have shown that ASA and its associated lipid mediators shift
lipid mediator production from pro-inflammatory to pro-resolving, inhibit in vitro
wound healing phenomena. Data support that these findings are likely due to a
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reversal of TGFβ1-induced metabolic activity and protein expression in HTCFs
with exposure to ASA/ASA-triggered lipid mediators. These findings expand our
understanding of the mechanism of ASA as an anti-inflammatory and antiscarring agent in TGFβ1-induced HTCFs and provide the foundation for future in
vivo research, which may potentially explore the effects of topical ASA application
for ophthalmic pathologies. With the well-established safety profile of ASA in
human patients, translation of these findings may be rapid.
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Chapter 5

5

Acetylation of COX2: An Immuno-resolving and AntiCicatrizing Ocular Intervention3

Building on the promising results of Chapter 5, this chapter sought to further
modulate the production of LMs. Theoretically, after ASA acetylation, all
enzymatic machinery downstream of PLA2 – acetyl-COX2 and the endogenous
LOX enzymes – will act on PUFA precursors to generate RMs. This would
suggest that agonizing the activity of PLA2 under these conditions would
theoretically lead to increased PUFA precursor generation for downstream
processing into RMs. In Chapter 6, to test this hypothesis, we used ASA and a
second, more COX2 specific acetylating molecule to induce COX acetylation in
the presence of two separate PLA2 agonists. The effects of these interventions
on the in vitro wound healing phenomena of subconjunctival fibroblasts are
presented.

3

Parts of this chapter have been patented: Armstrong, J.J. and Hutnik, C.M.L. 2018. Compositions and
methods for treating ocular inflammation and ocular scarring. U.S. Provisional Patent Application No.
62/677,284, filed May 2018. Provisional status until May 2019.
Submission for peer reviewed publication will follow patent approval.
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5.1 Introduction
Inflammation driven myofibroblast transdifferentiation and activity is at the heart
of much currently unanswered ocular morbidity. Glaucoma filtration surgery,
corneal stromal injury, posterior capsule opacification after cataract surgery,
proliferative vitreoretinopathy and the sub-macular scarring associated with agerelated macular degeneration are some major contributors to ocular morbidity
with myofibroblast transdifferentiation at the core of the pathology.1 More broadly,
estimates implicate fibroproliferative disease in 45% of morbidity and mortality at
a systemic level in the developed world246 – it is unsurprising that the eye mirrors
the rest of the body in unanswered contributors to mortality. Recent changes in
our understanding of inflammation and, more importantly, its endogenously
controlled resolution necessitate a reimagining of treatments for inflammation
driven scarring.
Over the past twenty years, our understanding of inflammation and its resolution
has shifted. Long have the prostaglandin family of lipid mediators, derived from
cyclooxygenase 2 (COX2), been tied with the cardinal signs of inflammation.
More recently, however, we have come to understand the subsidence of these
cardinal signs, or the resolution of inflammation, to be an active process that is
endogenously controlled by the pro-resolving superfamily of lipid mediators.16
These resolving mediators (RMs) are produced mainly from the actions of
lipoxygenase (LOX) enzymes on the polyunsaturated fatty acid (PUFA)
precursors arachidonic acid (AA), eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA).10 The actions of RMs on inflammatory cells have
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been well established (i.e. inhibiting tissue infiltration of polymorphonuclear
(PNM) cells, promoting phagocytosis of cellular and wound debris, and
decreasing the antibiotic requirements for bacterial clearance) and their
cumulative effects are understood to decrease the duration and impact of
inflammation-induced cellular activity.28,247
Fibroblasts have been considered by some to be early sentinels of the immune
system, capable of both mounting and modulating inflammatory processes.30
Further, the process of fibroproliferation itself could be considered an appropriate
innate immune response to contain certain infectious organisms that can evade
immune cell killing. If myofibroblasts were to be modelled as inflammationactivated fibroblasts, one would expect high levels of endogenous prostaglandin
production to be observed within the myofibroblast phenotype. It would then
follow that, if RM secretion was promoted and resolution triggered, myofibroblasts
may abrogate their fibroproliferative activity. In fact, much recent work has
demonstrated the anti-fibrotic properties of RMs when stimulated endogenously
through overexpression of lipoxygenase enzymes,35 or when applied
exogenously as individual lipid mediators.21,36,37,248
Therapeutically, the endogenous stimulation of RMs can be accomplished
through a specific in situ acetylation of COX2. Acetylation at specific residues
induces a change in enzymatic function and repurposes COX2 from an
endogenous producer of pro-inflammatory prostaglandins, to one that resembles
a LOX enzyme in function and produces RMs. Recently, an enzyme endogenous
to murine neurons was found to acetylate murine COX2 at Ser565. The authors
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noted that acetylation of COX2 by this enzyme impaired PG production, enabled
production of RMs and induced resolution of dysfunctional microglial
inflammation within the Alzheimer’s disease model they employed.249 These
findings illustrate a naturally occurring example of COX2 repurposing.
Acetylsalicylic acid (ASA) was long thought to inactivate COX2 through
acetylation of Ser516,250 however we now understand this modification to not
only inhibit prostaglandin production, but to also enable RM generation through
the acetylated enzyme.10,224,251–253 This property of ASA has been measured in
enzymatic assays,224 cell-based systems228 as well as in human subjects taking
ASA in a randomized controlled trial.226
Prior to understanding the potential immuno-resolving impact of generating RMs
from acetylated COX2, several COX2 specific acetylators were developed as
potential inhibitors of prostaglandin production.225 However, little is known
regarding the potential of more specific COX2 acetylators to trigger the
production of LMs akin to ASA. As COX1 function is abrogated completely by
acetylation, one would hypothesize that a more specific COX2 acetylator would
lead to more acetyl groups being attached to COX2 enzymes relative to COX1
enzymes and therefore illicit greater RM production than a non-specific COX2
acetylator such as ASA. This would be especially true in the setting of high levels
of inflammation induced COX2. From this we hypothesized that acetylating COX2
in a pro-inflammatory and wound healing microenvironment would lead to
increased generation of RMs relative to prostaglandins and decreased in vitro
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cell-mediated wound healing phenomena through the impairment of
myofibroblast transdifferentiation and activity.

5.2 Materials and Methods
5.2.1

COX2 Acetylating Agents and PLA2 Agonists

To our knowledge, the most specific COX2 Ser516 acetylating agent identified to
date is o-(acetoxyphenyl)hept-2-ynyl sulfide (APHS),225,254 which was purchased
from Santa-Cruz Biotechnology (Catalog #sc-200668). ASA was purchased from
Sigma Aldrich (A5376). Both melittin (M4171) and gentamicin (G1391) were
purchased from Sigma-Aldrich. Molecular structures with key moieties are
displayed in Figure 5-1. Structures of COX1 and COX2 are shown in Figure 5-2.

Figure 5-1 A) depicts
the molecular structure
of ASA. B) depicts the
molecular structure of
APHS. C) summarizes
how the molecular
moieties of ASA/APHS
have been shown to
interact with the active
site of COX1/2.
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Figure 5-2: A) displays a schematic representation of COX1 and COX2. The
location of Ser530 and Ser516 are indicated in bold (the residues acetylated by
ASA and APHS on COX 1 and 2, respectively). Other key residues are indicated
for schematic orientation. Important differences to note are the larger overall size
of COX2 vs COX1 (72 kDA vs 68 kDa) and the hydrophobic side pocket on
COX2 absent in COX1. B) displays the same schematic representations of COX1
and COX2, with ASA superimposed over the active site of COX1 and APHS
superimposed over the active site of COX2. The longer, hydrophobic tail of APHS
leverages the overall larger enzymatic structure and side pocket unique to COX2
in order to attain 60x greater affinity to COX2 compared to ASA. ASA has
approximately 20x greater specificity to COX1 vs. COX2.
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5.2.2

Inflammatory and Wound Healing Cytokines

Ocular tissues respond to injury or insult by eliciting the cellular programs defined
grossly as inflammation and wound healing. Specific factors, found within the
aqueous humor and surgical sites of ophthalmic patients, are thought to drive
inflammatory and fibroproliferative responses observed in ocular tissues.84–88 To
model these in vitro, we used physiologically relevant mixtures (1ng/ml each) of
inflammatory and wound healing cytokines IL-1β (SRP6169), TNFα (SRP2102),
INFɣ (MSST0040) and TGFβ1 (T7039), all from Sigma-Aldrich.

5.2.3

Isolation and Culture of Tenon’s Capsule Fibroblasts

This study followed the tenants of the Declaration of Helsinki and was approved
by the office of Human Research Ethics at Western University (REB# 106783).
Primary ocular fibroblast cell lines were derived from 2-4 mm3 surgically resected
segments of Tenon’s capsule. After the acquisition of informed consent, tissue
specimens were obtained from male and female glaucoma patients undergoing
primary trabeculectomy at St. Josephs’ Hospital, London, Canada. The samples
were obtained by ophthalmic surgeons who removed segments of Tenon’s
capsule and placed them into primary culture growth media containing Dulbecco
modified Eagle's minimal essential medium (DMEM), 10% Fetal Bovine Serum
(FBS), 1% penicillin/streptomycin, and 1% amphotericin, all from Sigma-Aldrich
(Oakville, Canada). After, specimens were placed in fibronectin (Sigma-Aldrich)
coated 6-well culture plates, submerged in primary culture media, and
subcultured upon confluency for further use. Cell cultures were used for
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experimentation prior to passage five. Table 3-1 provides a summary of donor
characteristics for the ocular fibroblast cell lines used in experiments.

5.2.4

Stimulated Lipid Mediator of Inflammation / Resolution
Secretion Assays

Relative quantification of secreted pro-inflammatory and pro-resolving lipid
mediators was achieved using liquid chromatography tandem mass spectrometry
(LC-MS/MS). Specifically, we focused our analyses on the COX2 derived lipid
mediators, kPGF1a and PGE2; as well as the acetyl-COX2 derived mediators, 5HETE, 15-HETE, 17-OHDHA and 18-HEPE; and their PUFA precursors, AA,
DHA and EPA. Known quantities of deuterated internal standards of the analyzed
the lipid mediators were added to each sample to enable relative quantification
between samples (Item Numbers: #10007737, #320110, #314010, #11182,
#315210, #319030, #390030, #10006410, #10006199, #334230, and
#10008040, Cayman Chemical). This is a well-established method to determine
the relative activity of lipid biosynthetic pathways.233,234 In brief, the ratios of the
integrated areas of the chromatographic peaks corresponding to each analyte
and the integrated areas of the peaks corresponding to each analyte’s internal
standard (with known absolute quantity) are used to determine the relative
quantity of each analyte in a given sample. After supernatant sample collection,
250ul of methanol containing 100pg of each deuterated internal standard was
added. Samples were then vigorously vortexed and centrifuged at 10,000g for
10min before loading onto solid-phase extraction cartridges (Strata-X 33um
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Polymeric Reversed Phase, 10mg, Phenomenex 8B-S100-AAK), that were
previously activated with 2ml methanol and rinsed with 2ml water. Samples were
diluted upon loading so that the final concentration of methanol was between 10
and 15% of total volume. After washing with 5ml water, extracts were eluted with
1ml methanol. Solvent was then evaporated under vacuum in a SpeedVac
centrifuge, and the extract was resuspended in 100μl acetonitrile/water 60:40
(v/v). An aliquot of 20μl was injected into the LC-MS/MS system for analysis. A
Sciex ExionLC Integrated System was used with a 0.3ml/min flow rate, initial
mobile phase of 10% water / 0.1% formic acid followed by 100% acetonitrile /
0.1% formic acid on a Kinetex 2.6um C18 100 Å 100x2.1mm, Phenomax column
(OOD-4462-AN). A Sciex Triple Quad 6500+ mass spectrometer with multiple
reaction monitoring was used in negative ion mode. The chromatographic profile
of the ion count for each m/z transition was monitored, and the area under the
peaks (ion intensity vs elution time) was integrated using commercial software
(MultiQuant, Sciex). Total cellular protein concentration was used for
normalization of the supernatant samples.

5.2.5

Collagen Contraction Assays

The delayed release fibroblast populated collagen lattice model,185 based on the
model first proposed by Bell,186 was used to assess the effects of experimental
treatments on ocular fibroblast-mediated gel contraction. In brief, ocular
fibroblasts were mixed within an extracellular matrix (ECM) mixture containing
80% type I collagen (1.8mg/ml; A1048301, Gibco), 16% neutralizing solution
(equal parts Waymouth media (Sigma-Aldrich) and 0.275M NaOH) and 4%
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vol./vol. ocular fibroblast conditioned media (concentrated to 25x to obtain a 1x
final concentration within the 500μl construct volume) in order to achieve a final
cell density of 2.5 x 105 cells/mL within the solution. Cell free collagen lattices
were prepared identically, albeit without the inclusion of ocular fibroblasts, as
negative control. The solution was pipetted gently to ensure homogenous
distribution of ocular fibroblasts while avoiding the production of air bubbles, then
500μl were pipetted into each well of a 24-well tray. Collagen constructs were
allowed to polymerize at 37°C and 5% CO2 for 45 minutes before adding low
serum culture media containing DMEM, 2% Fetal Bovine Serum (FBS), 1%
penicillin/streptomycin.
After incubation at 37°C and 5% CO2 for 72 hours, a sterile spatula was used to
detach each collagen construct from the edges of the culture well. Plates were
then immediately scanned on a flatbed laser scanner (Scanjet 8200, HewlettPackard) to record baseline area, and then periodically for the duration of the
experiment. The surface area of each collagen construct was measured using
ImageJ187 and standardized against the baseline surface area measurement to
express changes in area as a percentage of original surface area.

5.2.6

Collagen Remodeling Assays

To assess collagen remodeling unconfounded by cell-mediated contraction,
collagen constructs were left attached to culture wells for the duration of the
experiment. At experimental conclusion (12 days incubation), collagen constructs
were fixed in 4% paraformaldehyde for 3h. After fixation, they were dehydrated in

122

ethanol, embedded in paraffin blocks, sectioned (5µM) and mounted on glass
microscope slides using standard methods. Sections were deparaffinized and
hydrated using standard protocols. Sections were then stained with picrosirius
red. Briefly, a solution of 0.1% Sirius red in saturated picric acid was applied for
60 min, followed by 2 x 0.5% acetic acid washes. Collagen birefringence, used to
determine collagen fibrillar hue,188 was assessed by circularly polarized light
microscopy of picrosirius red stained sections. Images were taken with an Abrio
quantitative birefringence imaging system (Hinds Instruments) mounted on an
Olympus BX-51 microscope. Specifically, a constant light intensity, a 45° angle to
the polarizing filter and the same analyzer were used to facilitate comparisons
between each sample.
When viewed under polarized light, the color of the collagen fibers stained with
picrosirius red depends upon fiber thickness, spatial orientation and packing
density; with the color changing from blue to yellow to orange to red as fiber
maturity, thickness and density increase.189,190 This method has been used
previously in rabbit experimental filtration surgery to examine subconjunctival
fibrosis, and blue(green)/yellow staining was associated with improved bleb
function.105 Using ImageJ, this property was leveraged to determine the relative
proportions of different color fibers within the stained collagen constructs. This
quantitative method has been previously described,191 and is employed within the
current experiment to assess changes in collagen architecture due to the
remodelling activity of ocular fibroblasts. In short, relative color content of the
images is obtained by separating the digital images into their hue, saturation and
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value components. The hue component contains information on the color of each
pixel within the image. Every pixel can have one of 256 possible colors. To
identify the relative proportions of red, orange, yellow and blue pixels within a
given image, a propriety script was written and run using the following hue
definitions within ImageJ: red 2-9 and 230-256, orange 10-38, yellow 39-51 and
green 52-128. The number of pixels within each hue range is calculated and
expressed as a proportion of the total number of pixels.

5.2.7

Fluorescent Microscopy

Expression of the contractile protein alpha smooth muscle actin (α-SMA), the
myofibroblastic phenotype marker,255 by ocular fibroblasts within collagen
constructs was assessed through immunohistochemistry. Deparaffinized and
hydrated sections were permeabilized for 30 minutes with 1% Triton X-100 in
PBS. After blocking of nonspecific sites with 1% BSA in PBS, sections were
incubated for 40 minutes with Alexa Fluor 568–conjugated primary antibody
against α-SMA (Abcam, CAT. NO: ab202295). Finally, slides were stained with
4,6-diamidino-2-phenylindole for 10 minutes. For each tissue section, the area
positive for α-SMA staining was measured in ImageJ and then divided by the
number of nuclei counted within that same frame, this number was then
compared between treatment groups. Ten random frames were taken per tissue
section, with five tissue sections imaged per patient cell line and treatment group.
Cellular proliferation was assessed through immunohistochemistry. Briefly,
deparaffinized and hydrated sections were permeabilized for 30 minutes with 1%
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Triton X-100 in PBS. After blocking of nonspecific sites with 1% BSA in PBS,
sections were incubated for 40 minutes with Alexa Fluor 568–conjugated primary
antibody against Ki-67 (Abcam, CAT. NO: ab197234) a marker of active cellular
proliferation.256 Slides were then stained with 4,6-diamidino-2-phenylindole for 10
minutes and imaged with a laser-scanning confocal microscope (A1R HD; Nikon
Instruments Inc., Tokyo, Japan). Cells were counted by nuclei using ImageJ, and
the proportion expressing Ki-67 was taken as an estimate of relative cellular
proliferation between treatment groups. Ten random frames were taken per
tissue section, with five tissue sections imaged per patient cell line and treatment
group.
Collagen constructs were cast with equal cell density, therefore there should be
equal variance in cell density between treatment groups after the experimental
incubation period. This was assessed through fluorescent microscopy. Briefly,
deparaffinized and hydrated sections were permeabilized for 30 minutes with 1%
Triton X-100 (Sigma-Aldrich) in PBS (Sigma-Aldrich). Slides were then stained
with 4,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) for 10 minutes and
imaged with a laser-scanning confocal microscope (A1R HD; Nikon Instruments
Inc., Tokyo, Japan). Relative cell density was determined by cell (nucleus) count
standardized to area of collagen autofluorescence (in pixels) within each section
and measured using ImageJ. Ten random frames were taken with the 40x
objective per tissue section, with three tissue sections imaged per patient cell line
and treatment group. The laser intensity settings were kept consistent between
slides to facilitate consistent comparison between replicates.
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5.2.8

LIVE/DEAD Cytotoxicity Assays

To assess the relative cellular viability between different experimental conditions,
an in situ fluorescence-based LIVE/DEAD assay was used. This is a well
reported method for estimating the cytotoxicity of an intervention. In brief, two
florescent dyes, fluorescein diacetate and propidium iodide, are added to the
culture media surrounding the collagen constructs. Fluorescein diacetate is
converted into a blue fluorescent molecule by esterases within living cells.
Propidium iodide (red) cannot pass through a viable cell’s membrane, however it
can penetrate disordered areas of dead cell membranes and then intercalates
with the nuclear DNA. After a 5min incubation with the staining solution, collagen
constructs were washed with PBS and immediately imaged on a laser-scanning
confocal microscope (A1R HD; Nikon Instruments Inc., Tokyo, Japan). Ten
random frames were taken with the 20x objective per tissue section, with three
tissue sections imaged per patient cell line and treatment group. The laser
intensity settings were kept consistent between samples to facilitate consistent
comparison between replicates.
Using imageJ, blue signals were counted as living cells and totalled within every
frame. The same was done for red signals, and these were counted as dead
cells. The ratio of living (blue) to total (blue+red) cells was recorded.

126

5.2.9

Cell Culture and Western Blot

Ocular fibroblasts were grown in 6-well culture plates in DMEM with 10% FBS at
37°C and 5% CO2 until 80-90% confluent. The cultures were then starved of
serum for 24hrs, after which they were switched to experimental treatment media.
For experiments involving inhibition of PPARɣ, we used the small molecule
inhibitor GW9662 (Item Number: #70785, Cayman Chemical) at a concentration
of 1uM.
After 48hrs incubation with the indicated experimental treatment, western blot
was used to assess relative protein expression between the experimental
treatment groups. Briefly, cells were lysed in lysis buffer (PhosphoSafe Extraction
Reagent, Novagen) containing a protease inhibitor cocktail (P2714, SigmaAldrich) and the crude protein lysate (10μg) was resolved using a Novex
WedgeWell 4-20% tris-glycine gel (Invitrogen). Using an iBlot Gel Transfer
Device (IB1001, Invitrogen), the separated protein was transferred to a
nitrocellulose membrane (IB301001, iBlot Transfer Stack, Invitrogen) which was
then blocked with 5% (w/v) bovine serum albumin (Sigma- Aldrich) in Tris
buffered saline (TBST) for 1 hour at room temperature. The membranes were
incubated overnight at 4°C with primary antibody diluted in TBST containing 5%
BSA (w/vol). Primary antibodies used were as follows: collagen 1 (ab138492,
Abcam), αSMA (ab5694, Abcam), MMP9 (ab38898, Abcam), PPARɣ (sc-7273,
SantaCruz Biotechnology), SMAD2/3 (ab63672, Abcam), pSMAD2/3 (ab63399,
Abcam) and GAPDH (sc-47724, Santa Cruz Biotechnology, Inc.). After incubation
with primary antibodies, the blots were washed and hybridized with 1:3000 (v/v)
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dilutions of goat anti-rabbit or anti-mouse IgG conjugated with horseradish
peroxidase (Santa Cruz Biotechnology, Inc.). Visualization was accomplished by
applying WesternBright Quantum chemiluminescent reagent (Advansta, Inc.),
with GAPDH used as a protein loading control. Imaging and relative densiometric
quantification was accomplished using a ChemiDoc MP System (Bio-Rad
Laboratories, Inc.) connected to Image Lab (Version 6, Bio-Rad Laboratories,
Inc.).

5.2.10

Statistical Analysis

For reporting purposes, “N” denotes the number of biological replicates within an
experiment and “n” denotes the number of technical replicates performed of each
biological replicate. Comparisons between two groups were accomplished with
Student’s t test. When more than two groups were compared to each other at a
single time point, a one-way analysis of variance was used, followed by Tukey’s
post hoc test if necessary. In cases where more than two groups were compared
to each other at multiple time points, a two-way analysis of variance was used,
followed by Dunnett’s multiple comparisons post hoc test with a single pooled
variance if necessary. All statistical analyses were performed using Prism 8
(Version 8.01, GraphPad Software Inc.) statistical software. Values for *p < 0.05,
**p < 0.01, ***p < 0.001, and ****p < 0.0001 were considered significant.
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5.3 Results and Discussion
5.3.1

Within inflammation induced fibroblasts, melittin increases
the production of acetyl-COX2 products relative to COX2
products after ASA exposure

Relatively small amounts of acetyl-COX2 products have been measured in vivo
after ASA-induced COX2 acetylation in humans.226 This led us to hypothesize
that the acetylated COX2 enzyme may be limited in its production of acetyl-COX2
products, potentially by the competitive inhibitory activity of the co-localized
salicylate ion – the byproduct of ASA’s de-acetylation. In an effort to displace the
salicylate ion from the active site of acetyl-COX2, we employed an extremely
potent phospholipase A2 agonist to increase the availability of PUFA precursors
for downstream processing through COX2 or acetyl-COX2. Melittin, isolated from
wasp venom, directly increases the activity of PLA2 and is responsible for the
swelling associated with their sting. It was previously measured to profoundly
increase the production of AA by PLA2 in cell based systems.257,258
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To assess the impact of COX2 Ser516 acetylation on inflammation induced
ocular fibroblasts, they were pre-incubated with inflammatory and wound healing
cytokines (Inf. Cytokines: 1ng/ml each of IL-1β, TNFα, INFɣ and TGFβ1) for 12
hours before being treated with vehicle, ASA alone or ASA+Melittin (a potent
phospholipase A2 agonist). Melittin significantly increased the relative abundance
of precursor PUFA’s compared to both vehicle and ASA only treated ocular
fibroblasts, by 200 to 400 fold (Figure 5-3A-C). ASA alone impaired the secretion
of PG products kPGF1a (Figure5-3D) and PGE2 (Figure5-3E), however no
significant increases were observed in acetyl-COX2 derived products, 5-HETE
(Figure5-3F), 15-HETE (Figure5-3G), 17-OHDHA (Figure5-3H) and 18-HEPE
(Figure5-3I). When melittin was combined with ASA, significant increases were
observed in all lipid mediators analyzed (Figure5-3D-I). While the relative PG
secretion was increased by approximately 2 to 20-fold, the relative RM secretion
was increased by 3 to 400-fold – depending on the mediator analyzed. This
suggested that a small fraction of un-acetylated COX2 was still present at the
concentration of ASA assayed, however, a much greater proportion of the
acetylated enzyme was likely present which accounts for the dramatic relative
difference observed in COX2 vs. acetyl-COX2 product secretion.

130

Figure 5-3 Relative inf. cytokine-induced LM secretion was determined by
supernatant sampling and LC-MS/MS analysis at the indicated timepoints after
exposure of inf. cytokine induced ocular fibroblasts to the indicated experimental
treatment. A-C) PUFA precursors: AA, EPA and DHA. D-E) COX2 prostaglandin
products: kPGF1a and PGE2. F-I) Acetyl-COX2 RM products: 5-HETE, 15HETE, 18-HEPE and 17-OHDHA. A-I) Two-way ANOVA with Dunnett’s post hoc
test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Figure 5-4 summarizes the relative biosynthetic activity of acetyl-COX2 vs. COX2
enzymes. The mean relative production of COX2 products (PGE2 and kPGF1a)
was calculated and from this figure the mean relative production of acetyl-COX2
products (5-HETE, 15-HETE, 17-OHDHA and 18-HEPE) was subtracted. This
way a value of zero would indicate equal relative biosynthetic activity between
acetyl-COX2 and COX2 enzymes; positive values would indicate COX2
dominated biosynthesis of lipid mediators; and negative values would indicate
acetyl-COX2 dominated lipid mediator biosynthesis. Under induced inflammatory
conditions, ASA slightly reduces the proportion of COX2 derived products relative
to acetyl-COX2 products, and that the addition of melittin causes a profound shift
toward acetyl-COX2 dominated lipid mediator production - by several orders of
magnitude (Figure5-4A).
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Figure 5-4 Lipid mediator secretion is shifted from a pro-inflammatory to a proresolving profile. Graphs display the differential mean relative secretion between
pro-inflammatory mediators (PGE2 and kPGF1a) and pro-resolving mediators (5HETE, 15-HETE, 18-HEPE and 17OH-DHA). A value of zero indicates equal
relative biosynthetic activity between acetyl-COX2 and COX2; positive values
indicate COX2 dominated biosynthesis of lipid mediators; and negative values
indicate acetyl-COX2 dominated lipid mediator biosynthesis. Supernatant was
sampled from cultured ocular fibroblasts after co-incubation with inf. cytokines
and one of: A) ASA ± melittin (µg/ml, N=3), B and C) ASA ± gentamicin (µg/ml,
N=4), or D) APHS ± gentamicin (µg/ml, N=4) at the indicated timepoints. The
vehicle control was serum free DMEM and did not contain inf. cytokines.
Differential mean relative secretion: ((PGE2 + kPGF1a) / 2) – ((5-HETE + 15HETE + 18-HETE + 17-OHDHA)/4). Two-way ANOVA with Dunnett’s post hoc:
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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5.3.2

Less potent PLA2 agonist and more specific COX2 Ser516
acetylating agent exert similar modulatory effects on lipid
mediator production

Previous authors have modelled lipid derived signaling molecules similar to
neurotransmitters in that, theoretically, modulation of signaling activity should be
preferred to its abrogation.259 The concept of modulating the production of LMs to
avoid the negative consequences of inflammation on patient tissues is not new.
The competitive NSAID drugs partially block COX2, eliciting a dampening of PG
production and therefore mitigating their impact. However, altering enzymatic
activity in order to stimulate PUFA precursor production at the same time as
redirecting the bulk of the downstream, now acetylated, COX2 enzymatic activity
toward RM production is a novel approach, and has the potential to function as
an immuno-resolvent intervention. Immuno-resolvents are theoretically preferable
to immuno-suppressive modalities. Thus, we wished to determine if additional
molecules with similar effects on COX2 and PLA2 could recreate the modulatory
effects observed in the previous LM secretion experiment with ASA and melittin.
The second LM secretion experiment we conducted involved the gentler PLA2
agonist, gentamicin,260 and the more potent COX2 Ser516 acetylating agent,
APHS. APHS possesses the same COX2 Ser516 acetylating function as ASA,
and, due to its larger lipophilic structure, it was shown to be approximately 20x
more specificity for COX2 over COX1.254 For reference, ASA has previously been
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measured to have approximately 10 to 20 times greater specificity for COX1 over
COX2.261,262
Gentamicin had a small stimulatory effect on the relative secretion of PUFA
precursors AA, EPA and DHA when compared to the inf. cytokines induction
group (Figure 5-5A-C). Both ASA and APHS were able to significantly reduce the
secretion of PG products kPGF1a (Figure 5-5D-F) and PGE2 (Figure 5-5G-I).
The addition of gentamicin to any experimental treatment group had no effect on
PG synthesis (Figure 5-5D-I). These results confirmed the ability of both COX2
Ser516 acetylating agents to prevent PG synthesis within ocular fibroblasts.
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Figure 5-5 Relative inf. cytokine-induced LM secretion was determined by
supernatant sampling and LC-MS/MS analysis at the indicated timepoints after
exposure of inf. cytokine induced ocular fibroblasts to the indicated experimental
treatment. A-C) PUFA precursors: AA, EPA and DHA. D-I) COX2 prostaglandin
products: kPGF1a and PGE2. A-I) Two-way ANOVA with Dunnett’s post hoc test:
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

When examining the secretion of RMs, we noticed ASA had a small stimulatory
effect on 5-HETE (Figure 5-6A), 15-HETE (Figure 5-6D) and 18-HEPE (Figure
5-6G) secretion in the presence of inf. cytokines, relative to inf. cytokines alone.
However, the significant effects observed were transient and small. APHS alone
had a profoundly significant stimulatory effect on the relative secretion of 5-HETE
(Figure 5-6C), which peaked at 6hrs and returned to inf. cytokine treated only
levels by 24hrs. APHS alone also had profound stimulatory effects on 15-HETE
(Figure 5-6F) and 18-HEPE (Figure 5-6I) secretion under inflammatory
conditions, relative to inf. cytokine treatment alone, and remained significant past
48hrs post-treatment. Finally, when ASA or APHS were combined with
gentamicin, significant and lasting increases in 5-HETE (Figure 5-6B and C), 15HETE (Figure 5-6E and D) and 18-HEPE (Figure 5-6H and I) in were observed in
the presence of inf. cytokines, relative to either ASA or APHS alone in the
presence of inf. cytokines. To our knowledge this is the first characterization of
acetyl-COX2 products being triggered by APHS exposure under inflammatory
conditions.
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Figure 5-6: Relative inf. cytokine-induced LM secretion was determined by
supernatant sampling and LC-MS/MS analysis at the indicated timepoints after
exposure of inf. cytokine induced ocular fibroblasts to the indicated experimental
treatment. A-C) PUFA precursors: AA, EPA and DHA. D-I) Acetyl-COX2 RM
products: 5-HETE, 15-HETE and 18-HEPE. A-I) Two-way ANOVA with Dunnett’s
post hoc test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
Figure 5-4B, C and D illustrate the summary effects of ASA, APHS and
gentamicin on the relative secretion of COX2 vs acetyl-COX2 products. ASA and
APHS alone were both able to disrupt COX2 activity and induce a significant and
dose dependent shift toward acetyl-COX2 dominated LM production. When
gentamicin was combined with ASA or APHS, significantly greater acetyl-COX2
activity was observed relative to ASA or APHS alone in the presence of inf.
cytokines. These results support ASA and APHS having similar modulatory
effects on the production of pro-inflammatory and pro-resolving lipid mediators.
Results also demonstrate that both melittin and gentamicin can augment the proresolving effects of COX2 acetylating molecules.

5.3.3

COX2 acetylation inhibits in vitro wound healing, PLA2
agonist increases effect

Cell-mediated extracellular matrix contraction is a hallmark of in vivo wound
healing. We assessed the effects of lipid mediator modulation using ASA and
gentamicin on cell-mediated collagen contraction. A collagen contraction assay
with a double dose response for each drug was used to determine the optimal
concentrations for inhibition of cell-mediated contraction. Gentamicin did not have
a significant effect on cell-mediated collagen contraction at any tested
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concentration (Figure 5-7A). Alone, ASA significantly impaired cell-mediated
collagen contraction in a dose dependent manner (Figure 5-7B). Gentamicin was
not able to increase the effect of low dose ASA on cell-mediated collagen
contraction (Figure 5-7C); however, significantly greater inhibitory effects on cellmediated contraction were seen when gentamicin was combined with higher
doses of ASA (Figure 5-7D and E).
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Figure 5-7 Effects of ASA and gentamicin on ocular-fibroblast mediated collagen
contraction. A) Gentamicin alone had no significant effect relative to vehicle
control on the area of collagen expressed as a proportion of baseline area at any
timepoint. B) ASA alone had a dose dependent inhibitory effect. C) The effects of
500 µg/ml ASA were not significant, and not potentiated significantly by
gentamicin, although a trend was evident. D) The effects of 1000 µg/ml ASA
were significantly inhibitory, and gentamicin significantly increased the observed
inhibition. E) The effects of 1500 µg/ml ASA were significantly inhibitory, and
gentamicin significantly increased the inhibition observe. A-E) Two-way ANOVA
with Dunnett’s post hoc test: N=3, n=2; *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
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Two-drug dose-optimization is illustrated in Figure 5-8A. Complete inhibition of
cell-mediated collagen contraction was achieved with 2000 μg/ml of ASA and
1000μg/ml gentamicin (Figure 5-8B). Cell-mediated collagen remodeling was also
assessed under the indicated treatment conditions (Figure 5-8C). Cell free
collagen matrices stained a uniform blue with picrosirius red staining, indicating a
homogeneous and loosely packed collagen fibril arrangement. When ocular
fibroblasts were cultured within the collagen matrices, areas of red, orange and
yellow staining became apparent, which are regions of high collagen fibril density
and are inferred to indicate the local occurrence of cell-mediated collagen
remodeling. ASA alone was able to decrease the relative proportion of red,
orange and yellow stained collagen fibrils within matrices containing ocular
fibroblasts, implying an impairment of cell-mediated matrix remodeling. When
gentamicin was combined with ASA, an even greater inhibition of cell-mediated
matrix remodeling was observed relative to both ASA alone and vehicle control.
Matrices and the contained cells were fixed and stained immunohistochemically
to evaluate cellularity (Figure 5-8D) as well as the expression of myofibroblastic
and proliferative biomarkers, αSMA (Figure 5-8E) and Ki-67 (Figure 5-8F)
respectively. Combined, ASA and gentamicin treatment had an inhibitory effect
on cellularity, as measured by the number of nuclei per unit area of collagen
section. Combined, ASA and gentamicin were able to significantly reduce the
amount of αSMA staining per nuclei relative to vehicle control. Finally, the
combination treatment was able to significantly decrease the proportion of cells
expressing Ki-67 within the collagen matrix relative to vehicle control. These data
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suggest that the LM modulating composition, ASA and gentamicin, causes an
impairment of the wound healing related functions and biomarkers of ocular
fibroblasts.
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Figure 5-8 ASA ± gentamicin can modulate the unstimulated in vitro wound
healing functions of ocular fibroblasts. A) Graph representing the effects of ASA
and gentamicin (µg/ml) on the ocular fibroblast-mediated contraction of collagen
matrices. Bars depict mean ± SD area (as a proportion of baseline area) of
collagen remaining after 96hrs of contraction (N=3, n=3). B) Temporal effects of
ASA ± gentamicin (µg/ml) on cell-mediated collagen contraction over a period of
96hrs. Two-way ANOVA with Dunnett’s post hoc test (N=6, n=3; *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001). C) The effects of ASA and gentamicin
(ug/ml) on ocular fibroblast-mediated collagen remodelling after 12 days
incubation. Picrosirius red stain: collagen fibril density increases as color
changes from blue to yellow to orange to red. One-way ANOVA with Tukey’s
post hoc test: N=3, n=3, frames=10; *p<0.05, **p<0.01, ***p<0.001. D) After 12
days of culture, effects of ASA combined with gentamicin (µg/ml) on the number
of fibroblasts per unit area of collagen matrix (N=3, n=3, frames=10. E) ASA and
gentamicin (µg/ml) reduced the amount of area positive for αSMA per nuclei
within the collagen matrix (N=3, n=3, frames=10), and F) the proportion of nuclei
that stained positive for the proliferative biomarker, Ki-67, was also reduced
(N=3, n=3, frames=10). D-F) Student’s t test: **p<0.01, ***p<0.001, ****p<0.0001.
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5.3.4

COX2 acetylation w/PLA2 agonist can overcome TGFβ1
induced collagen contraction

To assess how robust the inhibition of cell-mediated collagen contraction
observed with COX2 acetylation was, we added 2ng/ml TGFβ1 to the culture
media of actively contracting collagen constructs at the experiment’s midpoint
(Figure 5-9A). During the two days prior to TGFβ1 stimulation, a dose dependent
inhibition of contraction was observed for both concentrations of ASA assessed.
Further, gentamicin was able to significantly augment these effects. After TGFβ1
stimulation, contraction was accelerated greatly in the control groups, however
less so in the ASA treated groups. In fact, after TGFβ1 stimulation, the dose
dependent, ASA-induced impairment of contraction became more apparent and,
the effect continued to be significantly augmented by gentamicin. Cellular viability
was assessed within the collagen constructs by incubating them in FDA and PI to
label living and dead cells, respectively, and then imaging on a confocal laser
scanning microscope (Figure 5-9B and C). When the ratio of living cells to total
cells was compared across treatment groups, there were no significant
differences observed between any of the groups assessed. This suggests the
observed treatment effects stem from a modulation of cellular activity as opposed
to the by-product of a cytotoxic effect.
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Figure 5-9 The effects of ASA and gentamicin can overcome TGFb1-induced
cell-mediated collagen contraction without suppressing cellular viability. A) Uninduced contraction was assessed for the first 48hrs with the indicated
experimental treatments, after 48hrs of experimental conditions, 2ng/ml was
added to the culture media to assess the lasting ability of experimental
treatments to impede TGFb1-induced contraction. No further experimental
treatments were added at this point. Results of two-way repeated measures
ANOVA with Dunnett’s post hoc test. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001 for 1500ASA+750G vs. 1500ASA. B) Relative cellular viability was
compared at the conclusion of the contraction assay by in situ LIVE/DEAD
staining. One-way ANOVA showed no significant differences between groups
(N=3, n=3, frames=10). C) Representative LIVE/DEAD fluorescent micrographs
for the indicated treatment groups.

5.3.5

Inhibition of Inf. Cytokine-induced wound healing with COX2
acetylation and PLA2 agonist is comparable to that of
mitomycin C in vitro

To model the ocular scarring in vitro, we assessed cell-mediated collagen
contraction in the presence of inf. cytokines and compared the inhibitory actions
of COX2 acetylation to that of a short duration exposure to MMC – the current
clinical gold standard for reducing sub-conjunctival scarring (Figure 5-10A). Inf.
cytokines significantly stimulated cell-mediated collagen contraction relative to
vehicle control, supporting these growth factors’ contribution to the pathological
changes observed in the subconjunctiva after glaucoma surgery. On its own,
ASA was able to significantly inhibit inf. cytokine-induced collagen contraction
(Figure 5-10A). The effect size, however, was significantly smaller than that of a
four-minute MMC application immediately prior to the initiation of contraction.
When gentamicin was combined with ASA, the effect size increased significantly
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and was statistically indistinguishable from that of a 4-minute exposure to MMC
prior to contraction (Figure 5-10A and D). Cellular viability was assessed within
the collagen constructs to assess the contribution of cytotoxicity to the observed
effects on cell-mediated collagen contraction (Figure 5-10B and C). Relative to
vehicle control, exposure to all tested durations of MMC exposure significantly
decreased the proportion of living to total cells – confirming MMC’s cytotoxic
mechanism of action. No significant differences in cellular viability were observed
relative to vehicle control with exposure to either ASA alone or in combination
with gentamicin.
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C)
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D)

Figure 5-10 ASA ± gentamicin (µg/ml) can modulate inf. cytokine induced in vitro
wound healing functions of ocular fibroblasts without increased cell death. A) Inf.
cytokines potentiate ocular fibroblast-mediated collagen contraction relative to
vehicle control. Proportion of baseline area remaining at the indicated timepoints is
reported for the indicated experimental groups (N=5, n=3). B) After 96hrs of
contraction, relative cytotoxicity of exposures was assessed by LIVE/DEAD
staining of collagen matrices and comparing the proportion of living (blue) to total
cells (blue + red) within the collagen matrices (N=4, n=3, frames=10). C)
Representative LIVE/DEAD images of the indicated treatment groups. D)
Representative scans of collagen matrices exposed to the indicated treatments
and allowed to contract for 96hrs. A) Two-way ANOVA with Dunnett’s post hoc
test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. B) One-way ANOVA with
Tukey’s post hoc test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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APHS impaired cell-mediated collagen contraction in a dose dependent manner,
and the effect was significantly augmented by gentamicin at all tested dose
(Figure 5-11A). At the highest dose, APHS alone was significantly more effective
at impairing contraction than a 4-minute exposure to MMC, however the effect
was transient and lost significance after 48hrs. The combination of APHS and
gentamicin, at the highest dose, was significantly more effective than a fourminute exposure to MMC at impairing inf. cytokine-induced collagen contraction.
Figure 5-11B displays representative scans of contracted collagen matrices
clearly displaying the described effects.

A)
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Figure 5-11 APHS, ASA ± gentamicin (µg/ml) can modulate inf. cytokine induced in
vitro wound healing functions of ocular fibroblasts without increased cell death. A)
effects of APHS ± gentamicin on the inf. cytokine-induce ocular fibroblast-mediated
contraction of collagen matrices relative to a 4 minute exposure to MMC (N=4, n=3).
B) Representative scans of collagen matrices exposed to the indicated treatments
and allowed to contract for 96hrs. A) Two-way ANOVA with Dunnett’s post hoc test:
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. C) One-way ANOVA with Tukey’s post
hoc test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Relative cellular viability was again compared between experimental treatments
(Figure 5-12A and B). Relative to the inf. cytokine control, APHS alone or in
combination with gentamicin did not have a significant effect on cellular viability.
Together, these results suggest that the modulation of lipid mediators with COX2
Ser516 acetylating agents is associated with a modulation of fibroblast function.
The effect of MMC appears to be mediated through cytotoxic means, whereas
the effects of COX2 acetylating agents do not seem to be mediated through
cytotoxic means.
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A)

B)

Figure 5-12 A) Effects of APHS ± gentamicin (µg/ml) on the cellular viability
(N=3, n=6, frames=10). B) Representative LIVE/DEAD images of the indicated
treatment groups. A) One-way ANOVA with Tukey’s post hoc test: *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001.
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5.3.6

COX2 acetylation inhibits inf. cytokine-induced myofibroblast
metabolic activity and pathognomonic protein expression

We wished to investigate the effects of COX2 acetylation on the fibroblast and
myofibroblast phenotype as a means to better understand the mechanism
responsible for modified function within collagen-based culture. First, we
assessed the effect of ASA and APHS on the metabolic activity of TGFβ-induced
myofibroblasts and control ocular fibroblasts (Figure 5-13A and B). Both COX2

A)

Figure 5-13 Effects of A) ASA, or B) APHS (µg/ml) on the TGFb1 (2ng/ml)induced metabolic activity ocular fibroblasts. A-B) Results from MTT assays
48hrs after the indicated treatments, the optical density of the experimental
groups was normalized to the vehicle control group. One-way ANOVA with
Tukey’s post hoc test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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acetylating agents had a relatively small effect on the metabolic activity of the
non-induced fibroblasts, until the extreme of the dose range tested. TGFβ1 had a
significant stimulatory effect on fibroblast metabolic activity. When TGFβ1 was
co-incubated with either COX2 acetylating agent, a significant reduction in
metabolic activity was noted, with return to non-TGFβ stimulated levels in a dose
dependent manner.
The protein alpha smooth muscle actin (αSMA) is pathognomonic of the
myofibroblast phenotype and essential for contraction of the extracellular matrix
to occur. Matrix metalloproteinase nine (MMP9) is essential for invasion and
remodeling of the extracellular matrix. Using monolayer cell culture and western
blot, we found that inf. cytokines induced differentiation of ocular fibroblasts into
myofibroblasts, exhibiting increased expression of both αSMA and MMP9 relative
to non-induced fibroblasts (Figure 5-14A and B). The inf. cytokines-induced
expression of αSMA and MMP9 expression was significantly reversed ASA in a
dose dependent manner (Figure 5-14A). APHS, at the concentration assessed
(10μg/ml), has approximately equal COX2 acetylating power as 500μg/ml ASA
(1/60th as many moles, with approx. 60x COX2 specificity). It was also able to
significantly inhibit the observed inf. cytokine-induced expression of αSMA
(Figure 5-14B). These results support the impairment of myofibroblast
transdifferentiation by both COX2 acetylating agents.
The effects of adding the PLA2 agonist, gentamicin, was assayed using the same
methodology (Figure 5-15A-C). Gentamicin alone had no significant effect on the
inf. cytokine-induced expression of collagen 1 and αSMA. Both ASA and
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APHS were able to impair the cytokine induced expression of collagen 1 and
αSMA on their own. The effects of both COX2 acetylating agents on inf. cytokineinduced collagen 1 and αSMA expression were significantly potentiated by their
co-incubation with gentamicin.

A)

B)

Figure 5-14 Assessment of inf. Cytokine induced αSMA and/or MMP9 expression
by western blot of ocular fibroblast total protein lysate after 48hrs of culture with
the indicated exposures (µg/ml). Results from a one-way ANOVA with Tukey’s
post hoc test are shown. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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A)

B)
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C)

Figure 5-15 Effects of APHS, ASA ± gentamicin (µg/ml) on the cytokine-induced protein expression of
ocular fibroblasts. A-B) Expression of αSMA and collagen 1 by western blot of ocular fibroblast total
protein lysate after 48hrs of culture with the indicated exposures. C) Representative western blots from
two patient replicates. A-B) One-way ANOVA with Tukey’s post hoc multiple comparisons test: *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001

5.3.7

COX2 acetylation results in differential regulation of
transcription factors PPARɣ and SMAD2/3

Previous work has demonstrated the ability of ASA to suppress MMP9
expression in mouse celiac macrophages.239 These authors’ conclusions
implicated activation of PPARɣ as mechanistic rationale for the ASA-induced
changes in protein expression. Conceptually, these findings are supported by our
findings that the production of endogenous PPARɣ ligands, such as 15-HETE,263
can be generated by the acetylated COX2 enzyme. Another study reported the
effects of troglitazone, a potent synthetic PAPRy agonist, on collagen synthesis in
human hypertrophic scar fibroblasts.264 These authors found that agonizing
PPARɣ led to impaired collagen expression and demonstrated this to occur
through induction of miR-145, which itself causes inhibition of SMAD3. We
hypothesized that the same intracellular mechanisms were responsible for the
effects observed within ocular fibroblasts after exposure to ASA and APHS. We
expected to see differential regulation of PPARɣ and SMAD2/3 after COX2
acetylation (Figure 5-16).
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Figure 5-16 Schematic representation of the hypothesized mechanism leveraged
for the modulation of lipid mediator production.
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We first investigated the ability of ASA and APHS to influence PPARɣ after inf.
cytokine-stimulation. Inf. cytokines significantly inhibited PPARɣ expression
relative to vehicle control (Figure 5-17A and B). ASA was able to rescue inf.
cytokine-induced PPARɣ expression in a dose dependent manner, exceeding the
relative expression levels of the vehicle control group (Figure 5-17A). The effects
of APHS alone on PPARɣ expression were inhibitory relative to vehicle control,
however when APHS was co-incubated with inf. cytokine-induced fibroblasts, a
significant increase in PPARɣ expression level was observed relative to both inf.
cytokine control and vehicle control groups (Figure 5-17B). This finding in
particular supports the requirement for COX2’s induction before the therapeutic
effects of its acetylation can be observed.

Figure 5-17 Effects of A) ASA and B) APHS (µg/ml) on the transcription factors
PPARy. Expression of PPARy relative to GAPDH was assessed by western blot
of ocular fibroblast total protein lysate after 48 hours of culture with the indicated
exposures (N=5). A-B) One-way ANOVA with Tukey’s post hoc multiple
comparisons test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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To investigate the occurrence of a corresponding SMAD2/3 downregulation, we
analyzed the relative expression of both phosphorylated SMAD2/3 and total
SMAD2/3 (Figure 5-18). Inf. cytokines induced high levels of SMAD2/3
expression and phosphorylation relative to vehicle control. Gentamicin had no
effect on the inf. cytokine-induced phosphorylation or expression of SMAD2/3.
ASA and APHS were able to significantly repress both the inf. cytokine-induced
phosphorylation and expression of SMAD2/3, and gentamicin was able to
significantly augment the effects of both COX2 acetylating agents. The ratio of

Figure 5-18 APHS, ASA ± gentamicin’s (µg/ml) effects on the transcription factor
SMAD2/3 total expression and phosphorylation state. Expression of phosphorylated
SMAD2/3, total SMAD2/3 and the ratio of phosphorylated to total SMAD2/3 relative
to GAPDH after 48hrs of culture with the indicated exposures (N=5). One-way
ANOVA with Tukey’s post hoc multiple comparisons test: *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001.
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activated (phosphorylated) to total SMAD2/3 was returned to vehicle control
expression levels from inf. cytokine-induced levels with the application of
1000μg/ml ASA and 500μg/ml gentamicin or 12μg/ml APHS and 250μg/ml
gentamicin.
To confirm PPARɣ’s involvement in the effects observed, we co-incubated the
COX2 acetylating agents with a PPARɣ inhibitor, GW9662 (1 µM). When either
ASA or APHS were co-incubated with GW9662, no significant inhibition of inf.
cytokine-induced αSMA expression within ocular fibroblasts was noted (Figure 519A and B). These findings support PPARɣ’s role in mediating the effects of
COX2 acetylating agents on myofibroblast transdifferentiation.

Figure 5-19 PPARy inhibition (GW9662, 1 µM) attenuates the effects seen with
COX2 Ser516 acetylating agents. A) Densiometric analysis of multiple (N=4)
western blots. One-way ANOVA with Tukey’s post hoc test: ***p<0.001. B)
Representative western blot of total protein lysate from ocular fibroblasts 48hrs
after the indicated exposures. ASA (µg/ml); APHS (µg/ml).
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5.4 Conclusions
The presented evidence suggests that, within inflammation activated ocular
fibroblasts, the modulation COX2 and PLA2 enzymatic function and activity can
illicit a shift in pro-inflammatory and pro-resolving lipid mediator production that
greatly favors the generation of pro-resolving mediators. Under these conditions,
differential regulation of PPARɣ and SMAD2/3 were observed within ocular
fibroblasts and corresponded with inhibition of inflammation-induced
myofibroblast transdifferentiation. Together, these results suggest that the
resolution of inflammatory and fibroproliferative signaling can be triggered within
ocular fibroblasts by acetylation of COX2 at Ser516 and this effect appears to be
augmented by stimulation of PLA2 activity.
Inflammation induced myofibroblast transdifferentiation and activity remains one
of the largest unanswered contributors to ocular morbidity. To our knowledge, this
is the first report of COX2 Ser516 acetylating agents being used to trigger
endogenous mechanisms of resolution within ocular fibroblasts causing an
impairment of myofibroblast transdifferentiation and function. Immuno-resolvent
interventions are theorized to be associated with fewer off target effects, as they
function to promote the ordered return to homeostasis after inflammatory insult.
Immuno-suppressive interventions, on the other hand, attempt to prevent the
initial inflammation-induced deviation from homeostasis and hinder the
endogenous resolution of inflammation. A subtle difference, but one which
implies that immuno-resolvent interventions attempt to engage synergistically
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with an endogenous process, whereas immuno-suppressive interventions
attempt to counter an endogenously occurring process. The ready availability of
safety data pertaining to ASA’s human use should provide a rapid path to
assessing its efficacy in human ophthalmological pathologies. Based on the
presented data, APHS has the potential to exhibit even greater efficacy, and
animal studies assessing its ophthalmological safety and efficacy are warranted.
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Chapter 6

6

Summary and Future Directions

6.1 Overall Findings and Implications
Excessive myofibroblast transdifferentiation and activity within delicate ocular
structures is a major impediment to successful ophthalmological outcomes
across the discipline. This thesis focused on the critical wound healing that
occurs within the post-operative subconjunctival tissues of glaucoma surgery
patients, however wound healing is a fundamental process, and lessons from the
subconjunctiva could easily be translated to the other non-nervous tissues of the
eye.
This thesis began with a survey of risk factors for glaucoma surgery revision. We
used this large retrospective database study as a springboard for subsequent in
vitro investigation. The subsequently generated data was enough to successfully
fund a clinical trial that is scheduled to begin patient recruitment concurrent with
this thesis’s evaluation. Looking ahead and based on what was learned about
RMs impact on wound healing, we subsequently designed a novel immunoresolvent intervention that demonstrates significant efficacy in vitro at impairing
cytokine-driven subconjunctival wound healing phenomena.
The implications of this body of work are far reaching. Immediate benefit to
patients may be gained should NSAIDs outperform corticosteroids in the planned
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randomized controlled trial – as many NSAID eye drops are currently approved
and could easily be switched to as current standard of care. Long term benefits
may be derived from a deeper understanding of the interactions between
inflammatory mediator production, resolving mediator production and the
development of scarring. Understanding the effects of COX2 Ser516 acetylation
within animal models of progressive fibrotic diseases is warranted – especially
considering the recent discovery of an endogenous COX2 acetylating protein that
contributes to the resolution of neuroinflammation in mice.249 Strategies that
capitalize on the body’s endogenous resolving mechanisms to avoid the dangers
associated with inflammation are likely to enjoy more success than those which
act against endogenous systems. Such immuno-resolvent modalities should gain
a prominent position in the future fight against chronic inflammatory or
dysregulated inflammatory diseases.

6.2 Limitations
The study which inspired all subsequent investigations was retrospective in
nature, thus we could only assess exposures to drugs that are available to the
public. This resulted in a potential blind spot; the inability to investigate the effects
of novel wound modulating agents. Fortunately, there were two anti-inflammatory
drugs within the database records that exhibited significantly different
associations with surgical success, and I was subsequently inspired by their
differing mechanisms of action. However, this initial study set the direction for
future work, and this limitation undoubtedly restricted the theoretical framework
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upon which Chapters 3 to 7 are based. It was fortunate that NSAIDs and
corticosteroids lead me to investigate the interactions of LMs with wound healing,
as this is a novel area of research and supported much subsequent investigation.
Although we make a case for fibroblasts themselves being immune cells –
especially in the inflammatory and wound healing microenvironment – the
presented studies do not incorporate more classical examples of immune cells in
our models. The interaction of macrophages and other inflammatory cells with
fibroblasts is critical to the wound healing process34 and future studies should
incorporate co-cultures of the two cell types to more accurately recreate the in
vivo microenvironment. However, one can take comfort in the fact that the
interventions discussed within this thesis have a very high likelihood of mitigating
the impact of inflammatory cells in a similar manner – as almost all immune cells
express PLA2 and COX2. In fact the overall effects of these interventions may be
even more pronounced in inflammatory cells – as they have been shown to be
extremely sensitive to RM signals and subsequently function to locally amplify
their presence in vivo – potentially initiating a feedforward pro-resolution signal
from which any local fibroblasts would also benefit.18,265,266

6.3 Future Directions
In Chapter 6 we explored the intracellular signaling cascade mediating the effects
of COX2 Ser516 acetylators. We demonstrated involvement of SMAD2/3 and
PPARɣ in the transduced effects. Previous work has implicated miR-145 as
mediating PPARɣ-induced interference with SMAD2/3 signaling within human
172

hypertrophic scar fibroblasts.264 Investigating the potential role of this microRNA
in turning off myofibroblast associated gene sets in response to PPARɣ activation
should yield new knowledge and strategies to impair myofibroblast
transdifferentiation and activity.
Results presented warrant further investigation in animal models of ophthalmic
disease. There are several validated animal model systems in which these
interventions could be assessed for their anti-fibrotic properties. Corneal stromal
injury,267 posterior capsule opacification after cataract surgery,268 and ocular
neovascularization269 all have validated animal models and are natural
translations for the presented interventions.
Given the results in Chapter 6, APHS should be explored further as an immunoresolvent agent. Subsequent animal safety and toxicity studies, should they prove
promising, could open whole new avenues of research into more specific COX2
acetylating molecules and a new frontier for immuno-resolvent interventions.

173

References
1.

Shu, D. Y. & Lovicu, F. J. Myofibroblast transdifferentiation: The dark force in
ocular wound healing and fibrosis. Prog. Retin. Eye Res. (2017).
doi:10.1016/j.preteyeres.2017.08.001

2.

Skuta, G. & Parrish, R. Wound healing in glaucoma fltering surgery. Surv.
Ophthalmol. 32, (1987).

3.

Yamanaka, O., Kitano-Izutani, A., Tomoyose, K. & Reinach, P. S. Pathobiology of
wound healing after glaucoma filtration surgery. BMC Ophthalmol. 15 Suppl 1,
157 (2015).

4.

Zada, M., Pattamatta, U. & White, A. Modulation of Fibroblasts in Conjunctival
Wound Healing. Ophthalmology 125, 179–192 (2017).

5.

Serhan, C. N. & Savill, J. Resolution of inflammation: the beginning programs the
end. Nat. Immunol. 6, 1191–1197 (2005).

6.

Serhan, C. N. & Levy, B. D. Resolvins in inflammation : emergence of the proresolving superfamily of mediators. 128, 2657–2669 (2018).

7.

Coyne, C. B., Zeh, H. J., Lotze, M. T., Tang, D. & Kang, R. PAMPs and DAMPs:
signal 0s that spur autophagy and immunity. Immunol. Rev. 249, 158–75 (2012).

8.

Rubartelli, A. & Lotze, M. T. Inside, outside, upside down: damage-associated
molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 28, 429–436
(2007).

9.

Mack, M. Inflammation and fibrosis. Matrix Biology (2018).
doi:10.1016/j.matbio.2017.11.010

10.

Serhan, C. N., Arita, M., Hong, S. & Gotlinger, K. Resolvins, docosatrienes, and
neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirintriggered epimers. Lipids 39, 1125–1132 (2004).

11.

Smith, W. L. Prostanoid biosynthesis and mechanisms of action. Am. J. Physiol.
263, F181–F191 (1992).

12.

Leslie, C. C. Cytosolic phospholipase A 2 : physiological function and role in
disease. J. Lipid Res. 56, 1386–1402 (2015).

13.

Dhall, S. et al. Arachidonic acid-derived signaling lipids and functions in impaired
healing. Wound Repair Regen. 23, 644–656 (2015).

14.

Oga, T. Prostaglandin F2α receptor signaling facilitates bleomycin-induced
pulmonary fibrosis independently of transforming growth factor-β. Nat. Med. 15,
(2009).

174

15.

Liu, Y., Ko, J., Yanai, R., Kimura, K. & Chikama, T. Induction by Latanoprost of
Collagen Gel Contraction Mediated by Human Tenon Fibroblasts : Role of
Intracellular Signaling Molecules. Investig. Ophthalmol. Vis. Sci. 2, (2008).

16.

Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K. & Serhan, C. N. Lipid mediator
class switching during acute inflammation: signals in resolution. Nat. Immunol. 2,
612–619 (2001).

17.

Serhan, C. N. Discovery of specialized pro-resolving mediators marks the dawn of
resolution physiology and pharmacology. Mol. Aspects Med. (2017).
doi:10.1016/j.mam.2017.03.001

18.

Lopategi, A. et al. Frontline Science: Specialized proresolving lipid mediators
inhibit the priming and activation of the macrophage NLRP3 inflammasome.
Journal of Leukocyte Biology (2018). doi:10.1002/JLB.3HI0517-206RR

19.

Serhan, C. N. Novel Pro-Resolving Lipid Mediators in Inflammation Are Leads for
Resolution Physiology. Nature 510, 92–101 (2014).

20.

Serhan, C. N., Chiang, N. & Dalli, J. The resolution code of acute inflammation:
Novel pro-resolving lipid mediators in resolution. Semin. Immunol. 27, 200–215
(2015).

21.

Tian, H., Lu, Y., Sherwood, A. M., Hongqian, D. & Hong, S. Resolvins E1 and D1
in choroid-retinal endothelial cells and leukocytes: Biosynthesis and mechanisms
of anti-inflammatory actions. Investig. Ophthalmol. Vis. Sci. 50, 3613–3620 (2009).

22.

de la Rosa, X. et al. Identification and Complete Stereochemical Assignments of
the New Resolvin Conjugates in Tissue Regeneration in Human Tissues that
Stimulate Proresolving Phagocyte Functions and Tissue Regeneration. Am. J.
Pathol. (2018). doi:10.1016/j.ajpath.2018.01.004

23.

Powell, W. S. & Rokach, J. Biosynthesis, biological effects, and receptors of
hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxoETEs) derived from arachidonic acid. Biochimica et Biophysica Acta - Molecular
and Cell Biology of Lipids (2015). doi:10.1016/j.bbalip.2014.10.008

24.

Marion-Letellier, R., Savoye, G. & Ghosh, S. Fatty acids, eicosanoids and PPAR
gamma. Eur. J. Pharmacol. 785, 44–49 (2016).

25.

Hong, C. & Tontonoz, P. Coordination of inflammation and metabolism by PPAR
and LXR nuclear receptors. Curr. Opin. Genet. Dev. 18, 461–467 (2008).

26.

Li, N., He, J., Schwartz, C. E., Gjorstrup, P. & Bazan, H. E. P. Resolvin E1
Improves Tear Production and Decreases Inflammation in a Dry Eye Mouse
Model. J. Ocul. Pharmacol. Ther. 26, 431–439 (2010).

27.

Recchiuti, A. & Serhan, C. N. Pro-resolving lipid mediators (SPMs) and their
actions in regulating miRNA in novel resolution circuits in inflammation. Front.
Immunol. 3, (2012).

28.

Fullerton, J. N. & Gilroy, D. W. Resolution of inflammation: A new therapeutic
175

frontier. Nat. Rev. Drug Discov. 15, 551–567 (2016).
29.

Serhan, C. N. et al. Proresolving lipid mediators resolvin D1, resolvin D2, and
maresin 1 are critical in modulating T cell responses. Sci. Transl. Med. 8,
353ra111-353ra111 (2016).

30.

Bautista-Hernández, L. A., Gómez-Olivares, J. L., Buentello-Volante, B. &
Bautista-de Lucio, V. M. Fibroblasts: the unknown sentinels eliciting immune
responses against microorganisms. Eur. J. Microbiol. Immunol. 7, 151–157
(2017).

31.

Yao, C. et al. Toll-like receptor family members in skin fibroblasts are functional
and have a higher expression compared to skin keratinocytes. Int. J. Mol. Med.
35, 1443–1450 (2015).

32.

Kendall, R. T. & Feghali-Bostwick, C. A. Fibroblasts in fibrosis: Novel roles and
mediators. Frontiers in Pharmacology (2014). doi:10.3389/fphar.2014.00123

33.

Artlett, C. M. Inflammasomes in wound healing and fibrosis. Journal of Pathology
(2013). doi:10.1002/path.4116

34.

Borthwick, L. A., Wynn, T. A. & Fisher, A. J. Cytokine mediated tissue fibrosis.
Biochim. Biophys. Acta - Mol. Basis Dis. 1832, 1049–1060 (2013).

35.

Krönke, G. et al. The 12/15-lipoxygenase pathway counteracts fibroblast activation
and experimental fibrosis. Ann. Rheum. Dis. 71, 1081–1087 (2012).

36.

Qu, X. et al. Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed
kidney via inhibition of local fibroblast proliferation. J. Pathol. 228, 506–519
(2012).

37.

Zheng, S. et al. ResolvinD1stimulates epithelial wound repair and inhibits TGF-βinduced EMT whilst reducing fibroproliferation and collagen production. Lab.
Investig. 98, 130–140 (2018).

38.

Gonzalez, A. C. de O., Andrade, Z. de A., Costa, T. F. & Medrado, A. R. A. P.
Wound Healing - A literature review. Ann. Bras. Dermatology 91, 614–620 (2016).

39.

Hinz, B. Myofibroblasts. Exp. Eye Res. 142, 56–70 (2015).

40.

Paul Ehrlich, H., Sun, B., Kainth, K. S. & Kromah, F. Elucidating the mechanism of
wound contraction: Rapid versus sustained myosin ATPase activity in attacheddelayed-released compared with free-floating fibroblast-populated collagen
lattices. Wound Repair Regen. 14, 625–632 (2006).

41.

Peters, A. S., Brunner, G., Krieg, T. & Eckes, B. Cyclic mechanical strain induces
TGFβ1-signalling in dermal fibroblasts embedded in a 3D collagen lattice. Arch.
Dermatol. Res. 307, 191–197 (2015).

42.

Kessler, D. et al. Fibroblasts in Mechanically Stressed Collagen Lattices Assume
a ‘Synthetic’ Phenotype. J. Biol. Chem. 276, 36575–36585 (2001).

176

43.

Hinz, B. The extracellular matrix and transforming growth factor-β1: Tale of a
strained relationship. Matrix Biol. 47, 54–65 (2015).

44.

Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C. & Brown, R. a.
Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat.
Rev. Mol. Cell Biol. 3, 349–63 (2002).

45.

Karamanos, N. K., Theocharis, A. D., Neill, T. & Iozzo, R. V. Matrix modeling and
remodeling: A biological interplay regulating tissue homeostasis and diseases.
Matrix Biol. (2018). doi:10.1016/j.matbio.2018.08.007

46.

Xue, M. & Jackson, C. J. Extracellular Matrix Reorganization During Wound
Healing and Its Impact on Abnormal Scarring. Adv. wound care 4, 119–136
(2015).

47.

Tham, Y. C. et al. Global prevalence of glaucoma and projections of glaucoma
burden through 2040: A systematic review and meta-analysis. Ophthalmology
121, 2081–2090 (2014).

48.

Fingeret, M. Glaucoma medications, glaucoma therapy, and the evolving
paradigm. J. Am. Optom. Assoc. 69, 115–21 (1998).

49.

Kass, M. A., Gordon, M., Morley, R. E., Meltzer, D. W. & Goldberg, J. J.
Compliance with topical timolol treatment. Am. J. Ophthalmol. 103, 188–193
(1987).

50.

Okeke, C. O. et al. Adherence with topical glaucoma medication monitored
electronically: the Travatan Dosing Aid Study. Ophthalmology 116, 191–199
(2009).

51.

Robin, A. L., Novack, G. D., Covert, D. W., Crockett, R. S. & Marcic, T. S.
Adherence in glaucoma: objective measurements of once-daily and adjunctive
medication use. Am. J. Ophthalmol. 144, 533–540 (2007).

52.

Tsai, J. C. A comprehensive perspective on patient adherence to topical glaucoma
therapy. Ophthalmology 116, S30–S36 (2009).

53.

Kholdebarin, R., Campbell, R. J., Jin, Y.-P., Buys, Y. M. & Group, C. C. S.
Multicenter study of compliance and drop administration in glaucoma. Can. J.
Ophthalmol. Can. d’Ophtalmologie 43, 454–461 (2008).

54.

Stone, J. L., Robin, A. L., Novack, G. D., Covert, D. W. & Cagle, G. D. An
objective evaluation of eyedrop instillation in patients with glaucoma. Arch.
Ophthalmol. 127, 732–736 (2009).

55.

Baudouin, C. et al. The Ocular Surface of Glaucoma Patients Treated over the
Long Term Expresses Inflammatory Markers Related to Both T-Helper 1 and THelper 2 Pathways. Ophthalmology 115, 109–115 (2008).

56.

Ammar, D. A., Noecker, R. J. & Kahook, M. Y. Effects of benzalkonium chlorideand polyquad-preserved combination glaucoma medications on cultured human
ocular surface cells. Adv. Ther. 28, 501–510 (2011).
177

57.

Everitt, D. E. & Avorn, J. Systemic effects of medications used to treat glaucoma.
Ann. Intern. Med. 112, 120–125 (1990).

58.

Müller, M. E., van der Velde, N., Krulder, J. W. & Van Der Cammen, T. J. Syncope
and falls due to timolol eye drops. BMJ 332, 960–961 (2006).

59.

Gardiner, B. S., Smith, D. W., Coote, M. & Crowston, J. G. Computational
modeling of fluid flow and intra-ocular pressure following glaucoma surgery. PLoS
One 5, (2010).

60.

Johnstone, M. A. The aqueous outflow system as a mechanical pump - Evidence
from examination of tissue and aqueous movement in human and non-human
primates. J. Glaucoma 13, 421–438 (2004).

61.

Seibold, L. K., Sherwood, M. B. & Kahook, M. Y. Wound Modulation After
Filtration Surgery. Surv. Ophthalmol. 57, 530–550 (2012).

62.

Yamanaka, O., Kitano-izutani, A., Tomoyose, K. & Reinach, P. S. Pathobiology of
wound healing after glaucoma filtration surgery. BMC Ophthalmol. 15, (2015).

63.

Shin, J. Y. et al. The morphometric analysis of filtering bleb using anterior
segment optical coherence tomography: pilot study. J. Korean Ophthalmol. Soc.
51, 234–240 (2010).

64.

Mietz, H., Raschka, B. & Krieglstein, G. K. Risk factors for failures of
trabeculectomies performed without antimetabolites. Br. J. Ophthalmol. 83, 814–
821 (1999).

65.

Araujo, S. V., Spaeth, G. L., Roth, S. M. & Starita, R. J. A Ten-year Follow-up on a
Prospective, Randomized Trial of Postoperative Corticosteroids after
Trabeculectomy. Ophthalmology 102, 1753–1759 (1995).

66.

Awai-Kasaoka, N. et al. Prognostic factors in trabeculectomy with mitomycin C
having history of previous glaucoma surgery. Jpn. J. Ophthalmol. 57, 514–519
(2013).

67.

Armstrong, J. J., Welk, B. K., Reid, J. N. S., Kansal, V. & Hutnik, C. M. L.
Secondary surgical intervention after primary glaucoma filtration surgery: an
Ontario population-based study. Can. J. Ophthalmol. 1–11 (2018).
doi:10.1016/j.jcjo.2018.04.004

68.

Boimer, C. & Birt, C. M. Preservative exposure and surgical outcomes in
glaucoma patients: The PESO study. J. Glaucoma 22, 730–5 (2013).

69.

Broadway, D. C., Bates, A. K., Lightman, S. L., Grierson, I. & Hitchings, R. A. The
importance of cellular changes in the conjunctiva of patients with uveitic glaucoma
undergoing trabeculectomy. Eye (Lond). 7 ( Pt 4), 495–501 (1993).

70.

Broadway, D. C., Grierson, I., O’Brien, C. J. & Hitchings, R. A. Adverse Effects of
Topical Antiglaucoma Medication II: The Outcome of Filtration Surgery. Arch.
Ophthalmol. 112, 1446–1454 (1994).
178

71.

Broadway, D. C., Grierson, I. & O’Brien, C. J. Adverse Effects of Topical
Antiglaucoma Medication I. The Conjunctival Cell Profile. Arch. Ophthalmol. 112,
1437–1445 (1994).

72.

Broadway, D. C. & Chang, L. P. Trabeculectomy, risk factors for failure and the
preoperative state of the conjunctiva. J. Glaucoma 10, 237–249 (2001).

73.

Awai-Kasaoka, N. et al. Impact of phacoemulsification on failure of trabeculectomy
with mitomycin-C. J. Cataract Refract. Surg. 38, 419–424 (2012).

74.

Cantor, L. B. et al. Economic evaluation of medication, laser trabeculoplasty and
filtering surgeries in treating patients with glaucoma in the US. Curr. Med. Res.
Opin. 24, 2905–2918 (2008).

75.

Noecker, R. Effects of common ophthalmic preservatives on ocular health. Adv.
Ther. 18, 205–15 (2001).

76.

Mietz, H., Niesen, U. & Krieglstein, G. K. The effect of preservatives and
antiglaucomatous medication on the histopathology of the conjunctiva. Graefe’s
Arch. Clin. Exp. Ophthalmol. 232, 561–565 (1994).

77.

Lacey, J., Cate, H. & Broadway, D. C. Barriers to adherence with glaucoma
medications: a qualitative research study. Eye 23, 924–932 (2009).

78.

Baudouin, C. et al. Prevalence and risk factors for ocular surface disease among
patients treated over the long term for glaucoma or ocular hypertension. Eur. J.
Ophthalmol. 23, 47–54 (2012).

79.

Ceballos, E. M., Beck, A. D. & Lynn, M. J. Trabeculectomy with antiproliferative
agents in uveitic glaucoma. J. Glaucoma 11, 189–196 (2002).

80.

Freedman, J. & Iserovich, P. Pro-inflammatory cytokines in glaucomatous
aqueous and encysted Molteno implant blebs and their relationship to pressure.
Investig. Ophthalmol. Vis. Sci. 54, 4851–4855 (2013).

81.

Kawai, M. et al. Elevated levels of monocyte chemoattractant protein-1 in the
aqueous humor after phacoemulsification. Invest. Ophthalmol. Vis. Sci. 53, 7951–
60 (2012).

82.

Inoue, T. et al. Simultaneous increases in multiple proinflammatory cytokines in
the aqueous humor in pseudophakic glaucomatous eyes. J. Cataract Refract.
Surg. 38, 1389–1397 (2012).

83.

Gater, R. et al. Investigation of Conjunctival Fibrosis Response Using a 3D
Glaucoma Tenon’s Capsule + Conjunctival Model. Invest. Ophthalmol. Vis. Sci.
(2019). doi:10.1167/iovs.18-25335

84.

Epstein, E. Fibrosing Response To Aqueous: Its Relation to Glaucoma. Br. J.
Ophthalmol. 43, 641–647 (1959).

85.

Sharma, R. K., Rogojina, A. T. & Chalam, K. V. Multiplex immunoassay analysis
of biomarkers in clinically accessible quantities of human aqueous humor. Mol.
179

Vis. 15, 60–69 (2009).
86.

Tripathi, R. C., Li, J., Chan, W. F. & Tripathi, B. J. Aqueous humor in
glaucomatous eyes contains an increased level of TGF-beta 2. Experimental eye
research 59, 723–727 (1994).

87.

Chua, J. et al. Expression profile of inflammatory cytokines in aqueous from
glaucomatous eyes. Mol. Vis. 18, 431–8 (2012).

88.

Kuchtey, J., Rezaei, K. A., Jaru-Ampornpan, P., Sternberg, P. & Kuchtey, R. W.
Multiplex cytokine analysis reveals elevated concentration of interleukin-8 in
glaucomatous aqueous humor. Investig. Ophthalmol. Vis. Sci. 51, 6441–6447
(2010).

89.

Tailor, R., Batra, R. & Mohamed, S. A national survey of glaucoma specialists on
the preoperative (trabeculectomy) management of the ocular surface. in Seminars
in ophthalmology 31, 519–525 (Taylor & Francis, 2016).

90.

Yuen, D. et al. Corticosteroids versus NSAIDs on intraocular pressure and the
hypertensive phase after Ahmed glaucoma valve surgery. J. Glaucoma 20, 439–
444 (2011).

91.

Siriwardena, D., Edmunds, B., Wormald, R. P. L. & Khaw, P. T. National survey of
antimetabolite use in glaucoma surgery in the United Kingdom. Br. J. Ophthalmol.
88, 873–6 (2004).

92.

Khaw, P. T. Advances in glaucoma surgery: evolution of antimetabolite adjunctive
therapy. J. Glaucoma 10, S81–S84 (2001).

93.

Dhingra, S. & Khaw, P. T. The Moorfields Safer Surgery System. Middle East Afr.
J. Ophthalmol. 16, 112–115 (2009).

94.

Cordeiro, M. F., Constable, P. H., Alexander, R. A., Bhattacharya, S. S. & Khaw,
P. T. Effect of varying the mitomycin-C treatment area in glaucoma filtration
surgery in the rabbit. Investig. Ophthalmol. Vis. Sci. 38, 1639–1646 (1997).

95.

Nguyen, K. D. & Lee, D. a. Effect of steroids and nonsteroidal antiinflammatory
agents on human ocular fibroblast. Invest. Ophthalmol. Vis. Sci. 33, 2693–2701
(1992).

96.

Armaly, M. F. Inheritance of Dexamethasone Hypertension and Glaucoma. Arch.
Ophthalmol. 77, 747–751 (1967).

97.

Chang, D. F., Tan, J. J. & Tripodis, Y. Risk factors for steroid response among
cataract patients. J. Cataract Refract. Surg. 37, 675–681 (2011).

98.

Kronfeld, P. C. Functional Characteristics of Surgically Produced Outflow
Channels: The 25th Edward Jackson Memorial Lecture. Am. J. Ophthalmol. 67,
451–463 (1969).

99.

Muecke, J. & Brian, G. Steroid‐induced ocular hypertension in the presence of a
functioning Molteno seton. Clin. Experiment. Ophthalmol. 23, 67–68 (1995).
180

100. Seibold, L. K., Sherwood, M. B. & Kahook, M. Y. Wound Modulation After
Filtration Surgery. Surv. Ophthalmol. 57, 530–550 (2012).
101. Thomas, R. & Jay, J. L. Raised intraocular pressure with topical steroids after
trabeculectomy. Graefe’s Arch. Clin. Exp. Ophthalmol. 226, 337–340 (1988).
102. Wilensky, J. T., Snyder, D. & Gieser, D. Steroid-induced ocular hypertension in
patients with filtering blebs. Ophthalmology 87, 240–244 (1980).
103. Zhan, G. L., Miranda, O. C. & Bito, L. Z. Steroid glaucoma: Corticosteroid-induced
ocular hypertension in cats. Exp. Eye Res. 54, 211–218 (1992).
104. Klein, R. et al. Fifteen-Year Cumulative Incidence of Age-Related Macular
Degeneration The Beaver Dam Eye Study. Ophthalmology 253–262 (2007).
doi:10.1016/j.ophtha.2006.10.040
105. How, A. et al. Combined treatment with bevacizumab and 5-Fluorouracil
attenuates the postoperative scarring response after experimental glaucoma
filtration surgery. Investig. Ophthalmol. Vis. Sci. 51, 928–932 (2010).
106. Noor, N. A., Mustafa, S. & Artini, W. Glaucoma drainage device implantation with
adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience.
Clin. Ophthalmol. 11, 1417–1422 (2017).
107. Van Bergen, T., Vandewalle, E., Moons, L. & Stalmans, I. Complementary effects
of bevacizumab and MMC in the improvement of surgical outcome after glaucoma
filtration surgery. Acta Ophthalmol. 93, 667–678 (2015).
108. Cheng, J., Cheng, S., Wei, R. & Lu, G. Anti‐vascular endothelial growth factor for
control of wound healing in glaucoma surgery. Cochrane Database Syst. Rev.
(2016).
109. Daniel, E. et al. Risk of Scar in the Comparison of Age-related Macular
Degeneration Treatments Trials. Ophthalmology 121, 656–666 (2014).
110. Daniel, E. et al. Development and Course of Scars in the Comparison of AgeRelated Macular Degeneration Treatments Trials. Ophthalmology 125, 1037–1046
(2018).
111. Tillmanns, J. et al. Fibroblast activation protein alpha expression identifies
activated fibroblasts after myocardial infarction. J. Mol. Cell. Cardiol. 87, 194–203
(2015).
112. Hinz, B., Celetta, G., Tomasek, J. J., Gabbiani, G. & Chaponnier, C. AlphaSmooth Muscle Actin Expression Upregulates Fibroblast Contractile Activity. Mol.
Biol. Cell 12, 2730–2741 (2001).
113. Annes, J. P., Munger, J. S. & Rifkin, D. B. Making sense of latent TGFbeta
activation. J. Cell Sci. 116, 217–24 (2003).
114. Rahimi, R. A. & Leof, E. B. TGF-b signaling: A tale of two responses. J. Cell.
Biochem. 102, 593–608 (2007).
181

115. Picht, G. & Grehn, F. Development of the filtering bleb after trabeculectomy.
Classification, histopathology, wound healing process. Der Ophthalmol. Zeitschrift
der Dtsch. Ophthalmol. Gesellschaft 95, W380-7 (1998).
116. Agnifili, L. et al. Histological findings of failed gold micro shunts in primary openAngle glaucoma. Graefe’s Arch. Clin. Exp. Ophthalmol. (2012).
doi:10.1007/s00417-011-1778-6
117. Thieme, H., Choritz, L., Hofmann-Rummelt, C., Schloetzer-Schrehardt, U. &
Kottler, U. B. Histopathologic findings in early encapsulated blebs of young
patients treated with the ahmed glaucoma valve. J. Glaucoma 20, 246–251
(2011).
118. Zhu, X. et al. Evaluation of chitosan/aptamer targeting TGF-β receptor II thermosensitive gel for scarring in rat glaucoma filtration surgery. Investig. Ophthalmol.
Vis. Sci. 56, 5465–5476 (2015).
119. Mead, A. L., Wong, T. T. L., Cordeiro, M. F., Anderson, I. K. & Khaw, P. T.
Evaluation of anti-TGF-b2 antibody as a new postoperative anti-scarring agent in
glaucoma surgery. Investig. Ophthalmol. Vis. Sci. 44, 3394–3401 (2003).
120. Cordeiro, M. F., Gay, J. A. & Khaw, P. T. Human Anti-Transforming Growth
Factor-b2 Antibody: A New Glaucoma Anti-Scarring Agent. Ophthalmol. Vis. Sci.
40, 2225–2234 (1999).
121. CAT-152 0102 Trabeculectomy Study Group. A Phase III Study of Subconjunctival
Human Anti-Transforming Growth Factor b2 Monoclonal Antibody (CAT-152) to
Prevent Scarring after First-Time Trabeculectomy. Ophthalmology 114, (2007).
122. Siriwardena, D. et al. Human antitransforming growth factor β2 monoclonal
antibody—a new modulator of wound healing in trabeculectomy: a randomized
placebo controlled clinical study. Ophthalmology 109, 427–431 (2002).
123. Sapitro, J. et al. Suppression of transforming growth factor-β effects in rabbit
subconjunctival fibroblasts by activin receptor-like kinase 5 inhibitor. Mol. Vis. 16,
1880–92 (2010).
124. Yu-wai-man, C. & Khaw, P. T. Developing novel anti-fibrotic therapeutics to
modulate post-surgical wound healing in glaucoma : big potential for small
molecules. Expert Rev. Ophthalmol. 9899, (2015).
125. Daniels, J. T. et al. Matrix metalloproteinase inhibition modulates fibroblastmediated matrix contraction and collagen production in vitro. Investig. Ophthalmol.
Vis. Sci. 44, 1104–1110 (2003).
126. Wong, T. T. L., Mead, A. L. & Khaw, P. T. Prolonged antiscarring effects of
ilomastat and MMC after experimental glaucoma filtration surgery. Investig.
Ophthalmol. Vis. Sci. 46, 2018–2022 (2005).
127. Mohamed-Ahmed, A. H. A. et al. An ilomastat-CD eye drop formulation to treat
ocular scarring. Investig. Ophthalmol. Vis. Sci. 58, 3425–3431 (2017).
182

128. Kitajima, S. et al. Overcoming resistance to dual innate immune and MEK
inhibition downstream of KRAS. Cancer Cell 34, 439–452 (2018).
129. De Saint, J. M. et al. Toxicity of preserved and unpreserved antiglaucoma topical
drugs in an in vitro model of conjunctival cells. Curr Eye Res 20, 85–94 (2000).
130. Gedde, S. J. et al. Treatment outcomes in the tube versus trabeculectomy (TVT)
study after five years of follow-up. Am. J. Ophthalmol. 153, 789-803.e2 (2012).
131. Cankaya, A. B. & Elgin, U. Comparison of the outcome of repeat trabeculectomy
with adjunctive mitomycin C and initial trabeculectomy. Korean J. Ophthalmol. 25,
401–8 (2011).
132. Jampel, H. D. et al. Perioperative complications of trabeculectomy in the
Collaborative Initial Glaucoma Treatment Study (CIGTS). Am. J. Ophthalmol. 140,
16–22 (2005).
133. Rosentreter, A., Schild, A. M., Jordan, J. F., Krieglstein, G. K. & Dietlein, T. S. A
prospective randomised trial of trabeculectomy using mitomycin C vs an ologen
implant in open angle glaucoma. Eye 24, 1449–1457 (2010).
134. Khaw, P. et al. Factors Affecting the Outcome of Trabeculectomy. Ophthalmology
114, 1831-1838.e4 (2007).
135. Mietz, H., Raschka, B. & Krieglstein, G. K. Risk factors for failures of
trabeculectomies performed without antimetabolites. Br. J. Ophthalmol. 83, 814–
821 (1999).
136. Schwartz, A. L. et al. The advanced glaucoma intervention study (AGIS): 5.
Encapsulated bleb after initial trabeculectomy. Am. J. Ophthalmol. 127, 8–19
(1999).
137. Sugimoto, Y. et al. Intraocular Pressure Outcomes and Risk Factors for Failure in
the Collaborative Bleb-Related Infection Incidence and Treatment Study.
Ophthalmology 122, 2223–2233 (2015).
138. Edmunds, B., Bunce, C. V., Thompson, J. R., Salmon, J. F. & Wormald, R. P.
Factors Associated with Success in First-Time Trabeculectomy for Patients at Low
Risk of Failure with Chronic Open-Angle Glaucoma. Ophthalmology 111, 97–103
(2004).
139. AL-Obeidan, S. A., Mousa, A., Naseem, A., Abu-Amero, K. K. & Osman, E. A.
Efficacy and safety of non-penetrating deep sclerectomy surgery in saudi patients
with uncontrolled open angle glaucoma. Saudi Med. J. 34, 54–61 (2013).
140. Bovee, C. E. & Pasquale, L. R. Evolving surgical interventions in the treatment of
glaucoma. in Seminars in ophthalmology 32, 91–95 (Taylor & Francis, 2017).
141. Lockwood, A., Brocchini, S. & Khaw, P. T. New developments in the
pharmacological modulation of wound healing after glaucoma filtration surgery.
Curr. Opin. Pharmacol. 13, 65–71 (2013).
183

142. Elm, E. von et al. Annals of Internal Medicine Academia and Clinic The
Strengthening the Reporting of Observational Studies in Epidemiology ( STROBE
) Statement : Guidelines for Reporting. Ann. Intern. Med. 147, 573–578 (2014).
143. Bressler, B. et al. Rates of new or missed colorectal cancers after colonoscopy
and their risk factors: a population-based analysis. Gastroenterology 132, 96–102
(2007).
144. Williams, J. I. & Young, W. A summary of studies on the quality of health care
administrative databases in Canada. Patterns Heal. care Ontario ICES Pract.
atlas. 2nd ed. Ottawa Can. Med. Assoc. 339, 45 (1996).
145. Levy, A. R., O’Brien, B. J., Sellors, C., Grootendorst, P. & Willison, D. Coding
accuracy of administrative drug claims in the Ontario Drug Benefit database. Can.
J. Clin. Pharmacol. J. Can. Pharmacol. Clin. 10, 67–71 (2002).
146. Tu, K., Chen, Z. & Lipscombe, L. L. Prevalence and incidence of hypertension
from 1995 to 2005: a population-based study. Cmaj 178, 1429–1435 (2008).
147. Guttmann, A. et al. Validation of a health administrative data algorithm for
assessing the epidemiology of diabetes in Canadian children. Pediatr. Diabetes
11, 122–128 (2010).
148. Gershon, A. S. et al. Identifying patients with physician-diagnosed asthma in
health administrative databases. Can. Respir. J. 16, 183–188 (2009).
149. Juurlink, D. et al. Canadian institute for health information discharge abstract
database: a validation study. ICES Investig. report. Inst. Clin. Eval. Sci. Toronto
(2006).
150. Borugian, M. J., Spinelli, J. J., Mezei, G. & Wilkins, R. Childhood Leukemia and
Socioeconomic Status in Canada. Epidemiology 16, 526–531 (2005).
151. Deyo, R. & Ciol, M. A. Adapting a Clinical Comorbidity Index for Use With ICD-9CM Administrative Databases. J. Clin. Epidemiol. 6196, (1992).
152. Quan, H. et al. Data Coding Algorithms for Defining Comorbidities in ICD-9-CM
and ICD-1 0 Administrative Data. Med. Care 43, 1130–1139 (2005).
153. Tu, K. et al. Validity of administrative data for identifying patients who have had a
stroke or transient ischemic attack using emrald as a reference standard. Can. J.
Cardiol. 29, 1388–1394 (2013).
154. McIsaac, D. I. et al. Identifying Obstructive Sleep Apnea in Administrative Data.
Anesthesiology 123, 253–263 (2015).
155. Borucka, J. Extensions of Cox Model for Non-Proportional Hazards Purpose.
Ekonometrika 3, 85–101 (2014).
156. Austin, P. C. & Fine, J. P. Practical recommendations for reporting Fine-Gray
model analyses for competing risk data. Stat. Med. 36, 4391–4400 (2017).

184

157. Landers, J., Martin, K., Sarkies, N., Bourne, R. & Watson, P. A twenty-year followup study of trabeculectomy: Risk factors and outcomes. Ophthalmology 119, 694–
702 (2012).
158. Gedde, S. J. et al. Treatment Outcomes in the Tube Versus Trabeculectomy
Study After One Year of Follow-up. Am. J. Ophthalmol. (2007).
doi:10.1016/j.ajo.2009.06.018
159. Mietz, H., Jacobi, P. C., Welsandt, G. & Krieglstein, G. K. Trabeculectomies in
fellow eyes have an increased risk of Tenon’s capsule cysts. Ophthalmology 109,
992–997 (2002).
160. Iwasaki, K. et al. Comparing trabeculectomy outcomes between first and second
operated eyes: A multicenter study. PLoS One 11, 1–13 (2016).
161. Lochhead, J., Casson, R. J. & Salmon, J. F. Long term effect on intraocular
pressure of phacotrabeculectomy compared to trabeculectomy. Br. J. Ophthalmol.
87, 850–852 (2003).
162. Murthy, S. K., Damji, K. F., Pan, Y. & Hodge, W. G. Trabeculectomy and
phacotrabeculectomy, with mitomycin-C, show similar two-year target IOP
outcomes. Can. J. Ophthalmol. Can. d’Ophtalmologie 41, 51–59 (2006).
163. Breusegem, C. et al. Preoperative nonsteroidal anti-inflammatory drug or steroid
and outcomes after trabeculectomy: A randomized controlled trial. Ophthalmology
117, 1324–1330 (2010).
164. Hottendorf, G. H. & Williams, P. D. Aminoglycoside Nephrotoxicity. Toxicol.
Pathol. (1986).
165. Avent, M. L., Rogers, B. A., Cheng, A. C. & Paterson, D. L. Current use of
aminoglycosides: Indications, pharmacokinetics and monitoring for toxicity. Intern.
Med. J. 41, 441–449 (2011).
166. Kupin, T. H., Juzych, M. S., Shin, D. H., Khatana, A. K. & Olivier, M. M. G.
Adjunctive mitomycin C in primary trabeculectomy in phakic eyes. Am. J.
Ophthalmol. 119, 30–39 (1995).
167. Masoumpour, M. B., Nowroozzadeh, M. H. & Razeghinejad, M. R. Suppl 1: M5:
Current and Future Techniques in Wound Healing Modulation after Glaucoma
Filtering Surgeries. Open Ophthalmol. J. 10, 68 (2016).
168. Panarelli, J. F., Nayak, N. V & Sidoti, P. A. Postoperative management of
trabeculectomy and glaucoma drainage implant surgery. Curr. Opin. Ophthalmol.
27, 170–176 (2016).
169. Fuller, J. R., Bevin, T. H., Molteno, A. C. B., Vote, B. J. T. & Herbison, P. Antiinflammatory fibrosis suppression in threatened trabeculectomy bleb failure
produces good long term control of intraocular pressure without risk of sight
threatening complications. Br. J. Ophthalmol. 86, 1352–1355 (2002).
170. Rodriguez Una, I. et al. Perioperative pharmacological management in patients
185

with glaucoma. Arch. Soc. Esp. Oftalmol. 90, 274–284 (2015).
171. Kent, A. R. et al. The efficacy and safety of diclofenac 0.1% versus prednisolone
acetate 1% following trabeculectomy with adjunctive mitomycin-C. Ophthalmic
Surgery, Lasers Imaging Retin. 29, 562–569 (1998).
172. Levkovitch-Verbin, H., Katz, G., Kalev-Landoi, M. & Goldenfeld, M. Postoperative
Treatment With Topical Diclofenac Versus Topical Dexamethasone After
Combined Phacotrabeculectomy With Mitomycin C. J. Glaucoma 22, 1 (2011).
173. Scott, G. R. et al. Can topical ketorolac 0.5% improve the function of Ahmed
glaucoma drainage devices? Ophthalmic Surg. Lasers Imaging2 42, 190–195
(2011).
174. Almatlouh, A., Bach-Holm, D. & Kessel, L. Steroids and nonsteroidal antiinflammatory drugs in the postoperative regime after trabeculectomy - which
provides the better outcome? A systematic review and meta-analysis. Acta
Ophthalmol. 1–12 (2018). doi:10.1111/aos.13919
175. Levkovitch-Verbin, H., Katz, G., Kalev-Landoi, M. & Goldenfeld, M. Postoperative
Treatment With Topical Diclofenac Versus Topical Dexamethasone After
Combined Phacotrabeculectomy With Mitomycin C. J. Glaucoma 22, 177–182
(2013).
176. Nakano, T., Ohara, O., Teraoka, H. & Arita, H. Glucocorticoids suppress group II
phospholipase A2production by blocking mRNA synthesis and post-transcriptional
expression. J. Biol. Chem. 265, 12745–12748 (1990).
177. Funk, C. D. Prostaglandins and Leukotrienes : Advances in Eicosanoid Biology.
Science (80-. ). 294, (2001).
178. Ricciotti, Emanuela and FitzGerald, G. A. Prostaglandins and Inflammation. Arter.
Thromb Vasc Biol. 31, 986–1000 (2011).
179. Dennis, E. A. & Norris, P. C. Eicosanoid Storm in Infection and Inflammation. Nat.
Rev. Immunol. 15, 511–523 (2016).
180. Almeida, D. R. P. et al. Effect of prophylactic nonsteroidal antiinflammatory drugs
on cystoid macular edema assessed using optical coherence tomography
quantification of total macular volume after cataract surgery. J. Cataract Refract.
Surg. 34, 64–69 (2008).
181. Asano, S. et al. Reducing angiographic cystoid macular edema and bloodaqueous barrier disruption after small-incision phacoemulsification and foldable
intraocular lens implantation. Multicenter prospective randomized comparison of
topical diclofenac 0.1% and betamethason. J. Cataract Refract. Surg. 34, 57–63
(2008).
182. Laurell, C. G. & Zetterström, C. Effects of dexamethasone, diclofenac, or placebo
on the inflammatory response after cataract surgery. Br. J. Ophthalmol. 86, 1380–
1384 (2002).
186

183. Sun, R., Gimbel, H. V, Liu, S., Guo, D. & Hollenberg, M. D. Effect of diclofenac
sodium and dexamethasone on cultured human Tenon’s capsule fibroblasts.
Ophthalmic Surgery, Lasers Imaging Retin. 30, 382–388 (1999).
184. Baker, B. M. & Chen, C. S. Deconstructing the third dimension: how 3D culture
microenvironments alter cellular cues. J. Cell Sci. 125, 3015–24 (2012).
185. Dallon, J. C., Ph, D. & Ehrlich, H. P. A Review of Fibroblast Populated Collagen
Lattices. 1–20 (2008).
186. Bell, E., Ehrlich, H. P., Buttle, D. J. & Nakatsuji, T. Living tissue formed in vitro and
accepted as skin-equivalent tissue of full thickness. Science (80-. ). 211, 1052–
1054 (1981).
187. Eliceiri, K., Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to
ImageJ : 25 years of image analysis HISTORICAL commentary NIH Image to
ImageJ : 25 years of image analysis. Nat. Methods 9, 671–675 (2012).
188. Schmitz, N., Laverty, S., Kraus, V. B. & Aigner, T. Basic methods in
histopathology of joint tissues. Osteoarthr. Cartil. 18, S113–S116 (2010).
189. Eberth, J. F. et al. Importance of pulsatility in hypertensive carotid artery growth
and remodeling. J. Hypertens. 27, 2010–2021 (2009).
190. Whittaker, P., Kloner, R. A., Boughner, D. R. & Pickering, J. G. Quantitative
assessment of myocardial collagen with picrosirius red staining and circularly
polarized light. Basic Res. Cardiol. 89, 397–410 (1994).
191. Rich, L. & Whittaker, P. Collagen and Picrosirius Red Staining : a Polarized Light
Assessment of Fibrillar Hue and Spatial Distribution. Braz J Morphol Sci 22, 97–
104 (2005).
192. Ophir, A. Encapsulated filtering bleb. A selective review--new deductions. Eye
(Lond). 6 ( Pt 4), 348–52 (1992).
193. Mietz, H., Arnold, G., Kirchhof, B., Diestelhorst, M. & Krieglstein, G. K.
Histopathology of episcleral fibrosis after trabeculectomy with and without
mitomycin C. Graefes Arch. Clin. Exp. Ophthalmol. 234, 364–8 (1996).
194. Mahale, A. et al. Histopathologic and immunohistochemical features of capsular
tissue around failed Ahmed glaucoma valves. 1–13 (2017).
195. Shinde, A. V., Humeres, C. & Frangogiannis, N. G. The role of a-smooth muscle
actin in fibroblast-mediated matrix contraction and remodeling. Biochim. Biophys.
Acta - Mol. Basis Dis. 1863, 298–309 (2017).
196. Sakaki, H. et al. Interleukin-1beta induces matrix metalloproteinase-1 expression
in cultured human gingival fibroblasts: role of cyclooxygenase-2 and prostaglandin
E2. Oral Dis. 10, 87–93 (2004).
197. Mapleson, J. L. & Buchwald, M. Effect of cycloheximide and dexamethasone
phosphate on hyaluronic acid synthesis and secretion in cultured human skin
187

fibroblasts. J. Cell. Physiol. 109, 215–222 (1981).
198. Smith, T. J. Dexamethasone regulation of glycosaminoglycan synthesis in cultured
human skin fibroblasts. Similar effects of glucocorticoid and thyroid hormones. J.
Clin. Invest. 74, 2157–2163 (1984).
199. Varkey, M., Ding, J. & Tredget, E. E. Differential collagen-glycosaminoglycan
matrix remodeling by superficial and deep dermal fibroblasts: Potential therapeutic
targets for hypertrophic scar. Biomaterials 32, 7581–7591 (2011).
200. Baudouin, C. et al. Efficacy of indomethacin 0.1% and fluorometholone 0.1% on
conjunctival inflammation following chronic application of antiglaucomatous drugs.
Graefe’s Arch. Clin. Exp. Ophthalmol. 240, 929–935 (2002).
201. Rhee, S. Fibroblasts in three dimensional matrices: cell migration and matrix
remodeling. Exp. Mol. Med. 41, 858–865 (2009).
202. Weinreb, R. N., Aung, T. & Medeiros, F. A. The pathophysiology and treatment of
glaucoma: a review. Jama 311, 1901–1911 (2014).
203. Tsai, J. C. Medication adherence in glaucoma: approaches for optimizing patient
compliance. Curr. Opin. Ophthalmol. 17, 190–195 (2006).
204. Huang, C. & Ogawa, R. Fibroproliferative Disorders and Their Mechanobiology.
Connect. Tissue Res. 53, 187–196 (2012).
205. Saika, S., Yamanaka, O., Okada, Y. & Sumioka, T. Modulation of Smad signaling
by non-TGFβ components in myofibroblast generation during wound healing in
corneal stroma. Exp. Eye Res. 142, 40–48 (2016).
206. Takai, Y., Tanito, M. & Ohira, A. Multiplex cytokine analysis of aqueous humor in
eyes with primary open-angle glaucoma, exfoliation glaucoma, and cataract.
Investig. Ophthalmol. Vis. Sci. 53, 241–247 (2012).
207. Cvenkel, B., Kopitar, A. N. & Ihan, A. Inflammatory molecules in aqueous humour
and on ocular surface and glaucoma surgery outcome. Mediators Inflamm. 2010,
(2010).
208. Darby, I. A., Zakuan, N., Billet, F. & Desmoulière, A. The myofibroblast, a key cell
in normal and pathological tissue repair. Cell. Mol. Life Sci. 1–13 (2015).
doi:10.1007/s00018-015-2110-0
209. Grinnell, F. Fibroblasts, Myofibroblasts, and Wound Contraction. J. Cell Biol. 124,
511–516 (1994).
210. Gabbiani, G. The myofibroblast in wound healing and fibrocontractive diseases. J.
Pathol. 200, 500–503 (2003).
211. Toh, Z. H., Lee, C. S. Y., Chew, A. C. Y. & Perera, S. Time Heals All Wounds:
Obstacles in Glaucoma Surgery from an Asian Perspective. Proc. Singapore
Healthc. 24, 103–112 (2015).

188

212. Schlötzer-Schrehardt, U., Lommatzsch, J., Küchle, M., Konstas, A. G. P. &
Naumann, G. O. H. Matrix metalloproteinases and their inhibitors in aqueous
humor of patients with pseudoexfoliation syndrome/glaucoma and primary openangle glaucoma. Investig. Ophthalmol. Vis. Sci. 44, 1117–1125 (2003).
213. Chintala, S. K. et al. Matrix metalloproteinase gelatinase B (MMP-9) is associated
with leaking glaucoma filtering blebs. Exp. Eye Res. 81, 429–436 (2005).
214. Acera, A., Vecino, E. & Duran, J. A. Tear MMP-9 levels as a marker of ocular
surface inflammation in conjunctivochalasis. Invest. Ophthalmol. Vis. Sci. 54,
8285–8291 (2013).
215. Serhan, C. N., Krishnamoorthy, S., Recchiuti, A. & Chiang, N. Novel antiinflammatory--pro-resolving mediators and their receptors. Curr. Top. Med. Chem.
11, 629–47 (2011).
216. Uderhardt, S. & Krönke, G. 12/15-Lipoxygenase during the regulation of
inflammation, immunity, and self-tolerance. J. Mol. Med. 90, 1247–1256 (2012).
217. Al Habash, A., Aljasim, L. A., Owaidhah, O. & Edward, D. P. A review of the
efficacy of mitomycin C in glaucoma filtration surgery. Clin. Ophthalmol.
(Auckland, NZ) 9, 1945 (2015).
218. Chang, L., Crowston, J. G., Cordeiro, M. F., Akbar, A. N. & Khaw, P. T. The role of
the immune system in conjunctival wound healing after glaucoma surgery. Surv.
Ophthalmol. 45, 49–68 (2000).
219. Spitzer, M. S. et al. Sodium hyaluronate gels as a drug-release system for
corticosteroids: Release kinetics and antiproliferative potential for glaucoma
surgery. Acta Ophthalmol. (2008). doi:10.1111/j.1755-3768.2007.01149.x
220. Cheng, J.-W., Cai, J.-P., Li, Y. & Wei, R.-L. Intraoperative mitomycin C for
nonpenetrating glaucoma surgery: a systematic review and meta-analysis. J.
Glaucoma 20, 322–326 (2011).
221. Jampel, H. D. et al. Risk factors for late-onset infection following glaucoma
filtration surgery. Arch. Ophthalmol. 119, 1001–8 (2001).
222. Cells, M. et al. Dexamethasone Stiffens Trabecular Meshwork, Trabecular
Meshwork Cells, and Matrix. (2018). doi:10.1167/iovs.15-16739
223. Armstrong, J. J., Denstedt, J. T., Trelford, C. B., Li, E. A. & Hutnik, C. M. L.
Differential effects of dexamethasone and indomethacin on Tenon’ s capsule
fibroblasts: Implications for glaucoma surgery. Exp. Eye Res. 182, 65–73 (2019).
224. Rowlinson, S. W. et al. Spatial Requirements for 15- ( R ) -Hydroxy-5 Z , 8 Z , 11 Z
, 13 E - eicosatetraenoic Acid Synthesis within the Cyclooxygenase Active Site of
Murine COX-2. J. Biol. Chem. 275, 6586–6591 (2000).
225. Kalgutkar, A. S., Kozak, K. R., Crews, B. C., Hochgesang, G. P. & Marnett, L. J.
Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl
sulfides, a new class of selective COX-2 inactivators. J. Med. Chem. 41, 4800–
189

4818 (1998).
226. Chiang, N., Bermudez, E. A., Ridker, P. M., Hurwitz, S. & Serhan, C. N. Aspirin
triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a
randomized human trial. Proc. Natl. Acad. Sci. 101, 15178–15183 (2004).
227. Claria, J. & Serhan, C. N. Aspirin triggers previously undescribed bioactive
eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad.
Sci. 92, 9475–9479 (1995).
228. Takano, B. T. et al. Aspirin-triggered 15-Epi-Lipoxin A 4 (LXA 4 ) and LXA 4
Stable Analogues Are Potent Inhibitors of Acute Inflammation: Evidence for Antiinflammatory Receptors. J Exp Med 185, 1693–704 (1997).
229. Endo, J. et al. 18-HEPE, an n-3 fatty acid metabolite released by macrophages,
prevents pressure overload–induced maladaptive cardiac remodeling. J. Exp.
Med. 211, 1673–1687 (2014).
230. Planagumà, A. et al. Docosahexaenoic acid (DHA) blunts liver injury by
conversion to protective lipid mediators: protectin D1 and 17 S -hydroxy-DHA .
FASEB J. 20, 2537–2539 (2006).
231. Lannan, K. L., Spinelli, S. L., Blumberg, N. & Phipps, R. P. Maresin 1 induces a
novel pro-resolving phenotype in human platelets. J. Thromb. Haemost. 15, 802–
813 (2017).
232. Purschke, M. et al. Omega-6 docosapentaenoic acid-derived resolvins and 17hydroxydocosahexaenoic acid modulate macrophage function and alleviate
experimental colitis. Inflamm. Res. 61, 967–976 (2012).
233. Le Faouder, P. et al. LC-MS/MS method for rapid and concomitant quantification
of pro-inflammatory and pro-resolving polyunsaturated fatty acid metabolites. J.
Chromatogr. B Anal. Technol. Biomed. Life Sci. 932, 123–133 (2013).
234. Martin-venegas, R., Olga, J. & Jose, J. Liquid chromatography-tandem mass
spectrometry analysis of eicosanoids and related compounds in cell models. 964,
41–49 (2014).
235. Saika, S. TGFβ pathobiology in the eye. Lab. Investig. 86, 106–115 (2006).
236. Wang, X. et al. Aspirin suppresses cardiac fibroblast proliferation and collagen
formation through downregulation of angiotensin type 1 receptor transcription.
Toxicol. Appl. Pharmacol. 259, 346–354 (2012).
237. Al-Nimer, M. S. M., Hameed, H. G. & Mahmood, M. M. Antiproliferative effects of
aspirin and diclofenac against the growth of cancer and fibroblast cells: In vitro
comparative study. Saudi Pharm. J. 23, 483–486 (2015).
238. Viñals, M. et al. Aspirin increases CD36, SR-BI, and ABCA1 expression in human
THP-1 macrophages. Cardiovasc. Res. 66, 141–149 (2005).
239. Yiqin, Y., Meilin, X., Jie, X. & Keping, Z. Aspirin inhibits MMP-2 and MMP-9
190

expression and activity through PPARα/γ and TIMP-1-mediated mechanisms in
cultured mouse celiac macrophages. Inflammation (2009). doi:10.1007/s10753009-9125-3
240. Lai, M. Y., Huang, J. A., Liang, Z. H., Jiang, H. X. & Tang, G. D. Mechanisms
underlying aspirin-mediated growth inhibition and apoptosis induction of
cyclooxygenase-2 negative colon cancer cell line SW480. World J. Gastroenterol.
14, 4227–4233 (2008).
241. Jian, Z. et al. Aspirin induces Nrf2-mediated transcriptional activation of haem
oxygenase-1 in protection of human melanocytes from H2O2-induced oxidative
stress. J. Cell. Mol. Med. 20, 1307–1318 (2016).
242. Liu, P. P. et al. Aspirin alleviates cardiac fibrosis in mice by inhibiting autophagy.
Acta Pharmacol. Sin. 38, 488–497 (2017).
243. Mehta, J. L., Chen, J., Yu, F. & Li, D. Y. Aspirin inhibits ox-LDL-mediated LOX-1
expression and metalloproteinase-1 in human coronary endothelial cells.
Cardiovasc. Res. 64, 243–249 (2004).
244. Bhatt, L. K. & Addepalli, V. Attenuation of diabetic retinopathy by enhanced
inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocindiabetic rats. Am. J. Transl. Res. 2, 181–189 (2010).
245. Claria, J., Nguyen, B. T., Madenci, A. L., Ozaki, C. K. & Serhan, C. N. Diversity of
lipid mediators in human adipose tissue depots. AJP Cell Physiol. (2013).
doi:10.1152/ajpcell.00351.2012
246. Wynn, T. A. Fibrotic Disease and the TH1/TH2 Paradigm. Nat Rev Immunol 4,
583–594 (2004).
247. Wei, J. & Gronert, K. Eicosanoid and Specialized Proresolving Mediator
Regulation of Lymphoid Cells. (2018). doi:10.1016/j.tibs.2018.10.007
248. Rius, B. et al. The specialized pro-resolving lipid mediator maresin 1 protects
hepatocytes from lipotoxic and hypoxia-induced endoplasmic reticulum stress.
FASEB J. fj.201700394R (2017). doi:10.1096/fj.201700394R
249. Lee, J. Y. et al. Neuronal SphK1 acetylates COX2 and contributes to
pathogenesis in a model of Alzheimer’s Disease. Nat. Commun. 9, (2018).
250. Roth, G. J., Stanford, N. & Majerus, P. W. Acetylation of prostaglandin synthase
by aspirin. Proc. Natl. Acad. Sci. U. S. A. 72, 3073–6 (1975).
251. Serhan, C. N. Lipoxins and aspirin-triggered 15-epi-lipoxins. pro-resolving
mediators in anti-inflammation and resolution. Handb. Cell Signaling, 2/e 2, 1235–
1242 (2010).
252. Birnbaum, Y. et al. Aspirin augments 15-epi-lipoxin A4production by
lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15epi-lipoxin A4in the rat heart. Prostaglandins Other Lipid Mediat. 83, 89–98
(2007).
191

253. Von Der Weid, P. Y., Hollenberg, M. D., Fiorucci, S. & Wallace, J. L. Aspirintriggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular
tone. Circulation 110, 1320–1325 (2004).
254. Kalgutkar, A. S. et al. Aspirin-like Molecules that Covalently Inactivate
Cyclooxygenase-2. Science (80-. ). 280, 1268–1270 (1998).
255. Hinz, B. Formation and function of the myofibroblast during tissue repair. J. Invest.
Dermatol. 127, 526–537 (2007).
256. Sun, X. & Kaufman, P. D. Ki-67: more than a proliferation marker. Chromosoma
1–12 (2018).
257. Pedersen, S. F., Poulsen, K. A. & Lambert, I. H. Roles of phospholipase A 2
isoforms in swelling- and melittin-induced arachidonic acid release and taurine
efflux in NIH3T3 fibroblasts. Am. J. Physiol. Physiol. 291, C1286–C1296 (2006).
258. Cajal, Y. & Jain, M. K. Synergism between mellitin and phospholipase A2 from
bee venom: Apparent activation by intervesicle exchange of phospholipids.
Biochemistry 36, 3882–3893 (1997).
259. Schuster, V. L., Chi, Y. & Lu, R. The Prostaglandin Transporter: Eicosanoid
Reuptake, Control of Signaling, and Development of High-Affinity Inhibitors as
Drug Candidates. Transactions of the American Clinical and Climatological
Association 126, (2015).
260. Martinez-Salgado, C., Rodriguez-Barbero, A., Rodriguez-Puyol, D., Pérez de
Lema, G. & Lopez-Novoa, J. M. Involvement of phospholipase A2 in gentamicininduced rat mesangial cell activation. Am. J. Physiol. Physiol. 273, F60–F66
(1997).
261. Vane, J. R. & Botting, R. M. Mechanism of action of anti-inflammatory drugs.
Scand. J. Rheumatol. 25, 9–21 (1996).
262. Meade, E. A., Smith, W. L. & DeWitt, D. L. Differential inhibition of prostaglandin
endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J. Biol. Chem. 268, 6610–6614 (1993).
263. Varga, T., Czimmerer, Z. & Nagy, L. PPARs are a unique set of fatty acid
regulated transcription factors controlling both lipid metabolism and inflammation.
Biochimica et Biophysica Acta - Molecular Basis of Disease 1812, 1007–1022
(2011).
264. Zhu, H. Y. et al. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist
inhibits collagen synthesis in human hypertrophic scar fibroblasts by targeting
Smad3 via miR-145. Biochem. Biophys. Res. Commun. (2015).
doi:10.1016/j.bbrc.2015.02.061
265. Menon, R., Krzyszczyk, P. & Berthiaume, F. Pro-Resolution Potency of Resolvins
D1, D2 and E1 on Neutrophil Migration and in Dermal Wound Healing. Nano Life
07, 1750002 (2017).
192

266. Bannenberg, G. L. et al. Molecular Circuits of Resolution: Formation and Actions
of Resolvins and Protectins. J. Immunol. 174, 4345–4355 (2005).
267. Chen, W. S., Cao, Z., Leffler, H., Nilsson, U. J. & Panjwani, N. Galectin-3 inhibition
by a small-molecule inhibitor reduces both pathological corneal neovascularization
and fibrosis. Investig. Ophthalmol. Vis. Sci. 58, 9–20 (2017).
268. Lois, N. et al. Effect of TGF-β2 and anti-TGF-β2 antibody in a new in vivo rodent
model of posterior capsule opacification. Investig. Ophthalmol. Vis. Sci. 46, 4260–
4266 (2005).
269. Ishikawa, K., Kannan, R. & Hinton, D. R. Molecular mechanisms of subretinal
fibrosis in age-related macular degeneration. Exp. Eye Res. 142, 19–25 (2014).
270. Pleyer, U., Ursell, P. G. & Rama, P. Intraocular pressure effects of common
topical steroids for post-cataract inflammation: are they all the same? Ophthalmol.
Ther. 2, 55–72 (2013).
271. Tajika, T., Miyake, K., Ogawa, T., Gow, J. A. & McNamara, T. R. Ocular
Pharmacokinetics of a Single Dose of Bromfenac Sodium Ophthalmic Solution
0.1% in Human Aqueous Humor. J. Ocul. Pharmacol. Ther. 24, 573–578 (2008).
272. Ahuja, M., Dhake, A. S., Sharma, S. K. & Majumdar, D. K. Topical Ocular Delivery
of NSAIDs. AAPS J. 10, 229–241 (2008).
273. Rubinstein, L. V, Gail, M. H. & Santner, T. J. Planning the duration of a
comparative clinical trial with loss to follow-up and a period of continued
observation. J. Chronic Dis. 34, 469–479 (1981).
274. Shaarawy, T. M., Sherwood, M. B. & Grehn, F. WGA Guidelines on Design and
Reporting of Glaucoma Surgical Trials. (2009).

193

Appendices
Appendix A: STROBE Statement—Checklist of items to be included in reports of
cohort studies

Title and abstract

Item
No.
1

Recommendation
(a) Indicate the study’s design with a commonly

Page
No.
1

used term in the title or the abstract
(b) Provide in the abstract an informative and

1

balanced summary of what was done and what
was found
Introduction
Background/rationale

2

Explain the scientific background and rationale

2

for the investigation being reported
Objectives

3

State specific objectives, including any

2

prespecified hypotheses
Methods
Study design

4

Setting

5

Present key elements of study design early in

3

the paper
Describe the setting, locations, and relevant

3-4

dates, including periods of recruitment,
exposure, follow-up, and data collection
Participants

6

(a) Give the eligibility criteria, and the sources

3-4

and methods of selection of participants.
Describe methods of follow-up
(b) For matched studies, give matching criteria

N/A

and number of exposed and unexposed
Variables

7

Clearly define all outcomes, exposures,

4,5

predictors, potential confounders, and effect
modifiers. Give diagnostic criteria, if applicable
Data sources/

8*

measurement

For each variable of interest, give sources of

4-5,

data and details of methods of assessment

Appendices A-

(measurement). Describe comparability of

F

assessment methods if there is more than one
group
Bias

9

Describe any efforts to address potential

3-5

sources of bias
Study size

10

Explain how the study size was arrived at

Quantitative

11

Explain how quantitative variables were handled

variables

Figure 1
4-5

in the analyses. If applicable, describe which
groupings were chosen and why

Statistical methods

12

(a) Describe all statistical methods, including
194

4-5

those used to control for confounding
(b) Describe any methods used to examine

4-5

subgroups and interactions
(c) Explain how missing data were addressed

4-5

(d) If applicable, explain how loss to follow-up

5, Figure 1

was addressed
(e) Describe any sensitivity analyses
Results
Participants

13*

(a) Report numbers of individuals at each stage

4
Figure 1

of study—eg numbers potentially eligible,
examined for eligibility, confirmed eligible,
included in the study, completing follow-up, and
analysed
(b) Give reasons for non-participation at each

Figure 1

stage
(c) Consider use of a flow diagram
Descriptive data

14*

Figure 1

(a) Give characteristics of study participants (eg

6, 7, Table 1,

demographic, clinical, social) and information on

S2

exposures and potential confounders
(b) Indicate number of participants with missing
data for each variable of interest
(c) Summarise follow-up time (eg, average and

Table 2, Table
S2
6

total amount)
Outcome data

15*

Report numbers of outcome events or summary

6, Table 1

measures over time
Main results

16

(a) Give unadjusted estimates and, if applicable,

Table 3

confounder-adjusted estimates and their
precision (eg, 95% confidence interval). Make
clear which confounders were adjusted for and
why they were included
(b) Report category boundaries when continuous

Table 2, Table

variables were categorized

S2

(c) If relevant, consider translating estimates of

N/A

relative risk into absolute risk for a meaningful
time period
Other analyses

17

Report other analyses done—eg analyses of

5,7

subgroups and interactions, and sensitivity
analyses
Discussion
Key results

18

Summarise key results with reference to study

8

objectives
Limitations

19

Discuss limitations of the study, taking into
195

8,9

account sources of potential bias or imprecision.
Discuss both direction and magnitude of any
potential bias
Interpretation

20

Give a cautious overall interpretation of results

8-10

considering objectives, limitations, multiplicity of
analyses, results from similar studies, and other
relevant evidence
Generalisability

21

Discuss the generalisability (external validity) of

8-10

the study results
Other information
Funding

22

Give the source of funding and the role of the

11

funders for the present study and, if applicable,
for the original study on which the present article
is based
*Information given separately for exposed and unexposed groups.
Note: An Explanation and Elaboration article discusses each checklist item and gives
methodological background and published examples of transparent reporting. The STROBE
checklist is best used in conjunction with this article (freely available on the Web sites of PLoS
Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/,
and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available
at http://www.strobe-statement.org.

196

Appendix B: Index Events and Outcome Definitions
Procedure
Solo-filtration surgery

Algorithm
Record of OHIP billing code E132, with no add-on codes, without a
prior record of E132 or E214 over the previous 10 years, in addition
to any one of the following CCI procedural codes: 1.CJ.52.LA,
1CJ.52.LA-SJ, 1.CJ.52.LA-QB and 1.CJ.52.WJ

Filtration surgery
+cataract extraction

Record of OHIP billing code E214, with no add-on codes, without a
prior record of E132 or E214 over the previous 10 years, in addition
to any one of the following CCI procedural codes: 1.CJ.52.LA,
1CJ.52.LA-SJ, 1.CJ.52.LA-QB and 1.CJ.52.WJ

Filtration surgery
+IDD

Record of OHIP billing code E132, with the E136 add-on code,
without a prior record of E132 or E214 over the previous 10 years, in
addition to any one of the following CCI procedural codes:
1.CJ.52.LA, 1CJ.52.LA-SJ, 1.CJ.52.LA-QB and 1.CJ.52.WJ

Filtration Surgery
+cataract extraction
+IDD

Record of OHIP billing code E214, with the E136 add-on code,
without a prior record of E132 or E214 over the previous 10 years, in
addition to any one of the following CCI procedural codes:
1.CJ.52.LA, 1CJ.52.LA-SJ, 1.CJ.52.LA-QB and 1.CJ.52.WJ

Revision Filtration Surgery

Within the follow-up period, a record of OHIP billing code E983 or
E984 and/or CCI intervention codes: 1.CJ.52.LA, 1CJ.52.LA-SJ,
1.CJ.52.LA-QB, and 1.CJ.52.WJ (accompanied by the intervention
attribute “revision”).

Bleb Repair

Within the follow-up period, record of OHIP billing code E212 or
E213 and/or CCI intervention codes 1.CS.80, 1.CS.72, 1.CS.84,
1.CS.87, 1.CS.52, 1.CC.80, 1.CD.80 revision, 1.CJ.54, 1.CJ.55,
1.CJ.80, 1.CJ.87, and 1.CD.52.LA revision.
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Appendix C: Comorbidity Coding Algorithms
Comorbidity
Diabetes

Algorithm
At least two OHIP claims bearing a diagnosis of diabetes or one OHIP fee
code claim, or one CIHI admission within two years. OHIP diagnosis code:
250 OHIP fee codes: K030, Q040, K045, K046, K029 CIHI ICD-9 code: 250
CIHI ICD-10 codes: E10, E11, E13, E14

Hypertension

One hospital admission with a hypertension diagnosis or an OHIP claim
with a hypertension diagnosis followed within two years by either an OHIP
claim or hospital admission with a hypertension diagnosis. OHIP diagnosis
codes: 401, 402, 403, 404, or 405 CIHI ICD-9 codes: 401x, 402x, 403x,
404x, or 405x CIHI ICD-10 codes: I10, I11, I12, I13, or I15

Asthma

One hospital admission with an asthma diagnosis or two OHIP claims with
asthma diagnosis within two years. CIHI ICD-9: 493 CIHI ICD-10: J45, J46
OHIP diagnosis code: 493

Stroke

At least 2 OHIP claims within 1 year bearing any one of OHIP diagnostic
codes (436, 432, 435) -or- if patient has any 1 CIHI-DAD ICD-10 code (I61
or I63 or I64 or H34.1 or G45 [ICD-9: 431, 433, 36231, 435]) within 1 year

Sleep Apnea

Any one OHIP billing code (J696, J896, J890, J690, J898, J899, J990,
J897, J697, J889, J689) or any one CIHI-DAD ICD-10 code (G4730, G4730
[ICD-9: 32720, 78051, 78053, 78057) within 5 year lookback window
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Appendix D: Ophthalmic Surgical History Variables
Variable
OHIP Definition
Secondary Glaucoma Surgical Interventions
Sclera
Sclerotomy, posterior

Vitreous

Retina

Conjunctival Disrupting
Sclera

Vitreous

Retina

Conjunctiva

Ciliary
Conjunctival Sparing
Lens

OHIP Code
E127

Removal of scleral implant

E161

Scleral resection or buckling procedure (primary or
secondary)
Vitrectomy by infusion suction cutter technique

E152

Vitrectomy by infusion suction cutter technique with
transscleral retinal suturing
Preretinal membrane peeling or segmentation to include
posterior vitrectomy and coagulation
Vitreous exchange

E938

Retinal and choroid re-attachment. Initial procedure

E151

Retinal reattachment. Second time

E153

Sclerotomy, posterior

E127

Removal of scleral implant

E161

Scleral resection or buckling procedure (primary or
secondary)
Vitrectomy by infusion suction cutter technique

E152

Vitrectomy by infusion suction cutter technique with
transscleral retinal suturing
Preretinal membrane peeling or segmentation to include
posterior vitrectomy and coagulation
Vitreous exchange

E938

Retinal and choroid re-attachment. Initial procedure

E151

Retinal reattachment. Second time

E153

Excision of conjunctival lesion

E210

Excision of conjunctival lesion w/mucous membrane graft

E948

Excision of conjunctival lesion w/autogenous conjunctival
transplant

E937

Ciliary body re-attachment

E135

Cataract extraction
Dislocated lens extraction or repositioning

E140
E141

Excision of secondary membrane with corneal section
following cataract extraction
Fixation of intra-ocular lens and/or capsular tension
device by suturing

E143
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E148

E142
E936

E148

E142
E936

E138

Removal of intraocular lens

E144

Repositioning dislocated intra-ocular lens

E145

Insertion of secondary intra-ocular lens

E146

Capsulotomy

E139

Corneal Transplant, Penetrating

E121

Corneal transplant, lamellar

E122

Laser iridotomy

E131

Iridectomy

E130

Laser Angle Surgery

Laser Angle Surgery

E134

Photocoagulation

Photocoagulation, retina

E154

Retina

Cryopexy

E155

Intravitreal injection for other than macular degeneration

E149

Cornea

Iris
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Appendix E: Glaucoma Eye Drops
Drug Class
Beta-blocker

Generic Name
LEVOBUNOLOL
HCL
LEVOBUNOLOL
HCL
LEVOBUNOLOL
HCL
LEVOBUNOLOL
HCL
TIMOLOL
MALEATE
BRIMONIDINE
TARTRATE &
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
BRIMONIDINE
TARTRATE &
TIMOLOL
MALEATE
BRINZOLAMIDE
& TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
LEVOBUNOLOL
HCL
LEVOBUNOLOL
HCL
LEVOBUNOLOL
HCL
LEVOBUNOLOL
HCL
LEVOBUNOLOL
HCL

Trade Name
APO-LEVOBUNOLOL

Strength
0.5%

SANDOZLEVOBUNOLOL
APO-LEVOBUNOLOL

0.5%

SANDOZLEVOBUNOLOL
RATIO-TIMOLOL

0.25%

COMBIGAN

0.2/0.5%

TIMOLOL MALEATE-EX

0.25%

TIMOLOL MALEATE-EX

0.5%

COMBIGAN

0.2/0.5%

AZARGA

1%/0.5%

0233162
4

APO-TIMOP GEL

0.5%

APO-TIMOP

0.25%

APO-TIMOP

0.5%

APO-TIMOP

0.25%

APO-TIMOP

0.5%

TIMOPTIC-XE

0.5%

APO-TIMOP GEL

0.25%

TIMOPTIC OCUDOSE

0.5%

APO-TIMOP

0.25%

BETAGAN

0.25%

BETAGAN

0.25%

BETAGAN

0.5%

BETAGAN

0.5%

BETAGAN

0.5%

0229081
2
0081227
7
0081228
5
0089808
2
0089809
0
0217188
9
0231585
8
6612398
8
6689809
0
0080129
1
0080130
5
0081173
4
0089573
3
0090759
6
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0.25%

0.5%

DIN
0224157
4
0224171
6
0224157
5
0224171
5
0224024
9
0224834
7

0224227
5
0224227
6
0985729
8

LEVOBUNOLOL
HCL
LEVOBUNOLOL
HCL
LEVOBUNOLOL
HCL
LEVOBUNOLOL
HCL
TIMOLOL
MALEATE
BETAXOLOL
HCL
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
BETAXOLOL
HCL
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
LEVOBUNOLOL
HCL
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE

NOVO-LEVOBUNOLOL

0.25%

NOVO-LEVOBUNOLOL

0.5%

LEVOBUNOLOL HCL

0.25%

LEVOBUNOLOL HCL

0.5%

TIMOPTIC

0.5%

BETOPTIC

0.5%

TIMOPTIC

0.25%

TIMOPTIC

0.5%

TIM-AK

0.5%

TIM-AK

0.25%

T-LO

0.25%

T-LO

0.5%

TIMOLOL

0.25%

TIMOLOL

0.5%

SANDOZ-BETAXOLOL

0.5%

DOM-TIMOLOL

0.25%

DOM-TIMOLOL

0.5%

SANDOZ-TIMOLOL

0.25%

SANDOZ-TIMOLOL

0.5%

TIMOPTIC

-

TIMOPTIC

0.25%

LEVOBUNOLOL HCL

5MG/ML

MED-TIMOLOL

0.25%

MED-TIMOLOL

0.5%

TEVA-TIMOLOL

0.25%

TEVA-TIMOLOL

0.5%

NU-TIMOLOL

0.25%

NU-TIMOLOL

0.5%
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0219745
6
0219746
4
0223679
2
0223679
3
0088943
1
0089637
3
0089682
9
0089683
7
0201024
0
0201025
9
0220249
2
0220250
6
0223002
8
0223002
9
0223597
1
0223877
0
0223877
1
0224173
1
0224173
2
4945120
7
6688942
3
0063769
6
0208431
7
0208432
5
0209491
6
0209492
4
0209493
2
0209494
0

LEVOBUNOLOL

RATIO-LEVOBUNOLOL

0.5%

TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
TIMOLOL
MALEATE
LEVOBUNOLOL
HCL
LEVOBUNOLOL
HCL
LEVOBUNOLOL
HCL
LEVOBUNOLOL
HCL
BETAXOLOL
HCL
LEVOBUNOLOL
HCL
TIMOLOL
MALEATE
TIMOLOL
MALEATE
BETAXOLOL
HCL
TIMOLOL
MALEATE
LEVOBUNOLOL

TIMOLOL

0.25%

TIMOLOL

0.5%

STORZ TIMOL

0.25%

STORZ TIMOL

0.5%

GEN-BUNOLOL

0.25%

GEN-BUNOLOL

0.5%

OPHTHO-BUNOLOL

0.25%

OPHTHO-BUNOLOL

0.5%

ALTI-BETAXOLOL

0.5%

PMS-LEVOBUNOLOL

0.25%

CROWN-TIM

0.25%

CROWN-TIM

0.5%

NOVO-BETAXOLOL

0.5%

RATIO-TIMOLOL

0.25%

RATIO-LEVOBUNOLOL

0.5%

TIMOLOL
MALEATE
DORZOLAMIDE
& TIMOLOL
DORZOLAMIDE
& TIMOLOL
DORZOLAMIDE
& TIMOLOL
DORZOLAMIDE
& TIMOLOL
BETAXOLOL
HCL &
PILOCARPINE
HCL
LATANOPROST
& TIMOLOL
TIMOLOL
MALEATE &
TRAVOPROST
TIMOLOL
MALEATE &
TRAVOPROST
LATANOPROST
& TIMOLOL

COMPOUND - TIMOLOL
PRESERVATIVE FREE
APO-DORZO/TIMOP

-

CO DORZOTIMOLOL

2/0.5%

SANDOZDORZOL/TIMOL
DORZOLAMIDETIMOLOL
BETOPTIC/PILO

1%

XALACOM

5MG/5MCG/ML

DUOTRAV PQ

0.004/0.5%

DUOTRAV PQ

0.004/0.5%

0985733
3

SDZLATANOP/TIMOLOL

5MG/5MCG/ML

0239468
5
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20MG/5MG/ML

1%
0.25% & 1.75%

0213116
7
0214747
5
0214748
3
0217602
5
0217603
3
0220081
3
0220082
1
0220084
8
0220085
6
0223062
0
0223799
0
0223930
0
0223930
1
0224005
0
0224024
8
2031167
0
2212329
5
0229961
5
0240438
9
0234435
1
0235780
1
0223853
9

0224661
9
0227825
1

LATANOPROST
& TIMOLOL

GDLATANOPROST/TIMOL
OL
DUOTRAV PQ

5MG/5MCG/ML

0237306
8

0.004/0.5%

0985751
2

DUOTRAV PQ

0.004/0.5%

0985751
3

PMS-LATANOPROSTTIMOLOL

5MG/50MCG/M
L

0240459
1

SANDOZDORZOLAMIDE
SANDOZ
BRINZOLAMIDE
DIAMOX

2%

DIAMOX

20MG

DIAMOX

2%/.5%

DORZOLAMIDE

2%

ACETAZOLAMID
E
DORZOLAMIDE
& TIMOLOL
DORZOLAMIDE
& TIMOLOL
DORZOLAMIDE
& TIMOLOL
DORZOLAMIDE
& TIMOLOL

ACETAZOLAMIDE

2%

APO-DORZO/TIMOP

20MG/5MG/ML

CO DORZOTIMOLOL

2/0.5%

SANDOZDORZOL/TIMOL
DORZOLAMIDETIMOLOL

1%

0231630
7
0236523
5
0001467
2
0203924
9
0223807
4
0236499
9
9910117
5
0229961
5
0240438
9
0234435
1
0235780
1

PILOCARPINE
HCL
DORZOLAMIDE
HCL & TIMOLOL
MALEATE
PILOCARPINE
HCL
CARBACHOL

MINIMS PILOCARPINE

4%

COSOPT

20MG/5MG/ML

PILOSTAT

4%

ISOPTO CARBACHOL

0.75%

PILOCARPINE
HBR
PILOCARPINE
HCL
CARBACHOL
CHLORIDE
PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
HCL

ADSORBO-CARPINE

2%

ISOPTO CARPINE

3%

MIOSTAT

0.01%

ISOPTO CARPINE

8%

AKARPINE

1%

AKARPINE

2%

TIMOLOL
MALEATE &
TRAVOPROST
TIMOLOL
MALEATE &
TRAVOPROST
LATANOPROST
& TIMOLOL
CAI

DORZOLAMIDE
BRINZOLAMIDE
ACETAZOLAMID
E SODIUM
ACETAZOLAMID
E SODIUM
ACETAZOLAMID
E SODIUM
DORZOLAMIDE

Miotic
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20MG/ML
2%

1%

0214847
1
0225869
2
0077236
4
0000064
7
0027883
1
0000087
6
0004254
4
0025253
0
0062773
9
0062774
7

PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
NITRATE
PILOCARPINE
NITRATE
PILOCARPINE
NITRATE
PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
NITRATE
EPINEPHRINE
BITARTRATE &
PILOCARPINE
HCL
EPINEPHRINE
BITARTRATE &
PILOCARPINE
HCL
EPINEPHRINE
BITARTRATE &
PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
HCL
ECOTHIOPATE
IODIDE
CHYMOTRYPSI
N
PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
HCL

AKARPINE

4%

ISOPTO CARPINE

1%

P.V. CARPINE

1%

P.V. CARPINE

2%

P.V. CARPINE

4%

MIOCARPINE

1%

MIOCARPINE

2%

MIOCARPINE

4%

MIOCARPINE

6%

MIOCARPINE

1%

MIOCARPINE

2%

MIOCARPINE

3%

PILOCARPINE NITRATE

1%

E-PILO # 1

1%

E-PILO # 2

2%

0028168
9

E-PILO # 4

4%

0028170
0

MIOCARPINE

0.5%

MIOCARPINE

4%

MIOCARPINE

6%

PHOSPHOLINE IOD

3MG

CATARASE

300U/VIAL

MIOCARPINE

6%

MIOCARPINE

0.5%

MIOCARPINE

1%

MIOCARPINE

2%

0028175
1
0028177
8
0028178
6
0028330
4
0052635
5
0052673
8
0052752
1
0052754
8
0052755
6
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0062775
5
2212301
7
0000117
1
0000119
8
0000122
8
0002896
7
0002897
5
0002899
1
0002900
9
0026509
8
0026510
1
0026512
8
0026911
5
0028167
0

PGA

PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
HCL
ECOTHIOPATE
IODIDE
ACETYLCHOLIN
E HYDROXIDE
CHLORIDE
PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
HCL
DAPIPRAZOLE
HCL
ACETYLCHOLIN
E HYDROXIDE
CHLORIDE
CARBACHOL

MIOCARPINE

3%

MIOCARPINE

4%

SPERSACARPINE

3%

PILOSTAT

2%

PILOSTAT

1%

PHOSPHOLINE IOD

3MG

MIOCHOL-E

10MG/ML

PILOCARPINE

2%

PILOCARPINE

1%

PILOCARPINE

4%

REV-EYES

25MG

MIOCHOL-E

10MG/ML

CARBASTAT

0.01%

ECOTHIOPATE
IODIDE
DORZOLAMIDE
& TIMOLOL
PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
HCL
PILOCARPINE
HCL &
EPINEPHRINE
BITARTRATE
BETAXOLOL
HCL &
PILOCARPINE
HCL

PHOSPHOLINE IOD

6.25MG

TEVA-DORZOTIMOL

20MG/5MG/ML

COMPOUND PILOCARPINE
COMPOUND PILOCARPINE
COMPOUND PILOCARPINE
E-PILO 2

0.25%

BETOPTIC/PILO

0.25% & 1.75%

0223853
9

TRAVOPROST

TRAVATAN

0.004%

BIMATOPROST

LUMIGAN

0.03%

TRAVOPROST

TRAVATAN Z

0.004%

TRAVOPROST

TRAVATAN Z

0.004%

BIMATOPROST

LUMIGAN RC

0.01%

0224489
6
0224586
0
0231800
8
0985733
2
0232499
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4%
2% & 1%

0052756
4
0052757
2
0072542
0
0077237
2
0077238
0
0086085
9
0088933
4
0190763
8
0190765
4
0190766
2
0197034
8
0213332
6
0219558
5
0223807
6
0232052
5
2212301
5
2212301
9
2212329
4
0002885
1

LUMIGAN RC

0.01%

LATANOPROST

APO-LATANOPROST

50MCG/ML

LATANOPROST

GD-LATANOPROST

50MCG

BIMATOPROST

LUMIGAN RC

0.01%

LATANOPROST

CO LATANOPROST

0.05MG/ML

LATANOPROST

50MCG/ML

TRAVOPROST

SANDOZLATANOPROST
TEVA-TRAVOPROST Z

TRAVOPROST

TEVA-TRAVOPROST Z

0.004%

TRAVOPROST

0.004%

TRAVOPROST

SANDOZ
TRAVOPROST
APO-TRAVOPROST Z

LATANOPROST

PMS-LATANOPROST

50MCG/ML

BIMATOPROST

LUMIGAN

0.03%

BIMATOPROST

LUMIGAN

0.03%

LATANOPROST

LATANOPROST

50MCG/ML

LATANOPROST
& TIMOLOL
TIMOLOL
MALEATE &
TRAVOPROST
TIMOLOL
MALEATE &
TRAVOPROST
LATANOPROST
& TIMOLOL
LATANOPROST
& TIMOLOL

XALACOM

5MG/5MCG/ML

DUOTRAV PQ

0.004/0.5%

DUOTRAV PQ

0.004/0.5%

0985733
3

SDZLATANOP/TIMOLOL
GDLATANOPROST/TIMOL
OL
DUOTRAV PQ

5MG/5MCG/ML

0239468
5
0237306
8

0.004/0.5%

0985751
2

DUOTRAV PQ

0.004/0.5%

0985751
3

PMS-LATANOPROSTTIMOLOL

5MG/50MCG/M
L

0240459
1

RATIO-BRIMONIDINE

0.2%

ALPHAGAN P
PMS-BRIMONIDINE

0.15%
0.2%

TIMOLOL
MALEATE &
TRAVOPROST
TIMOLOL
MALEATE &
TRAVOPROST
LATANOPROST
& TIMOLOL
Sympathomimeti
cs

7
0985736
8
0229652
7
0237304
1
0985739
8
0225478
6
0236733
5
0241206
3
0985750
4
0241316
7
0241573
9
0231712
5
0099014
6
9224586
0
0237550
8
0224661
9
0227825
1

BIMATOPROST

BRIMONIDINE
TARTRATE
BRIMONIDINE
TARTRATE
BRIMONIDINE
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0.004%

0.004%

5MG/5MCG/ML

0224302
6
0224815
1
0224628

TARTRATE
BRIMONIDINE
TARTRATE
BRIMONIDINE
BRIMONIDINE
TARTRATE
BRIMONIDINE
TARTRATE
BRIMONIDINE
TARTRATE
BRIMONIDINE
TARTRATE
BRIMONIDINE
TARTRATE
KETOTIFEN
FUMARATE
EPINEPHRYL
BORATE
EPINEPHRINE
BITARTRATE &
PILOCARPINE
HCL
EPINEPHRINE
BITARTRATE &
PILOCARPINE
HCL
EPINEPHRINE
BITARTRATE &
PILOCARPINE
HCL
EPINEPHRINE
BITARTRATE &
PILOCARPINE
HCL
EPINEPHRYL
BORATE
EPINEPHRYL
BORATE
EPINEPHRINE
BITARTRATE &
PILOCARPINE
HCL
EPINEPHRINE
BITARTRATE &
PILOCARPINE
HCL
EPINEPHRINE
BITARTRATE &
PILOCARPINE
HCL
EPINEPHRINE
BITARTRATE &
PILOCARPINE
HCL
EPINEPHRINE

APO-BRIMONIDINE

0.2%

SANDOZ-BRIMONIDINE

0.2%

APO-BRIMONIDINE P

0.15%

ALPHAGAN

0.5%

DOM-BRIMONIDINE

0.2%

BRIMONIDINE
BRIMONIDINE
TARTRATE

0.2%

KETOTIFEN

0.25MG/ML

EPINAL

1%

4
0226007
7
0230542
9
0230133
4
0223687
7
0224628
5
0224945
6
0224594
2
0240087
1
0000073
6

E-PILO # 2

2%

0003592
0

E-PILO # 4

4%

0003594
7

E-PILO # 3

3%

0028169
7

E-PILO # 6

6%

EPPY

0.5%

EPPY

1%

0028185
9
0032364
0
0032365
9

E-PILO # 1

1%

0052636
3

E-PILO # 2

2%

0052637
1

E-PILO # 3

3%

0052639
8

E-PILO # 4
E-PILO # 6

4%
6%

0052640
1
0052642
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0.2%

BITARTRATE &
PILOCARPINE
HCL
BRIMONIDINE
TARTRATE
BRIMONIDINE
TARTRATE
PILOCARPINE
HCL &
EPINEPHRINE
BITARTRATE

8

BRIMONIDINE
OPHTHALMIC

0.2%

APX-BRIMONIDINE P
E-PILO 2

0.15%
2% & 1%

209

0224628
3
0235073
4
0002885
1

Appendix F: Other Eye Drop Medications
Drug Class

Generic Name

Trade Name

Strength

DIN

Antibiotic

FUSIDIC ACID

FUCITHALMIC W/O
PRES
POLYSPORIN

1%

02243861

10MU

02239156

POLYSPORIN

10MU

02239157

FUCITHALMIC W/
PRES
CHLOROPTIC
POLYSPORIN

1%

02243862

1%
10MU

00001341
00004847

AUREOMYCIN

1%

00015075

ACHROMYCIN
ILOTYCIN
PENTAMYCETIN
TERRAMYCIN

1%

00015083
00015997
00024317
00024791

BORIC ACID
GANTRISIN

NOT AVLE
4%

GRAMICIDIN &
POLYMYXIN B SULFATE
BACITRACIN ZINC &
POLYMYXIN B SULFATE
FUSIDIC ACID
CHLORAMPHENICOL
BACITRACIN ZINC &
POLYMYXIN B SULFATE
CHLORTETRACYCLINE
HCL
TETRACYCLINE HCL
ERYTHROMYCIN
CHLORAMPHENICOL
OXYTETRACYCLINE HCL
& POLYMYXIN B
SULFATE
BORIC ACID
SULFISOXAZOLE
DIOLAMINE
CHLORAMPHENICOL &
HYDROCORTISONE
ACETATE
CHLORAMPHENICOL
ERYTHROMYCIN
BACITRACIN &
POLYMYXIN B SULFATE
CHLORAMPHENICOL
GRAMICIDIN &
NEOMYCIN SULFATE &
POLYMYXIN B SULFATE
SULFACETAMIDE
SODIUM
SULFACETAMIDE
SODIUM
SULFACETAMIDE
SODIUM
CHLORAMPHENICOL
FLUOROMETHOLONE &
NEOMYCIN SULFATE
CHLORAMPHENICOL
BORIC ACID & SODIUM
BORATE
CHLORAMPHENICOL
CHLORAMPHENICOL
CHLORAMPHENICOL
CHLORAMPHENICOL
ALLANTOIN & BORIC

10MG

CHLOROMYCETIN
W/HC

00050504
00115460
00155977

PENTAMYCETIN
PDP-ERYTHROMYCIN
NEO BACE

2.5MG
5MG

00163503
00191275
00221392

ISOPTO FENICOL
NEOSPORIN

0.5%
10MU

00239879
00243183

SULFACETAMIDE

10%

00269069

SULF-10

10%

00281867

OPTOSULFEX

10%

00343986

MINIMS
CHLORAMPHENICOL
FML-NEO LIQUIFILM

0.5%

00387525

0.1%

00395153

SOPAMYCETIN
COLLYRE
HYGIENIQUE SOKER
SOPAMYCETIN
SOPAMYCETIN
PENTAMYCETIN
PENTAMYCETIN
OPTREX
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11.1MG &
1.89MG
2MG
50MG
2.5MG
45MG

00402974
00425745
00438650
00438677
00446521
00504785
00520101

ACID & HAMAMELIS &
SALICYLIC ACID &
SODIUM BORATE & ZINC
SULFATE
ALLANTOIN & BORIC
ACID & GLYCEROL &
HAMAMELIS & SODIUM
BORATE
BORIC ACID
SULFACETAMIDE
SODIUM
BORIC ACID
SULFACETAMIDE
SODIUM
BORIC ACID & SODIUM
BORATE
GRAMICIDIN &
NEOMYCIN SULFATE &
POLYMYXIN B SULFATE
CEFAZOLIN SODIUM
CHLORAMPHENICOL
SULFACETAMIDE
SODIUM
CHLORAMPHENICOL
BORIC ACID &
BUTACAINE SULFATE
GRAMICIDIN &
NEOMYCIN SULFATE &
POLYMYXIN B SULFATE
ERYTHROMYCIN
GRAMICIDIN &
POLYMYXIN B SULFATE
CHLORAMPHENICOL
CHLORAMPHENICOL
CHLORAMPHENICOL
SULFACETAMIDE
SODIUM
SULFACETAMIDE
SODIUM
CHLORAMPHENICOL
CHLORAMPHENICOL
ERYTHROMYCIN
SULFACETAMIDE
SODIUM
SULFACETAMIDE
SODIUM
SULFACETAMIDE
SODIUM
SULFACETAMIDE
SODIUM
ERYTHROMYCIN
SULFACETAMIDE
TETRACYCLINE HCL
GRAMICIDIN &
NEOMYCIN SULFATE &
POLYMYXIN B SULFATE

OPTREX

00520128

EYE WASH
SULF-10

2.5%
10%

00524468
00527963

BORIC ACID
SULFEX

2.5%
10%

00540994
00554022

EYE EZE

1.11%

00581836

NEOSPORIN

10MU

00601659

CEFAZOLIN
AK-CHLOR
AK-SULF

NOT AVLE
0.5%
10%

00622360
00622958
00622966

AK-CHLOR
EYE LOTION

00627720
00629014

AK-SPOR

1%
2.3% &
0.14%
1.75MG

AK-MYCIN
OPTIMYXIN

5MG
10MU

00641324
00701785

PENTAMYCETIN
SPERSANICOL
SPERSANICOL
SPERSACET

10MG
0.5%
1%
10%

00704571
00725528
00725536
00729299

PMSSULFACETAMIDE
CEBENICOL
SOPAMYCETIN
ERYTHROTOPIC
BALSULPH

30%

00762059

0.4%
2MG
5MG
10%

00763454
00763535
00772305
00772313

SULAMYD

10%

00778053

SULAMYD

30%

00778061

SULAMYD

10%

00778347

ERYTHROMYCIN
BALSULPH
TETRACYCLINE
OPTIMYXIN PLUS

5MG
10%
1%
10MU

00785725
00790842
00792594
00807435
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00635065

BACITRACIN ZINC &
NEOMYCIN SULFATE &
POLYMYXIN B SULFATE
SULFACETAMIDE
SODIUM
CHLORAMPHENICOL
SULFACETAMIDE
SODIUM
CHLORAMPHENICOL
OXYMETAZOLINE HCL
GRAMICIDIN &
POLYMYXIN B SULFATE
POLYMYXIN B SULFATE
AMIKACIN SULFATE
CEFAZOLIN SODIUM
CYCLOSPORINE
VANCOMYCIN HCL
CLARITHROMYCIN
CYCLOSPORINE
ERYTHROMYCIN
ERYTHROMYCIN
ERYTHROMYCIN
OXYMETAZOLINE HCL
BORIC ACID
BACITRACIN ZINC &
NEOMYCIN SULFATE &
POLYMYXIN B SULFATE
SULFACETAMIDE
SODIUM
CHLORAMPHENICOL
PHENIRAMINE MALEATE
& PHENYLEPHRINE HCL
& POLYVINYL ALCOHOL
ERYTHROMYCIN
CHLORAMPHENICOL
BACITRACIN ZINC &
POLYMYXIN B SULFATE
CHLORAMPHENICOL
ALLANTOIN & BORIC
ACID & GLYCEROL &
HAMAMELIS & SODIUM
BORATE
ALLANTOIN & BORIC
ACID & HAMAMELIS &
SALICYLIC ACID &
SODIUM BORATE & ZINC
SULFATE
ERYTHROMYCIN
BORIC ACID
GRAMICIDIN &
POLYMYXIN B SULFATE
BACITRACIN ZINC &
POLYMYXIN B SULFATE

BACITRACINNEOMYCIN-POLY

10MU

00811971

SULFACETAMIDE
SODIUM
SOPAMYCETIN
PMSSULFACETAMIDE
PMSCHLORAMPHENICOL
VISINE L.R.
POLYSPORIN

10%

00811998

2MG
10%

00837369
00838934

0.5%

00861383

10MU

00892025
00898805

BIODERM
AMIKACIN EYE
DROPS
CEFAZOLIN
CYCLOSPORIN
VANCOMYCIN
CLARITHROMYCIN
RESTASIS
ILOTYCIN
ERYTHROMYCIN
PDP-ERYTHROMYCIN
VISINE L.R.
EYE WASH
DIOSPORIN

10000U/500G
NOT AVLE

00899380
00903067

NOT AVLE
NOT AVLE
NOT AVLE
NOT AVLE
0.05%

00903081
00903083
00903088
00903092
00903127
00904082
00906840
00912755
01942484
01943464
02023792

DIOSULF

10%

02023830

DIOCHLORAM
DIOROUGE

0.5%
0.5%

02023857
02026511

DIOMYCIN
MINIMS
CHLORAMPHENICOL
OPTIMYXIN

5MG/GM
0.5%

02141574
02148374

10MU

02160889

PENTAMYCETIN
OPTREX

0.5%

02164051
02185482

5MG/G
5MG
1.2%

OPTREX

02186853

ERYTHROMYCIN
EYE WASH
POLYCIDIN

0.5%
1.2%
10MU

02212935
02212994
02229903

POLYCIDIN

10MU

02230193
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ERYTHROMYCIN
POLYMYXIN B SULFATE
& TRIMETHOPRIM
SULFATE
POLYMYXIN B SULFATE
& TRIMETHOPRIM
SULFATE
AZITHROMYCIN
ERYTHROMYCIN
BESIFLOXACIN HCL
AZITHROMYCIN
CYCLOSPORINE
VANCOMYCIN HCL
CYCLOSPORINE
ERYTHROMYCIN
STEARATE
OFLOXACIN
OFLOXACIN
NORFLOXACIN
NORFLOXACIN
NORFLOXACIN
OFLOXACIN
OFLOXACIN
MOXIFLOXACIN HCL
CIPROFLOXACIN HCL
GATIFLOXACIN
CIPROFLOXACIN HCL
CIPROFLOXACIN HCL
CIPROFLOXACIN HCL
MOXIFLOXACIN HCL
PHENYLEPHRINE HCL &
SODIUM BORATE &
BORIC ACID
BETAMETHASONE
SODIUM PHOSPHATE &
GENTAMICIN SULFATE
DEXAMETHASONE &
FRAMYCETIN SULFATE
& GRAMICIDIN
PREDNISOLONE
ACETATE &
SULFACETAMIDE
SODIUM
PREDNISOLONE
ACETATE &
SULFACETAMIDE
SODIUM
PREDNISOLONE
ACETATE &
SULFACETAMIDE
SODIUM

ERYTHROMYCIN
SANDOZPOLYTRIMETHOPRIM

5MG
1%

02237041
02239234

PMSPOLYTRIMETHOPRIM

1%

02240363

AZASITE
OPHTH
ERYTHROMYCIN
BESIVANCE
AZASITE
RESTASIS
COMPOUND VANCOMYCIN
CYCLOSPORIN
ERYTHROMYCINE

1%
5MG

02321661
02326663

0.6%
1%
0.05%
NOT AVLE

02336847
02345498
02355655
22123297

4%
0.5%

66123446
99100766

APO-OFLOXACIN
PMS-OFLOXACIN
NOROXIN
NOROXIN
NOROXIN
OPHTHO-FLOX
SANDOZ-OFLOXACIN
VIGAMOX
PMSCIPROFLOXACIN
ZYMAR
APO-CIPROFLOX
NU-CIPROFLOX
SANDOZCIPROFLOXACIN
SANDOZ
MOXIFLOXACIN
OCCU-CAL

0.3%
0.3%
0.3%
0.3%
0.3%
.30%
0.3%
0.5%
0.3%

02248398
02252570
00908294
01908294
01918294
02243025
02247189
02252260
02253933

0.3%
0.3%
.3%
0.3%

02257270
02263130
02333228
02387131

0.5%

02411520

0.2MG/ML &
1.9MG/ML &
11.16MG/ML
3MG/ML

00540935

SANDOZ-OPTICORT

5MG

02247920

BLEPHAMIDE
LIQUIFILM

10%

00807788

CETAPRED

10%

00042617

CETAPRED

10%

00042625

SANDOZPENTASONE
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02244999

PREDNISOLONE
ACETATE &
SULFACETAMIDE
SODIUM
DEXAMETHASONE &
NEOMYCIN SULFATE &
POLYMYXIN B SULFATE
DEXAMETHASONE &
NEOMYCIN SULFATE &
POLYMYXIN B SULFATE
PREDNISOLONE
ACETATE &
SULFACETAMIDE
SODIUM
BACITRACIN ZINC &
HYDROCORTISONE &
NEOMYCIN SULFATE &
POLYMYXIN B SULFATE
DEXAMETHASONE &
NEOMYCIN SULFATE
CHLORAMPHENICOL &
HYDROCORTISONE
ACETATE
HYDROCORTISONE &
OXYTETRACYCLINE HCL
CHLORAMPHENICOL &
HYDROCORTISONE
ACETATE
CHLORAMPHENICOL &
HYDROCORTISONE
ACETATE
DEXAMETHASONE &
FRAMYCETIN SULFATE
& GRAMICIDIN
DEXAMETHASONE &
FRAMYCETIN SULFATE
& GRAMICIDIN
PREDNISOLONE
ACETATE &
SULFACETAMIDE
SODIUM
HYDROCORTISONE
ACETATE & NEOMYCIN
SULFATE
HYDROCORTISONE
ACETATE & NEOMYCIN
SULFATE
HYDROCORTISONE
ACETATE & NEOMYCIN
SULFATE
PREDNISOLONE
DISODIUM PHOSPHATE
& SULFACETAMIDE
SODIUM
HYDROCORTISONE &
NEOMYCIN SULFATE &

ISOPTO CETAPRED

10%

00042633

MAXITROL

0.1%

00042668

MAXITROL

0.1%

00042676

BLEPHAMIDE
LIQUIFILM

10%

00045632

CORTISPORIN

1%

00068772

NEO-DECADRON

0.1%

00140732

OPHTHOCORT

10MG

00156175

TERRA-CORTRIL

00158178

PENTAMYCETIN HC

10MG

00163511

PENTAMYCETIN HC

10MG

00163538

SOFRACORT

5MG

00173592

SOFRACORT

5MG

00173606

METIMYD

0.5%

00177024

NEO-CORTEF

0.5%

00194883

NEO-CORTEF

1.5%

00194921

NEO-CORTEF

1.5%

00194948

VASOCIDIN

0.25%

00218812

CORTISPORIN
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00243140

POLYMYXIN B SULFATE
BETAMETHASONE &
SULFACETAMIDE
SODIUM
PREDNISOLONE
DISODIUM PHOSPHATE
& SULFACETAMIDE
SODIUM
PREDNISOLONE
ACETATE &
SULFACETAMIDE
SODIUM
DEXAMETHASONE &
NEOMYCIN SULFATE &
POLYMYXIN B SULFATE
PREDNISOLONE
ACETATE &
SULFACETAMIDE
SODIUM
CHLORAMPHENICOL &
HYDROCORTISONE
ACETATE
HYDROCORTISONE &
OXYTETRACYCLINE HCL
BACITRACIN ZINC &
HYDROCORTISONE &
NEOMYCIN SULFATE &
POLYMYXIN B SULFATE
PREDNISOLONE
DISODIUM PHOSPHATE
& SULFACETAMIDE
SODIUM
BETAMETHASONE &
SULFACETAMIDE
SODIUM
BETAMETHASONE
SODIUM PHOSPHATE &
GENTAMICIN SULFATE
BETAMETHASONE
SODIUM PHOSPHATE &
GENTAMICIN SULFATE
DEXAMETHASONE &
NEOMYCIN &
POLYMYXIN B SULFATE
PREDNISOLONE
ACETATE &
SULFACETAMIDE
SODIUM
HYDROCORTISONE &
NEOMYCIN SULFATE &
POLYMYXIN B SULFATE
BACITRACIN ZINC &
HYDROCORTISONE &
NEOMYCIN SULFATE &
POLYMYXIN B SULFATE
CHLORAMPHENICOL &

CELESTONE-S

3MG

00271012

VASOCIDIN

0.25%

00281824

BLEPHAMIDE S.O.P.

10%

00307246

MAXITROL

0.1%

00358177

BLEPHAMIDE
LIQUIFILM

10%

00395145

SOPAMYCETIN HC

2MG

00438669

TERRA-CORTRIL

00443298

CORTISPORIN

1%

00520322

VASOCIDIN

0.25%

00527998

CELESTONE-S

3MG

00575194

GARASONE

0.3%

00586692

GARASONE

0.3%

00586706

AK-TROL

10MU

00626597

AK-CIDE

10/0.5%

00630640

CORTISPORIN

00666211

CORTISPORIN

1%

00701904

PENTAMYCETIN HC

10MG

00704563
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HYDROCORTISONE
ACETATE
CHLORAMPHENICOL &
HYDROCORTISONE
ACETATE
PREDNISOLONE
DISODIUM PHOSPHATE
& SULFACETAMIDE
SODIUM
CHLORAMPHENICOL &
HYDROCORTISONE
ACETATE
PREDNISOLONE
ACETATE &
SULFACETAMIDE
SODIUM
PREDNISOLONE
ACETATE &
SULFACETAMIDE
SODIUM
PREDNISOLONE
DISODIUM PHOSPHATE
& SULFACETAMIDE
SODIUM
PREDNISOLONE
ACETATE &
SULFACETAMIDE
SODIUM
CHLORAMPHENICOL &
HYDROCORTISONE
ACETATE
PREDNISOLONE
DISODIUM PHOSPHATE
& SULFACETAMIDE
SODIUM
PREDNISOLONE
ACETATE &
SULFACETAMIDE
SODIUM
PREDNISOLONE
DISODIUM PHOSPHATE
& SULFACETAMIDE
SODIUM
CHLORAMPHENICOL &
HYDROCORTISONE
ACETATE
CHLORAMPHENICOL &
HYDROCORTISONE
ACETATE
DEXAMETHASONE &
FRAMYCETIN SULFATE
& GRAMICIDIN
DEXAMETHASONE &
NEOMYCIN SULFATE &
POLYMYXIN B SULFATE
PREDNISOLONE

CORTIPHENAL H

1% & 1%

00750670

VASOCIDIN

0.25%

00760056

SOPAMYCETIN HC

2MG

00763543

BLEPHAMIDE S.O.P.

10%

00806617

BLEPHAMIDE
LIQUIFILM

10%

00807982

VASOCIDIN

0.25%

00808199

ISOPTO CETAPRED

10%

00810894

SOPAMYCETIN HC

10MG

00837350

VASOCIDIN

0.25%

00843741

BLEPHAMIDE
LIQUIFILM

10%

00903124

VASOCIDIN

0.25%

00903477

PENTAMYCETIN HC

10MG

01980572

PENTAMYCETIN HC

10MG

01980580

SOFRACORT

5MG

01987720

DIOPTROL

3.5MG

02023806

DIOPTIMYD

5MG

02023814
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ACETATE &
SULFACETAMIDE
SODIUM
DEXAMETHASONE &
NEOMYCIN SULFATE &
POLYMYXIN B SULFATE
PREDNISOLONE
DISODIUM PHOSPHATE
& SULFACETAMIDE
SODIUM
DEXAMETHASONE &
FRAMYCETIN SULFATE
& GRAMICIDIN
GENTAMICIN SULFATE &
BETAMETHASONE
SODIUM PHOSPHATE
GENTAMICIN SULFATE &
BETAMETHASONE
SODIUM PHOSPHATE
BACITRACIN &
HYDROCORTISONE &
NEOMYCIN SULFATE &
POLYMYXIN B SULFATE
GENTAMICIN SULFATE &
BETAMETHASONE
SODIUM PHOSPHATE
SULFACETAMIDE
SODIUM &
PHENYLEPHRINE HCL
PHENYLEPHRINE HCL &
SULFACETAMIDE
SODIUM
PHENYLEPHRINE HCL &
SULFACETAMIDE
SODIUM
Aminoglycoside

TOBRAMYCIN SULFATE
TOBRAMYCIN
FRAMYCETIN SULFATE
FRAMYCETIN SULFATE
GENTAMICIN SULFATE
GENTAMICIN SULFATE
GENTAMICIN SULFATE
GENTAMICIN SULFATE
GENTAMICIN
GENTAMICIN SULFATE
GENTAMICIN SULFATE
GENTAMICIN
GENTAMICIN SULFATE
GENTAMICIN
GENTAMICIN SULFATE
GENTAMICIN
TOBRAMYCIN
GENTAMICIN SULFATE

DIOPTROL

3.5MG

02023849

VASOCIDIN

0.25%

02133342

SOFRACORT

5MG

02224631

DOM-GENTAMICINBETAMETHASONE

0.3% & 0.1%

02238818

PMS-GENTAMICINBETAMETHASONE

0.3% & 0.1%

02238819

SANDOZCORTIMYXIN

10MU

02242485

BETAMYCIN

3MG/ML &
1MG/ML

02247446

VASOSULF

15% & .125%

00191965

VASOSULF

15%

00265152

VASOSULF

15%

00760048

SANDOZTOBRAMYCIN
APO-TOBRAMYCIN
SOFRAMYCIN
SOFRAMYCIN
GARAMYCIN
GARAMYCIN
GENTAMYTREX
GENTAMYTREX
GENTROSULF
PMS-GENTAMICIN
OPHTAGRAM
GENTROSULF
OPHTAGRAM
GENTACIDIN
GENTAK
RATIO-GARATEC
TOBRAMYCIN
GENTAMICIN
FORTIFIED

0.3%

02241755

0.3%
5MG
5MG
0.3%
0.3%
5MG/ML
5MG/GM
3%
0.5%
0.3%
3%
0.3%
0.3%
0.3%
3MG
-

02245698
02224887
02224895
00028126
00512912
00717940
00717959
00772429
00777781
00789100
00790753
00794317
00810282
00832162
00880191
00903080
00903082
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NETILMICIN SULFATE
GENTAMICIN
GENTAMICIN
GENTAMICIN SULFATE
GENTAMICIN
GENTAMICIN
FRAMYCETIN SULFATE
GENTAMICIN SULFATE
GENTAMICIN SULFATE

5%
0.3%
0.3%
0.3%
3MG
3MG
5MG
0.3%
0.3%

00910911
01932330
01932349
01933299
01987461
01987488
01987666
01989073
02009900

0.3%

02014548

0.3%
0.3%

02023776
02024500

0.3%
0.3%

02133245
02148404

0.3%

02229440

0.3%

02230888

0.3%
0.3%
0.3%
-

02237689
02238710
02261243
22123296

TOBRAMYCIN

NATACYN
CIDOMYCIN
CIDOMYCIN
GENTAMICIN
OCUGRAM
OCUGRAM
SOFRAMYCIN
GENTAK
MINIMS GENTAMICIN
SULF
GENTAMICIN
SULFATE
DIOGENT
GENTAMICIN
SULFATE
GENTACIDIN
MINIMS GENTAMICIN
SULF
GENTAMICIN
SULFATE
GENTAMICIN
SULFATE
PMS-GENTAMICIN
CROWN AK-TOBRA
TOBREXAN
COMPOUND TOBRAMYCIN
TOBRAMYCIN

300MG

99100845

Antifungal

VORICONAZOLE
VORICONAZOLE

VORICONAZOLE
VORICONAZOLE

1%
-

09854663
00903740

Antiviral

INTERFERON
INTERFERON
IDOXURIDINE
TRIFLURIDINE
TRIFLURIDINE
TRIFLURIDINE

INTERFERON
INTERFERON
STOXIL
VIROPTIC
APO-TRIFLURIDINE
SANDOZTRIFLURIDINE

1MU/ML
1MU/ML
1MG/ML
1%
1%
1%

09852751
00903448
00027014
00589055
02248119
02248529

Mydriatic

ATROPINE SULFATE
ATROPINE SULFATE
ATROPINE SULFATE
ATROPINE SULFATE
ATROPINE SULFATE
ATROPINE SULFATE
ATROPINE SULFATE
ATROPINE PLUS
ATROPINE SULFATE
ATROPINE SULFATE
ATROPINE SULFATE
ATROPINE SULFATE
ATROPINE SULFATE
ATROPINE SULFATE
ATROPINE SULFATE
ATROPINE SULFATE

ISOPTO ATROPINE
SMP ATROPINE
MINIMS ATROPINE
SMP ATROPINE
SMP ATROPINE
SMP ATROPINE
SMP ATROPINE
ISOPTO MYDRAPRED
SMP ATROPINE
SMP ATROPINE
SMP ATROPINE
ATROPINE AK
ATROPINE SULFATE
ATROPINE
ATROPINE
ATROPINE

1%
1%
1%
1%
0.5%
2%
1%
1%
0.5%
1%
2%
1%
1%
1%
1%
1%

00000639
00028800
00269255
00281603
00281611
00281638
00344842
00358215
00527939
00527947
00527955
00622907
00811963
01901311
01948601
02023695

GENTAMICIN SULFATE
GENTAMICIN SULFATE
GENTAMICIN SULFATE
GENTAMICIN
GENTAMICIN SULFATE
GENTAMICIN SULFATE
GENTAMICIN SULFATE
GENTAMICIN SULFATE
TOBRAMYCIN
TOBRAMYCIN
TOBRAMYCIN SULFATE
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ATROPINE SULFATE
ATROPINE SULFATE
ATROPINE SULFATE &
HYDROCORTISONE
ATROPINE SULFATE &
HYDROCORTISONE
SCOPOLAMINE
TROPICAMIDE
HOMATROPINE HBR
PHENYLEPHRINE HCL
PHENYLEPHRINE HCL
CYCLOPENTOLATE HCL
CYCLOPENTOLATE HCL
PHENYLEPHRINE HCL
HOMATROPINE HBR
CYCLOPENTOLATE HCL
PHENYLEPHRINE HCL
PHENYLEPHRINE HCL
PHENYLEPHRINE HCL &
PYRILAMINE MALEATE
PHENYLEPHRINE HCL
CYCLOPENTOLATE HCL
CYCLOPENTOLATE HCL
HYPROMELLOSE
TROPICAMIDE
PHENYLEPHRINE HCL
PHENYLEPHRINE HCL
TROPICAMIDE
PHENYLEPHRINE HCL
CYCLOPENTOLATE HCL
CYCLOPENTOLATE HCL
TROPICAMIDE
PHENYLEPHRINE HCL &
TROPICAMIDE
CYCLOPENTOLATE HCL
TROPICAMIDE
PHENYLEPHRINE HCL
TROPICAMIDE
CYCLOPENTOLATE HCL

TROPICAMIDE
CYCLOPENTOLATE HCL
TROPICAMIDE
TROPICAMIDE
CYCLOPENTOLATE HCL
PHENYLEPHRINE HCL &
TROPICAMIDE
PHENYLEPHRINE HCL
PHENYLEPHRINE HCL
CYCLOPENTOLATE HCL
CYCLOPENTOLATE HCL

MINIMS ATROPINE
ATROPINE
HC-ATROPINE

1%
1%
1%

02148358
02212951
00062251

HC-ATROPINE

1%

00062278

ISOPTO HYOSCINE
MYDRIACYL
HOMATROPINE HBR
NEO-SYNEPHRINE
NEO-SYNEPHRINE
CYCLOGYL
CYCLOGYL
PHENYLEPHRINE
HCL
MINIMS
HOMATROPINE
CYCLOPENTOLATE
PHENYLEPHRINE
PREFRIN LIQUIFILM
PREFRIN-A LIQUIFLM

0.25%
0.5%
5%
0.125%
10%
1%
0.5%
10%

00000957
00000981
00028916
00033502
00033529
00252506
00252549
00269123

2%

00269158

0.05%
10%
0.12%
0.1%

00269204
00281808
00385161
00400408

NEO-SYNEPHRINE
CYC
MYDPLEGIC
MURO TEARS
TROPICAMIDE
NEO-SYNEPHRINE
NEO-SYNEPHRINE
TROPICACYL
AK-DILATE
AK-PENTOLATE
AK-PENTOLATE
TROPICACYL
PHENYLTROPE

0.125%
1%
1%
1%
0.125%
10%
1%
2.5%
1%
0.5%
0.5%
5%

00482684
00506230
00527580
00544787
00544825
00561886
00561894
00622885
00622915
00626627
00626635
00627704
00629693

SPERSAPENTOL
TROPICAMIDE
SPERSAPHRINE
PMS-TROPICAMIDE
PMSCYCLOPENTOLATE
HCL
TROPICAMIDE
DIOPENTOLATE
DIOTROPE
DIOTROPE
DIOPENTOLATE
DIOPHENYL-T

1%
1%
2.5%
1%
1%

00751758
00751774
00751820
00872946
00878189

1%
1%
0.5%
1%
0.5%
0.8%

00896446
02023644
02023660
02023679
02023687
02023717

DIONEPHRINE
DIONEPHRINE
MINIMS
CYCLOPENTOLATE
MINIMS
CYCLOPENTOLATE

0.12%
2.5%
0.5%

02026473
02027100
02148331

1%

02148382
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HOMATROPINE HBR
PHENYLEPHRINE HCL
PHENYLEPHRINE HCL
TROPICAMIDE
CYCLOPENTOLATE HCL

TROPICAMIDE
NSAID

KETOROLAC
TROMETHAMINE
KETOROLAC
TROMETHAMINE
KETOROLAC
TROMETHAMINE
DICLOFENAC SODIUM
DICLOFENAC SODIUM
KETOROLAC
TROMETHAMINE
SUPROFEN
INDOMETHACIN
DICLOFENAC SODIUM
KETOROLAC
TROMETHAMINE
NEPAFENAC
KETOROLAC
TROMETHAMINE
NEPAFENAC
BROMFENAC SODIUM

Steroids

DEXAMETHASONE
BETAMETHASONE
HYDROCORTISONE
ACETATE
HYDROCORTISONE
ACETATE
MEDRYSONE &
POLYVINYL ALCOHOL
PREDNISOLONE
ACETATE
FLUOROMETHOLONE
PREDNISOLONE
DISODIUM PHOSPHATE
PREDNISOLONE
DISODIUM PHOSPHATE
HYDROCORTISONE
ACETATE
HYDROCORTISONE

MINIMS
HOMATROPINE
MINIMS
PHENYLEPHRINE
MINIMS
PHENYLEPHRINE
MINIMS
TROPICAMIDE
DOMCYCLOPENTOLATE
HCL
TROPICAMIDE

2%

02148420

2.5%

02148447

10%

02148455

1%

02148536

1%

02181436

1%

02212919

KETOROLAC
TROMETHAMINE
KETOROLAC
TROMETHAMINE
KETOROLAC
TROMETHAMINE
DICLOFENAC
SODIUM
DICLOFENAC
SODIUM
KETOROLAC
TROMETHAMINE
SUPROFEN
INDOMETHACIN
DICLOFENAC
SODIUM
KETOROLAC
TROMETHAMINE
NEPAFENAC
KETOROLAC
TROMETHAMINE
NEPAFENAC
BROMFENAC
SODIUM

0.5%

02247461

0.5%

02245821

0.45%

02369362

0.1%

00903755

0.1%

00940414

0.5%

00961272

1%
0.1%
0.1%

02132710
02219506
02238145

0.4%

02248722

0.1%
0.5%

02308983
02336693

0.3%
0.7%

02411393
02439123

MAXIDEX
BETNESOL
CORTRIL

1MG
0.1%
0.5%

00000698
00012173
00024775

CORTRIL

2.5%

00024783

HMS LIQUIFILM

1%

00036676

PREDNICON

1%

00252492

FML-NEO
INFLAMASE

0.1%
0.125%

00259454
00281735

INFLAMASE FTE

1%

00281743

CORTAMED

2.5%

00283231

CORTAMED
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00283258

ACETATE
METHYLPREDNISOLONE
FLUOROMETHOLONE
PREDNISOLONE
DISODIUM PHOSPHATE
PREDNISOLONE
DISODIUM PHOSPHATE
HYDROCORTISONE
ACETATE
PREDNISOLONE
ACETATE
DEXAMETHASONE
DEXAMETHASONE
SODIUM
PREDNISOLONE
ACETATE
PREDNISOLONE
ACETATE
PREDNISOLONE
ACETATE
FLUOROMETHOLONE &
POLYVINYL ALCOHOL
FLUOROMETHOLONE &
POLYVINYL ALCOHOL
PREDNISOLONE
ACETATE
PREDNISOLONE
ACETATE
FLUOROMETHOLONE
PREDNISOLONE
ACETATE
PREDNISOLONE
DISODIUM PHOSPHATE
PREDNISOLONE
ACETATE
PREDNISOLONE
ACETATE
PREDNISOLONE
ACETATE
PREDNISOLONE
ACETATE
PREDNISOLONE
SODIUM PHOSPHATE
DEXAMETHASONE
SODIUM PHOSPHATE
PREDNISOLONE
SODIUM PHOSPHATE
HYDROCORTISONE
ACETATE
DEXAMETHASONE
SODIUM PHOSPHATE
BETAMETHASONE
PREDNISOLONE
SODIUM PHOSPHATE
RIMELOXONE

MEDROL
SANDOZFLUOROMETHOLONE
INFLAMASE

0.1%
0.1%

00358711
00432814

0.125%

00526452

INFLAMASE FTE

1%

00526460

CORTAMED

2.5%

00704458

ULTRACORTENOL

0.5%

00727466

DEXAMETHASONE
CEBEDEX

0.1%
0.1%

00739839
00741752

BALPRED

1%

00764639

PREDOLONE FORTE

1%

00801186

PREDOLONE

1%

00809152

FML LIQUIFILM

0.1%

00893188

FML LIQUIFILM

0.1%

00894931

PRED FORTE

1%

00894958

AK-TATE

1%

00896144

FML FORTE
OPHTHO-TATE

0.25%
1%

00897469
00898732

INFLAMASE FTE

1%

00907626

R.O.-PREDPHATE
FORTE
PREDNISOLONE
ACETATE
PREDNISOLONE
ACETATE
PREDNISOLONE
ACETATE
PREDNISOLONE

1%

00908266

-

00961264

0.12%

01916181

1%

01916203

1%

01924400

DEXAMETHASONE

0.1%

01947044

PMS-PREDNISOLONE
SOD/PHO
CORTAMED

1%

01954237

2.5%

01980661

OCUDEX

0.1%

01995022

BETNESOL
MINIMS
PREDNISOLONE SOD
VEXOL

0.1%
0.5%

02060868
02148498

1%

02163691
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PREDNISOLONE
SODIUM PHOSPHATE
FLUOROMETHOLONE
PREDNISOLONE
SODIUM PHOSPHATE
LOTEPREDNOL
ETABONATE
LOTEPREDNOL
ETABONATE
LOTEPREDNOL
ETABONATE
PREDNISOLONE
ACETATE
PREDNISOLONE
SODIUM PHOSPHATE

PREDNISOLONE

1%

02213079

PMSFLUOROMETHOLONE
SAB-PREDNASE

0.1%

02238568

1%

02245858

ALREX

0.2%

02320924

LOTEMAX

0.5%

02321114

LOTEMAX OINTMENT

5MG

02421941

PRED FORTE

1%

99100258

PREDNISOLONE

1%

99100839
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Appendix G: Benzalkonium Chloride Content of Anti-Glaucoma Drugs
Generic Name

Trade Name

Strength

DIN

PILOCARPINE HCL
PILOCARPINE HCL

ISOPTO CARPINE
MINIMS
PILOCARPINE
MINIMS
PILOCARPINE
MINIMS
PILOCARPINE
SANDOZLATANOPROST
TEVATRAVOPROST Z
TEVATRAVOPROST Z
APO-TIMOP
APO-TIMOP
TIMOPTIC-XE
TIMOPTIC-XE
CO
DORZOTIMOLOL
BETAGAN
BETAGAN
RATIOLEVOBUNOLOL
RATIOLEVOBUNOLOL
PROPINE
EPIFRIN
PROBETA

0.5%
2%

00000833
00269107

BAK
(%vol.)
0
0

2%

02148463

0

4%

02148471

0

50MCG/ML

02367335

0

0.004%

02412063

0

0.004%

09857504

0

0.25%
0.5%
0.25%
0.5%
2/0.5%

00755826
00755834
02171880
02171899
02404389

0
0
0
0
0.0001

0.5%
0.25%
0.25%

00637661
00751286
02031159

0.004
0.004
0.004

0.5%

02031167

0.004

0.1%
2%
0.5%

00529117
00001112
02209071

0.004
0.004
0.004

SANDOZLEVOBUNOLOL
SANDOZLEVOBUNOLOL
ISOPTO
CARBACHOL
ISOPTO
CARBACHOL
EPIFRIN
EPIFRIN
ALPHAGAN
DPE
APO-DIPIVEFRIN
RATIOBRIMONIDINE
LUMIGAN
COMBIGAN

0.5%

02241716

0.004

0.25%

02241715

0.004

1.5%

00000655

0.005

3%

00000663

0.005

0.5%
1%
0.2%
0.1%
0.1%
0.2%

00001090
00001104
02236876
02152525
02242232
02243026

0.005
0.005
0.005
0.005
0.005
0.005

0.03%
0.2/0.5%

02245860
02248347

0.005
0.005

ALPHAGAN P
PMS-BRIMONIDINE
APO-BRIMONIDINE
COMBIGAN

0.15%
0.2%
0.2%
0.2/0.5%

02248151
02246284
02260077
09857298

0.005
0.005
0.005
0.005

PILOCARPINE HCL
PILOCARPINE HCL
LATANOPROST
TRAVOPROST
TRAVOPROST
TIMOLOL MALEATE
TIMOLOL MALEATE
TIMOLOL MALEATE
TIMOLOL MALEATE
DORZOLAMIDE & TIMOLOL
LEVOBUNOLOL HCL
LEVOBUNOLOL HCL
LEVOBUNOLOL
LEVOBUNOLOL
DIPIVEFRINE HCL
EPINEPHRINE HCL
DIPIVEFRINE HCL &
LEVOBUNOLOL HCL
LEVOBUNOLOL HCL
LEVOBUNOLOL HCL
CARBACHOL
CARBACHOL
EPINEPHRINE HCL
EPINEPHRINE HCL
BRIMONIDINE TARTRATE
DIPIVEFRINE HCL
DIPIVEFRINE HCL
BRIMONIDINE TARTRATE
BIMATOPROST
BRIMONIDINE TARTRATE &
TIMOLOL MALEATE
BRIMONIDINE TARTRATE
BRIMONIDINE TARTRATE
BRIMONIDINE TARTRATE
BRIMONIDINE TARTRATE &
TIMOLOL MALEATE
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BRIMONIDINE
BRIMONIDINE TARTRATE
PILOCARPINE HCL
DORZOLAMIDE HCL &
TIMOLOL MALEATE
DORZOLAMIDE
DORZOLAMIDE & TIMOLOL
TIMOLOL MALEATE
BRINZOLAMIDE & TIMOLOL
MALEATE
TIMOLOL MALEATE
BETAXOLOL HCL
TIMOLOL MALEATE
TIMOLOL MALEATE
TIMOLOL MALEATE
BETAXOLOL
TIMOLOL MALEATE
TIMOLOL MALEATE
TIMOLOL MALEATE
TIMOLOL MALEATE
BRINZOLAMIDE
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
DIPIVEFRINE HCL
TIMOLOL MALEATE
TRAVOPROST
TIMOLOL MALEATE &
TRAVOPROST
TRAVOPROST
TRAVOPROST
TIMOLOL MALEATE &
TRAVOPROST
TIMOLOL MALEATE &
TRAVOPROST
TIMOLOL MALEATE &
TRAVOPROST
LATANOPROST
LATANOPROST & TIMOLOL
BIMATOPROST
BIMATOPROST
LATANOPROST
BIMATOPROST
LATANOPROST & TIMOLOL

SANDOZBRIMONIDINE
APO-BRIMONIDINE
P
RATIOPILOCARPINE
COSOPT

0.2%

02305429

0.005

0.15%

02301334

0.005

1%

02229393

0.0075

20MG/5MG/ML

02258692

0.0075

SANDOZDORZOLAMIDE
SANDOZDORZOL/TIMOL
TIMOLOL MALEATEEX
AZARGA

2%

02316307

0.0075

1%

02344351

0.0075

0.5%

02242276

0.01

1%/0.5%

02331624

0.01

TIMOPTIC
BETOPTIC
TIMOPTIC
MYLAN-TIMOLOL
MYLAN-TIMOLOL
BETOPTIC S
SANDOZ-TIMOLOL
SANDOZ-TIMOLOL
PMS-TIMOLOL
PMS-TIMOLOL
AZOPT
ISOPTO CARPINE
ISOPTO CARPINE
ISOPTO CARPINE
PILOPINE HS
ISOPTO CARPINE
MINIMS
PILOCARPINE
DPE
TIMOLOL MALEATEEX
TRAVATAN
DUOTRAV PQ

0.5%
0.5%
0.25%
0.5%
0.25%
0.25%
0.5%
0.25%
0.5%
0.25%
2% & .5%
1%
2%
4%
4%
6%
4%

00451207
00695688
00451193
00893781
00893773
01908448
02166720
02166712
02083345
02083353
02238873
00000841
00000868
00000884
00575240
00000892
00269085

0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01

0.1%
0.25%

02145324
02242275

0.01
0.01

0.004%
0.004/0.5%

02244896
02278251

0.015
0.015

TRAVATAN Z
TRAVATAN Z
DUOTRAV PQ

0.004%
0.004%
0.004/0.5%

02318008
09857332
09857333

0.015
0.015
0.015

DUOTRAV PQ

0.004/0.5%

09857512

0.015

DUOTRAV PQ

0.004/0.5%

09857513

0.015

XALATAN
XALACOM
LUMIGAN RC
LUMIGAN RC
APOLATANOPROST
LUMIGAN RC
SDZ-

0.005%
5MG/5MCG/ML
0.01%
0.01%
50MCG/ML

02231493
02246619
02324997
09857368
02296527

0.02
0.02
0.02
0.02
0.02

0.01%
5MG/5MCG/ML

09857398
02394685

0.02
0.02
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TRAVOPROST

LATANOP/TIMOLOL
SANDOZ
TRAVOPROST
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0.004%

02413167

0.02

Reference
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*type of filtration surgery is our main exposure of interest

Conclusion: no immortality bias

Hazard ratios are consistent
across all tests (Cox, Cause-Specific,
and Subdistribution).

Age 75+
Age 66-74
No corneal transplant
Corneal Transplant
No surgeries on Iris
Surgeries on the Iris
No history of antibiotics
History of Antibiotics
No history of aminoglycosides
History of Aminoglycosides
No history of mydriatics
History of Mydriatics
No history of NSAIDs
History of NSAIDs
Filtering procedure (solo-procedure)
Filtering Surgery w/IDD
Filtering procedure (solo-procedure)
Combined w/cateract extraction only
combined w/cateract extraction and IDD Filtering procedure (solo-procedure)
1
CS HR: Cause-Specific Hazard Ratios, SD HR: Subdistribution Hazard Ratios

Covariables
1.35
1.95
0.70
1.48
3.21
2.19
0.63
0.67
0.45
0.15

0.0056
0.066
0.043
0.015
<.0001
<.0001
0.0081
0.064
<.0001
0.0012

0.46 <.0001
0.96
0.00
0.21
1.26
0.73
0.91
0.35
0.39
0.49
0.75
0.97
0.99
0.9
1.03
0.32
0.82
0.6
1.17

1.35 0.0055
0.044
1.96
0.045
0.70
0.01
1.48
3.21 <.0001
2.20 <.0001
0.63 0.0089
0.056
0.67
0.45 <.0001
0.15 0.0012

Hazar
d
Hazard
Hazard
Ratio
P-Value Ratio P-Value
Ratio P-Value

Risk factors for secondary surgical intervention after primary glaucoma filtration surgery: an Ontario population-based study
Armstrong et. al. 2018
CS HR (primary
SD HR1
CS HR (death)1
outcome)1

Appendix H: Death Competing Risk Analysis – Primary Outcome vs. Death
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survt=days

Filter 3= filtration surgery w. seton conbined with
cateract extraction

Fitler 2 = filtration surgery w. seton

Figure to left shows that across all types of
filtration sugeries the primary outcome
varies. The p-value is significant.

Gray's test for equality of cumulative incidence functions- p-value=<.0001, significant

Cumulative incidence function for primary outcome

Filter 1= filtration surgery w. cateract extraction

Filter 0= filtration surgery w. no combination

Legend for Filtration Surgeries:

Figure to left shows that across all types of
filtration sugeries the outcome death is
equalily distributed. The p-value is not
significant.

Gray's test for equality of cumulative incidence functions- p-value=0.7403, not significant

Cumulative incidence function for death (competing risk)

Appendix I:

Protocol / Funded Grant: An Investigator-Initiated Multi-Center
Prospective Clinical Trial to Examine the Efficacy of PeriOperative NSAID vs. Steroid Treatment in Trabeculectomy
Wound Management

Given the results described in Chapter 2 and Chapter 3, a randomized clinical
trial comparing the effects of steroidal and NSAID anti-inflammatory modalities
after glaucoma surgery is warranted. There was a desire to “close the
translational loop” and bring our retrospective clinical data-inspired in vitro
findings back to the clinical setting, however the duration of my PhD studies
denies the opportunity to collect any clinical trial results. Hence, the results of this
RCT are outside the scope of my PhD, however, the following RCT protocol is
included. It was submitted as a grant to the Glaucoma Research Society of
Canada and funded in 2018. Fifteen glaucoma surgeons from across Canada
have been recruited and patient enrollment is scheduled to begin summer 2019.
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Introduction, Purpose & Objectives
Perioperative inflammation control is essential to both the short and long-term
success of glaucoma surgery. Currently, this is accomplished with the use of
topical steroidal anti-inflammatory drugs, such as dexamethasone or
florometholone. Although these drugs have proven anti-inflammatory action,
there are associated adverse effects such as steroid associated intraocular
pressure (IOP) spikes and inhibition of wound healing.175,270 As elevation of IOP
following glaucoma surgery is undesirable, there is a need to explore alternatives
to corticosteroids with similar efficacy in inflammation control.
There have been recent studies to suggest non-steroidal anti-inflammatory drugs
(NSAIDs), such as diclofenac, may be a promising alternative to corticosteroids
following glaucoma surgery.90,175 A recent study by Yuen et al. compared
treatment with corticosteroids versus NSAIDs after Ahmed glaucoma valve
surgery and found the steroid group showed a greater mean IOP at all measured
follow-up points postoperatively.90 Yuen et al. conducted a similar comparison
and found that although there were no significant group differences in IOP at any
of the follow-up visits, there was a clinical trend toward lower IOP values in the
NSAID-treated group compared to the steroid-treated cohort.90 More interestingly
however, Levkovitch-Verbin et al. observed that the average number of glaucoma
medications being taken at the eight-month follow-up point was significantly
greater in the cohort treated with steroids post-phacotrabeculectomy compared to
the NSAID-treated group.

229

This study aims to examine the efficacy of bromfenac (0.07%) relative to
dexamethasone (0.1%) anti-inflammatory therapy in trabeculectomy wound
management. Previous in vitro results suggested that indomethacin was
preferable to dexamethasone for sub-conjunctival wound healing.223 The novel
ophthalmic NSAID bromfenac, contains bromine hydrophilic moieties such that its
penetration into sub-conjunctival and sub-corneal tissues is higher.271,272 It is
hypothesized that substitution of bromfenac (0.07%) NSAID anti-inflammatory
therapy one week after trabeculectomy will result in non-inferior IOP control with
the need for fewer post-operative interventions compared to patients remaining
on steroid only.

Study Objectives
•

To compare the effects of steroid only to steroid followed by NSAID perioperative therapy in achieving target IOP success following
trabeculectomy

•

To compare event-free survival time with an event defined as a post-op
intervention required to achieve target IOP in the two patient groups

•

To compare the bleb morphology in the two patient groups using the
standardized Moorfields bleb grading scale

Study Design & Outcomes
Description of Study Design
This will be a multi-center randomized prospective clinical trial. Figure I-1
illustrates the study treatment schedule.
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Figure I-1: RCT Drug Treatment Protocol
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Dex
0.1%
QID q2hrs

Surgery

Dex 0.1%
QID

1wk
pre-op

2mo
post-op

Dex 0.1% QD

Bromfenac 0.07% BID

Dex 0.1% BID

1mo
post-op

Dex 0.1% QID

Randomization:
@1wk post-op

Bromfenac 0.07%
TID

3mo
post-op

12mo monitoring

Study Outcomes
Main Outcome
The primary outcome is difference in event free survival (minimal and significant
events; Table 0-1) between the two arms over the first post-operative year. An
event is defined as a post-operative (secondary) intervention that is necessary to
achieve a patient’s target IOP.

Secondary Outcomes
Absolute intra-ocular pressure and percent reduction from baseline will be
monitored at all follow up visits to assess non-inferiority between experimental
groups in terms of IOP control.
Additional survival curves will be prepared to illustrate the difference in event free
survival between treatment groups – curves will be prepared based on time to
either a significant or minimal secondary intervention (Table 0-1).

Table I-1. Post-operative (secondary) interventions qualifying as minimal or
significant
QUALIFICATION GROUP
DEFINITION
Minimal Medical
Require fewer (but non-zero) glaucoma
Intervention
medications post-op than pre-op
Minimal Surgical
Require needling ± 5-FU, etc.
Intervention
Significant Medical
Require more glaucoma medications than pre-op
Intervention
to achieve target IOP
Significant Surgical
Require a new glaucoma surgical intervention –
Intervention
i.e. tube shunt, trab at new clock hour, etc.
Notes: laser suture lysis is not considered a secondary intervention
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Sample Size Analysis
The primary outcome is difference in event (defined within Table I-1) free survival
between the two arms over the first post-operative year. We will power our study
according to the primary outcome – an event from any qualification group
occurring. Secondary outcomes (time to the specific type of secondary
intervention) will be calculated based on the sample size attained – and are
expected to require more statistical power than the primary outcome due to their
lower individual occurrence rates. The logrank test will be used to compare the
survival curves generated for the primary and each secondary outcome. The
closest matching previous study was published by Levkovitch-Verbin et. al. 2013
in the Journal of Glaucoma, with 21 patients per arm. Ten percent of the
dexamethasone treated patients’ surgeries failed and 5% of the NSAID treated
patients’ surgeries failed.175 This gives an effective hazard of 0.1 for the control
arm and 0.05 for the experimental arm – with hazard ratio of 2. This was a
relatively large treatment effect reported by this study with others reporting
smaller differences to no significant difference – likely an artifact of all these
studies’ small sample sizes. This would suggest the true effect lies somewhere in
the middle, with a hazard ratio of 1 to 2. We want to power our study sufficiently
to detect a more modest/realistic treatment effect, that is still clinically relevant, so
we intend to use a more conservative estimated hazard ratio of 1.25 within our
sample size calculations. This will give us the ability to be more accurate than the
previously mentioned studies. Using the Rubinstein et al. 1981 approach to the
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logrank test sample size estimation (using: alpha = 0.05, beta = 0.8, minimum
hazard ratio = 1.25, equal randomization, and estimated mean survival time of 8
months) we calculated approximately 74 patients necessary per group. 273

Study Enrollment & Withdrawal
Participant Inclusion Criteria
In order to be eligible to participate in this study, an individual must meet all of the
following criteria:
1.

Adult patient over the age of 18 years

2.

Uncontrolled open angle glaucoma

3.

Scheduled to undergo stand-alone trabeculectomy

4.

No previous:

a.

incisional glaucoma surgery

b.

vitrectomy

c.

strabismus surgery

d.

extracapsular cataract extraction (ECCE)

5.

No ocular surgery of any kind in prior 6 months

Participant Exclusion Criteria
An individual who meets any of the following criteria will be excluded from
participation in this study:
1. Steroids contraindicated
2. NSAIDs contraindicated
3. Poor corneal epithelial health
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Participant Withdrawal or Termination
Reasons for Withdrawal or Termination
Participants are free to withdraw from participation in the study at any time upon
request. An investigator may terminate participation in the study if:
•

Any clinical adverse event (AE), laboratory abnormality, or other medical
condition or situation occurs such that continued participation in the study
would not be in the best interest of the participant.

•

The participant meets an exclusion criterion (either newly developed or not
previously recognized) that precludes further study participation.

Handling of Participant Withdrawals or Termination
Participants will be asked to notify their study doctor in the event they wish to
withdraw their consent and discontinue study participation. Participants will be
able to withdraw data pertaining to their study participation up until dissemination
of study results (e.g. study publication). In the event study results have already
been disseminated, the participant will be reassured that any published study
data are completely non-identifiable.
In the event a participant must be terminated from the study, the participant will
be contacted by their treating study team and the reason for termination will be
clearly disclosed. If the termination is pertaining to a medical issue, the
participant will be directly followed by the study team and/or referred for
additional treatment, if required.
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Study Drugs
Overall Study Drug Regimen
Pre-Operative Course
All study participants will complete a one-week course of topical dexamethasone
0.1% QID prior to the scheduled trabeculectomy.

Post-Operative Course
On the day after trabeculectomy (Day 1), all participants will resume
dexamethasone 0.1% QID for one additional week. At the investigator’s
discretion, the dexamethasone dose frequency may be increased up to q2h
during the one-week postoperative period.
At the Day 7 visit, participants will be randomized to one of two treatment groups:
Table I-2. Randomized Study Drug Regimen
Group One: Bromfenac 0.07%

Group Two: Continue Dexamethasone 0.1%

TID to one month post-op

QID to one month post-op

BID for two months
(from 1 month post-op to 3 months
post-op)

BID for one month
QD for one month

Participants will dose with their assigned study treatment until three months posttrabeculectomy.

Antibiotic Use
Participants will also complete a one-week course of fluoroquinolone antibiotic
(gatifloxacin ophthalmic solution 0.3%, QID) during the one-week postoperative
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period. Antibiotic use is considered standard of care for trabeculectomy
management.

Dosing and Administration
Study participants, or their caregiver, will administer study drug. Study
participants, and/or caregiver, will be instructed on study drug administration to
encourage proper study drug use.
Study participants will be provided with a Dosing Guide which outlines the study
drug regimen. This guide will be reviewed with each study participant to
encourage proper study drug dosing.

Route of Administration
Topical dexamethasone and bromfenac will be used for this study (eye drops).

Duration of Therapy
Study participants will dose with study drug for a total duration of three months
plus one week.
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Study Procedures & Schedule

Day 1

Week 1

Week 2

Month 1

Month 3

Month 6

Month 9

Month 12
or Early
Term.

Informed Consent
Inc/Exclu. Criteria
Demographics1
Medical History2
including medications
IOP
BCVA
Slit Lamp Exam
Bleb Grading Scale
(Moorfields)
C/D Ratio
Humphrey Perimetry
Trabeculectomy
Review Concomitant
Meds/Procedures5
Review AEs
GQL-15
GSS

Surgery
(Day 0)

Table I-3. Schedule
of Events Table

Screening
/ Baseline

Schedule of Events Table

x
x
x

x
x
x

x
x
x

x
x
x

x
x
x

x
x
x

x
x
x

x
x
x

x

x

x

x

x

x

x

x

x
x
x
x
x3
x4
x

x
x

x
x
x
x

x

x

x

x

x

x

x

x

x

x

x
x

x

x
x
x

x

x
x

x
x

x

1Including:

x

age, sex and race
of use and number of IOP-lowering medication(s)
3Baseline IOP: mean of 3 Goldmann applanation readings taken on different days
4Best-corrected visual acuity (VA) by the Snellen chart and converted to logarithm
of the minimum angle of resolution VA
5Inclusive of all postoperative medications, procedures and surgeries
2Inclusive
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Visit Windows
Study visits may occur within the following acceptable visit windows:
Table I-4. Study Visit Windows
STUDY VISIT

ACCEPTABLE WINDOW

Day 1

Must occur on the day after trabeculectomy

Week 1

Must occur one week from trabeculectomy

Week 2
Month 1
Month 3
Month 6
Month 9
Month 12

+/- 3 days
+/- 7 days
+/- 7 days
+/- 14 days
+/- 14 days
+/- 14 days

Study Procedures & Evaluations
Study procedures and evaluations conform to the standards set out by the World
Glaucoma Association for the Design and Reporting of Glaucoma Surgical
Trials.274

Informed Consent
Informed consent is a process that is initiated prior to the individual’s agreeing to
participate in the study and continues throughout the individual’s study
participation. Extensive discussion of risks and possible benefits of participation
will be provided to the participants. Consent forms will be ethics-approved prior to
use and the participant will be asked to read and review the document. The
Investigator, or their delegate, will explain the research study to the participant
and answer any questions that may arise.
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Participants will have the opportunity to carefully review the written consent form
and ask questions prior to signing. The participant will sign the informed consent
document prior to any procedures being done specifically for the study.
The participants may withdraw consent at any time throughout the course of the
trial. A copy of the informed consent document will be given to the participants for
their records. The rights and welfare of the participants will be protected by
emphasizing to them that the quality of their medical care will not be adversely
affected if they decline to participate in this study

Inclusion/Exclusion Criteria
The inclusion and exclusion criteria will be reviewed following the Informed
Consent discussion to determine if the participant is eligible to continue study
participation. In the event a participant is deemed ineligible, the reason for
Screen Failure will be documented.

Demographics
Patient demographics will be collected including age, sex and race.

IOP
IOP is to be measured using Goldmann applanation. The individual reading the
tonometer dial and recording the numerical value should not be the same person
who is manipulating the Goldmann tonometer.
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The baseline IOP will be the mean of three Goldmann readings taken on different
days. These readings should occur within a maximum period of one month.
For each Goldmann applanation reading, two measurements should be taken
and averaged to determine the mean IOP. Three measurements should be taken
if the first two measurements are greater than 3 mmHg difference. If more than
two measurements are taken, the median (rather than mean) IOP value will be
used.

Trabeculectomy & Mitomycin C Use
The following information pertaining to trabeculectomy is to be recorded for each
study participant:
•

MMC dose: 0.2 – 0.4 mg/mL

•

Limbal or fornix approach

•

Suture type to close conjunctiva

Study participants will receive MMC (0.2 – 0.4 mg/mL) delivered to the
subconjunctival space using injection.

Concomitant Medications & Procedures
The use of any concomitant medications or procedures will be assessed at each
study visit following the trabeculectomy. All concomitant medications and
procedures will be recorded on a designated study source worksheet.
Concomitant medications to be recorded include concomitant prescription
medications, over-the-counter medications and non-prescription medications.
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It will be documented whether the concomitant medication or procedure was
initiated as an intervention toward target IOP.

Adverse Events
The occurrence of any adverse events will be assessed at each study visit
following the trabeculectomy. If a Serious Adverse Event (SAE) has occurred, the
investigator will follow the reporting procedures as outlined in section 4.6.

Assessment of Safety
Specification of Safety Parameters
Definition of Adverse Events (AEs)
Adverse event means any untoward medical occurrence associated with the use
of an intervention in humans, whether or not considered intervention related.

Definition of Serious Adverse Events (SAEs)
An AE or suspected adverse reaction is considered "serious" if, in the view of the
investigator, it results in any of the following outcomes:
•

death

•

a life-threatening adverse event

•

inpatient hospitalization or prolongation of existing hospitalization

•

a persistent or significant incapacity or substantial disruption of the
ability to conduct normal life functions, or

•

a congenital anomaly/birth defect
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Important medical events that may not result in death, be life-threatening, or
require hospitalization may be considered serious when, based upon appropriate
medical judgment, they may jeopardize the patient or subject and may require
medical or surgical intervention to prevent one of the outcomes listed in this
definition. Examples of such medical events include allergic bronchospasm
requiring intensive treatment in an emergency room or at home, blood dyscrasias
or convulsions that do not result in inpatient hospitalization, or the development of
drug dependency or drug abuse.

Reporting Procedures
Adverse Event Reporting
All adverse events will be recorded within the designated source worksheets and
Case Report Form (CRF).

Serious Adverse Event Reporting
The site investigator will complete a SAE Form within the following timelines:
•

All deaths and immediately life-threatening events, whether related or
unrelated to the study intervention, will be recorded on the SAE Form
and submitted to the Lead Site within 24 hours of site awareness, if
reasonably possible.

•

Other SAEs will be submitted to the Lead Site within 72 hours of site
awareness.

All SAEs will be followed until satisfactory resolution or until the site investigator
deems the event to be chronic or the adherence to be stable.
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The site investigator will determine if the SAE is reportable per the guidelines of
their overseeing ethics committee and institution. A report to all necessary parties
will be prepared and submitted within the institution-specified timeline.

Safety Oversight
Safety oversight will be under the direction of the Lead Site study team. The Lead
Site will meet quarterly to review and assess safety data on each arm of the
study. The Lead Site will be responsible for distributing quarterly safety reports
and notifying study investigators of any ongoing study safety issues.
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Curriculum Vitae
Education
Post-Secondary
2014 - present

2013
Other
2016

MD/PhD, Schulich School of Medicine and Dentistry, London, Ontario
Modulating Inflammation and Wound Healing in the Surgical Management of Glaucoma
Laboratory of: Dr. Cindy Hutnik, Ivey Eye Institute, Departments of Ophthalmology and Pathology,
Schulich School of Medicine
Honors Bachelor of Science. Major in Medical Cell Biology and Major in Biology, Western
University, London, Ontario
CSTAR Inter-Professional Summer Surgery School 2016
Schulich School of Medicine, Arthur Labatt Family School of Nursing and Fanshawe College School
of Nursing
Master Class on Writing Research for Publication 2016
Center for Education Research and Innovation (CERI), Schulich School of Medicine, Continuing
Professional Development

Research Interests
Wound healing, inflammation and fibrosis
Microinvasive glaucoma surgery
Fibroproliferative and myofibroblast pathophysiology
Tissue engineering for disease modeling applications
Systematic review and meta-analysis
Electronic health records big data health analytics (ICES-Western)
Machine learning applications to medical record keeping and quality indicators
Blockchain applications for distributed, private medical record keeping
Clinical practice guideline development, methodological quality and their implementation

Research Profiles
Mendeley

https://tinyurl.com/JJA-Mendeley

Scopus

Author ID: 57061621900

OrcID

https://orcid.org/0000-0002-0848-7496

Research Gate

https://www.researchgate.net/profile/James_Armstrong14

Research Grants/Scholarships (successful in bold)
2018

Glaucoma Research Society of Canada. Funding to support a randomized controlled trial evaluating
the efficacy NSAIDs vs steroidal anti-inflammatory therapy after trabeculectomy – awarded $19,818
The McGrath Research Scholarship. Funding to provide graduate students with an opportunity to
undertake vision science research projects with established researchers in an environment that
provides strong mentorship - awarded $8,000.
AMOSO Innovation Fund. Lipid mediators of inflammation and resolution: investigating the
association with abnormal wound healing and surgical outcome – Awarded $146,560 over 2yrs

2017

Nomination - Vanier Canada Doctoral Scholarship. The proposal I put forward was nominated by
the University of Western Ontario’s Vanier Selection Committee for the 2018 competition –
nominated to receive $150,000. Ultimately ranked 75 of 100 national finalists, with the top 55
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receiving funding
Investigator initiated proposal – Alcon Canada. Modeling Aqueous Drainage through the
Supraciliary Space: a Tissue Engineering and Microfluidics Approach – applied for $56,000
Glaucoma Research Society of Canada. Funding to support Tenon’s capsule tissue mimetic model
validation. – awarded $20,000.
Private Fundraising Initiative. Funding to support ICES database research costs. Assessing
neuroprotective effects of Trazodone and other promising agents in an Ontario-based retrospective
cohort - raised $10,000 in private donations.
2016

The McGrath Research Scholarship. Funding to provide graduate students with an opportunity to
undertake vision science research projects with established researchers in an environment that
provides strong mentorship. - awarded $8,000.
Lawson Internal Research Fund. Funding to investigate patient and surgeon risk factors associated
with trabeculectomy failure – awarded $15,000.
Allergan Educational Grant. PhD stipend supplementation for research in novel methods of wound
healing modulation for glaucoma surgical patients - awarded $18,500.
Ivey Eye Institute. PhD stipend supplementation for research on microinvasive glaucoma surgery
optimization - $18,500/year for 3 years.

2015

Schulich Summer Research Training Program. Supported for one summer of epidemiological
research and a subsequent summer of tissue engineering and fibrosis related research - awarded
$9,000.

Patents / Provisional Patents
2018

Armstrong, J.J. and Hutnik, C.M.L. 2018. Compositions and methods for treating ocular
inflammation and ocular scarring. U.S. Provisional Patent Application No. 62/677,284, filed May
2018. Provisional status until May 2019.

Peer-Reviewed Publications
2019

Armstrong, J.J., Denstedt, J., Trelford, C., Li, E.A. and Hutnink, C.M.L. Differential effects of
dexamethasone and indomethacin on Tenon’s capsule fibroblasts: implications for glaucoma
filtration surgery. Experimental Eye Research, Volume 182, May 2019; 65-73.
DOI: https://doi.org/10.1016/j.exer.2019.03.015

Contribution: Developed research question with CH, designed experimental methods,
executed experiments with JC, CT and EL. Drafted manuscript, with edits from JD, CT,
EL and CH.
Kiatos, E., Armstrong, J.J., Tsioros, S., Hutnik, C.L.M., Malvankar-Mehta, M. and Hodge, W.G. Of
phaco and pain management: our review and meta-analysis of intravenous sedation in modern
cataract surgery. Ophthalmology Management Jan 2019, 46-54.
Contribution: Assisted with data collection and analysis, and drafting of manuscript
2018

Armstrong, J.J., Welk, B., Reid, J.N.S., Kansal, V. and Hutnik, C.M.L. Secondary surgical intervention
after primary glaucoma filtration surgery: an Ontario population-based study. Canadian Journal of
Ophthalmology, June 2018.
DOI: https://doi.org/10.1016/j.jcjo.2018.04.004
Contribution: Originator of research question, recruited authors, drafted database coding
strategy, first authored ICES DCP, created experimental groups, participated in data analysis,
and first authored manuscript.
Armstrong, J.J. and Hutnik, C.M.L. Comment re: Selective laser trabeculoplasty as replacement
therapy in medically controlled glaucoma patients. International Glaucoma Review 2018;18:4 52-3.
http://www.e-igr.com/ES/index.php?issue=184&ComID=1799
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Contribution: completed first and contributed to final drafts after consultation with Dr. Hutnik
and discussion of original article.
Kansal, V., Armstrong, J.J., Pintwala, R. and Hutnik, C.M.L. Optical Coherence Tomography for
Glaucoma Diagnosis: An Evidence Based Meta-Analysis. PLoSOne. Jan 2018.
DOI: https://doi.org/10.1371/journal.pone.0190621
Contribution: assisted in development of research question, recruited authors, developed
database search strategy and screening questions, participated in screening, collected and
analyzed data, edited manuscript.
2017

Michaelov, E., Armstrong. J.J., Nguyen, M., Instrum, B., Lam, T., Denstedt, J. and Hutnik, C.M.L.
Assessing the Methodological Quality of Glaucoma Clinical Practice Guidelines and their
Recommendations on Microinvasive Glaucoma Surgery: a Systematic Review and AGREE II
Assessment. Journal of Glaucoma.
DOI: 10.1097/IJG.0000000000000820
Contribution: Originator of research question, recruited authors, developed database search
strategy and screening questions, assisted in screening and data analysis, edited manuscript.
*Awarded: Canadian Glaucoma Society best paper of 2017
Kiatos, E., Armstrong, J. J., Hutnik, C.M.L., Tsioros, S., Malvankar-Mehta, M. S. and Hodge, W. G.
The value of corneoscleral rim cultures in keratoplasty: a systematic review and cost-effectiveness
analysis. ClinicoEconomics and Outcomes Research 2017:9 459-474.
Contribution: Participated in screening, data extraction and manuscript preparation.
Armstrong, J. J., Wasiuta, T., Kiatos, E., Malvankar, M. and Hutnik, C.M.L. The effects of
phacoemulsification on intra-ocular pressure and topical medication use in patients with glaucoma:
a systematic review and meta-analysis of three-year data, Journal of Glaucoma 2017;26:511-522.
Contribution: Originator of research question, recruited authors, developed database search
strategy and screening questions, carried out screening, collected and analyzed data, drafted
manuscript

2016

Rodrigues, I. B., Armstrong, J. J., MacDermid, J. C. Facilitators and barriers to exercise adherence in
patients with osteoporosis: a systematic review, Osteoporosis International 27(10):1-11 (2016).
Contribution: Optimized database search strategy, refined inclusion criteria and screening
questions, reference screening, GRADE quality assessment, edited manuscript
Armstrong, J. J., Goldfarb, A. M., Instrum, R. S., MacDermid, J. C. Improvement evident, but still
necessary in clinical practice guideline quality: a systematic review, Journal of Clinical Epidemiology
81:13-2 (2016),
DOI: 10.1016/j.jclinepi.2016.08.005.
Contribution: Originator of research question, recruited authors, developed database search
strategy and screening questions, carried out screening, collected and analyzed data, drafted
manuscript
Armstrong, J. J., Rodrigues, I. B., Wasiuta, T. & MacDermid, J. C. Quality assessment of
osteoporosis clinical practice guidelines for physical activity and safe movement: an AGREE II
appraisal. Arch. Osteoporos. 11, 6 (2016).
Contribution: Originator of research question, developed methods, recruited authors,
collected and analyzed data, drafted manuscript

Publications Submitted/Under Review/In Press
2018

Trelford, C., Denstedt, J., Armstrong, J.J. and Hutnik, C.M.L. Using a 3D bioartificial tissue of human
Tenon’s capsule fibroblasts to assess the fibrogenic and inflammatory properties of the Tenon’s
Capsule. Submitted to: Clinical and Experimental Ophthalmology, Nov 2018.
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2018

Kansal, V., Armstrong, J.J., and Hutnik, C.M.L. Canadian Trends in Glaucoma Filtration Procedures
from 2003 to 2016: Potential Impact of Minimally Invasive Glaucoma Surgery. Submitted to
Canadian Journal of Ophthalmology, Oct 2018.
Budure, A., Armstrong, J.J., Belrose, J., Ly, C. and Hutnik, C.M.L. Incidence of Perioperative
Hypertension in Phacoemulsification Surgery. Submitted to: Journal of Cataract & Refractive
Surgery. Sept 2018.
Michaelov, E, Armstrong, J.J., Kansal, V., Ly, C., Denstedt, J. and Hutnik. C.M.L. Evaluation of Microinvasive Glaucoma Surgery Devices: A Systematic Review and Meta-analysis. Submitted to:
Canadian Journal of Ophthalmology / Journal Canadien d’Ophtalmologie, December 2017.
Rejected: March 2018.

Rejected and Abandoned Submissions
2017

Armstrong, J. J., Pintwala, R., Michaelov, E. and Hutnik, C.M.L. Risk factors for bleb-forming
glaucoma surgery failure: a systematic review and meta-analysis. International Journal of
Ophthalmology (submitted Sept 1, 2017)
Contribution: Originator of research question, recruited authors, developed database search
strategy and screening questions, carried out screening, collected and analyzed data, drafted
manuscript.
Armstrong, J. J., Diaz, A. P., O’Gorman, D. B. Palmar fascia mimetics as novel models of Dupuytren’s
disease cord development, Advances in Wound Care (submitted, April 22, 2017)
Contribution: Collaboratively developed research question and methods with DO, carried out
experimental work with AD, drafted the manuscript and finalized it collaboratively with DO.

Abstracts: Podium Presentations
2019

Armstrong, J.J., Li, E., Vinokurtseva, A. and Hutnik, C.M.L. Repurposing COX-2: an immuno-resolving
and anti-cicatrizing therapy. Presented at the Canadian Ophthalmological Society Annual Meeting &
Exhibition 2019, June 13-16; Quebec City, Qc
Armstrong, J.J., Li, E., Vinokurtseva, A. Liu, H. and Hutnik, C.M.L. Acetylsalicylic acid reduces TGFbinduced myofibroblast transdifferentiation and activity. Presented at London Health Research Day
2019; April 30; London, On
Armstrong, J.J., Li, E. and Hutnik, C.M.L. Acetylsalicylic acid reduces collagen contraction,
remodeling and myofibroblast proliferation in a 3D Tenon's capsule tissue mimetic. Presented at
the American Glaucoma Society Annual Meeting 2019, March 14-17; San Francisco, CA, USA
Armstrong, J.J., Denstedt, J., Li, E., Dube, J., Trelford, C., Liu, H. and Hutnik, C.M.L. Modulating
wound healing after glaucoma surgery. Presented at Lawson Health Research InstituteTalks on
Fridays, February 1; London, On
Armstrong, J.J., Boyd, E. and Hutnik, C.M.L. Proposal for a Canadian Trial evaluating NSAIDs vs.
Steroid post-glaucoma Surgery. Presented at the Canadian Glaucoma Society Annual Meeting 2019,
January 8-19; Paradise Valley, AZ, USA

2018

Armstrong, J.J., Denstedt, J., Li, E., Tingey, D. and Hutnik, C.M.L. Development of a novel
acetylsalicylic acid-based adjuvant for glaucoma surgery. Presented at the Ivey Eye Institute
Research Day 2018; November 2; London, On
*Awarded Best Oral Presentation by a Graduate Student ($1000)
Denstedt, J., Armstrong, J. J. and Hutnik, C.M.L. Modulating wound healing in trabeculectomy with
SB-431542. Presented at the Ivey Eye Institute Research Day 2018; November 2; London, On
*Awarded Best Oral Presentation by a Medical Student ($1000)
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Armstrong, J.J., Trelford, C., Denstedt, J. and Hutnink, C.M.L. Modulation of wound healing after
glaucoma filtration surgery: a 3-minute thesis. Presented at the Schulich Summer Research Training
Program/Summer Research Opportunities Program Symposium; August 14; London, On
Armstrong, J.J. and Hutnik, CML. Acetylsalicylic acid reduces collagen contraction, remodeling and
myofibroblast proliferation in subconjunctival tissue mimetic. Presented at the Canadian
Ophthalmological Society Annual Meeting; 2018 June 3; Toronto, On
*COS Award for Excellence in Ophthalmic Research, 2nd place ($2000)
Kansal, V., Armstrong, J.J., Pintwala, R. and Hutnik, CML. Optical Coherence Tomography for
Glaucoma Diagnosis: an Evidence Based Meta-Analysis. Presented at the Canadian
Ophthalmological Society Annual Meeting; 2018 June 3; Toronto, On
Denstedt, J., Armstrong, J.J., Trelford, C. and Hutnik, CML. Assessing the effects of indomethacin
and dexamethasone on wound healing using a 3D bioartificial tissue of human Tenon’s capsule
fibroblasts. Presented at the Canadian Ophthalmological Society Annual Meeting; 2018 June 3;
Toronto, On
Kiatos, E., Armstrong, J.J., Hodge, W., Malvankar-Mehta, M. and Hutnik, CML. A systematic review
and meta-analysis of intravenous sedation in modern cataract surgery. Presented at the Canadian
Ophthalmological Society Annual Meeting; 2018 June 3; Toronto, On
Armstrong, J.J. and Hutnik, C.L.M. Why MD/PhD and why ophthalmology: research and your future
career. Co-presented to the Schulich School of Medicine MD/PhD students and prospective
students; 2018 Jan 27; London, On
2017

Michaelov, E., Armstrong. J.J., Nguyen, M., Instrum, B., Lam, T., Denstedt, J. and Hutnik, C.M.L.
Assessing the Methodological Quality of Glaucoma Clinical Practice Guidelines and their
Recommendations on Microinvasive Glaucoma Surgery: a Systematic Review and AGREE II
Assessment. Presented at Ivey Eye Institute Departmental Research Day; 2017 Nov 3; London, On
Denstedt, J., Armstrong, J.J., Trelford, C. and Hutnik, C. The Effects of Indomethacin and
Dexamethasone on Tenon’s Capsule Tissue Mimetics: avoidance of fibrotic outcomes. Presented at
Ivey Eye Institute Departmental Research Day; 2017 Nov 3; London, On
*Awarded 1st place
Armstrong, J.J., Welk, B., Reid, J.N.S., Kansal, V. and Hutnik, C.M.L. Risk Factors for Secondary
Surgical Intervention after Glaucoma Filtration Surgery: a population-based study. Presented at Ivey
Eye Institute Departmental Research Day; 2017 Nov 3; London, On
Kansal, V., Armstrong, J. J., Pintwala, R. and Hutnik, C.M.L. Optical Coherence tomography for
Glaucoma Diagnosis and Monitoring. Presented to the London Optometry Association; 2017 Sept.
20; London, On
Armstrong, J. J., Wasiuta, T., Kiatos, E., Malvankar, M. and Hutnik, C.M.L. The Effects of
Phacoemulsification on Intra-Ocular Pressure and Topical Medication Use in Patients with
Glaucoma: A Systematic Review and Meta-Analysis of Three Year Data. Presented at the Canadian
Ophthalmological Society Annual Meeting; 2017 June 18; Montreal, Qb
*Designated ‘Hot Topic’
Kiatos, E., Armstrong, J. J., Hutnik, C.M.L., Tsioros, S., Malvankar-Mehta, M. S. and Hodge, W. G.
The value of corneoscleral rim cultures in keratoplasty: a systematic review and cost-effectiveness
analysis. Presented at the Canadian Ophthalmological Society Annual Meeting; 2017 June 18;
Montreal, Qb
Trelford, C. B., Armstrong, J. J., Hutnik, C.M.L. Using transcriptome analysis to compare Tenon’s
capsule of patient derived samples, 2D monolayer cell culture and a novel bioartificial tissue
construct. Presented at Lawson Health Research Institute “Talks on Friday’s”; 2017 Jan 13; London,
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On

2016

Trelford, C. B., Armstrong, J. J., Hutnik, C.M.L. Validation of a novel bioartificial tissue model of
Tenon’s capsule through whole transcriptome comparison with ex vivo Tenon’s capsule and
Tenon’s capsule fibroblasts in 2D monolayer cell culture. Presented at the Department of Pathology
Honors Thesis Symposium; 2016 Dec 7; London, On
Armstrong, J. J., Wasiuta, T., Kiatos, E., Malvankar, M. and Hutnik, C.M.L. The Effects of
Phacoemulsification on Intra-Ocular Pressure and Topical Medication Use in Patients with
Glaucoma: A Systematic Review and Meta- Analysis of Three-Year Data. Presented at Ivey Eye
Institute Departmental Research Day; 2016 Nov 4; London, On
Armstrong, J.J., Diaz, A. P., O’Gorman, D. B. Creation of an in vitro model of fibrosis using
Dupuytren’s disease patient explant tissues. Presented at: Schulich School of Medicine Summer
Research Training Program (SRTP) Seminar Series; 2016 Aug 9; London, On
Armstrong J. J., Diaz, A. P., O’Gorman, D., B. Dupuytren’s disease: toward an in vitro model of
fibroproliferative disease. Presented at: 2016 Canadian Bone and Joint Conference; 2016 April 9;
London, On
*Awarded top oral presentation (value $250)

2015

Armstrong, J. J., Rodrigues, I. B., Wasiuta, T. & MacDermid, J. C. Quality assessment of osteoporosis
clinical practice guidelines for physical activity and safe movement: an AGREE II appraisal.
Presented at: Schulich School of Medicine Summer Research Training Program (SRTP) Seminar
Series; 2015 July 7; London, On

Abstracts: Poster Presentations
2019

Denstedt, J., Armstrong, J.J. and Hutnik, C.M.L. Improving glaucoma surgery with the small
molecule ALK-5 inhibitor SB-431542. Presented at the Canadian Ophthalmological Society Annual
Meeting & Exhibition 2019, June 13-16; Quebec City, Qc
*Awarded Second Place for Best Overall Poster
Armstrong, J.J. and Hutnik, C.M.L. Repurposing COX-2: an immunoresolving therapy. Accepted to
the Keystone Symposia for Lipidomics and Functional Metabolic Pathways in Disease 2019, March
31 – April 4; Steamboat Springs, Colorado, USA
*unpublished
Armstrong, J.J., Li, E.A., Vinokurtseva, A. and Hutnik, C.M.L. Repurposing COX-2: an immunoresolving and anti-cicatrizing therapy. Presented at the Schulich School of Medicine and Dentistry,
Department of Pathology and Laboratory Medicine Research Day 2019, March 29; London, On
Li, E.A., Armstrong, J.J., Vinodurtseva, A. and Hutnik, C.M.L. Acetylsalicylic acid inhibits
inflammation induced myofibroblast transdifferentiation in human tenons capsule fibroblasts.
Presented at the Schulich School of Medicine and Dentistry, Department of Pathology and
Laboratory Medicine Research Day 2019, March 29; London, On
Denstedt, J., Michaelov, E., Armstrong, J.J. and Hutnik, C.M.L. A Systematic Review and MetaAnalysis of Minimally Invasive Glaucoma Surgery Devices. Presented at the American Glaucoma
Society Annual Meeting 2019, March 14-17; San Francisco, CA, USA

2018

Budure, A., Armstrong, J.J., Belrose, J. and Hutnik, C.M.L. The incidence of perioperative
hypertension during routine cataract surgery. Presented at the Ivey Eye Institute Research Day
2018; November 2; London, On
Armstrong, J.J., Welk, B., Reid, J., Kansal, V. and Hutnik, C.M.L. Risk Factors for Secondary Surgical
Intervention after Glaucoma Filtration Surgery: A Population-Based Study. Presented at the
Canadian Ophthalmological Society Annual Meeting & Exhibition; June 1-3; Toronto, On
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Armstrong, J.J., Pena-Diaz, A. and O’Gorman, D.B. Palmar fascia mimetics as novel models of
Dupuytren’s Disease cord development. Presented at the Canadian Connective Tissue Conference
of Canada; May 25-27; Montreal, Qc
Denstedt, J., Armstrong, J.J. and Hutnik, C. The functional response of Tenon’s capsule fibroblast
cells to treatment with fibrotic growth factors in a 3D collagen lattice. Presented at London Health
Research Day; May 10, 2018; London, Ontario
Armstrong, J. J., Denstedt, J and Hutnik, C. Acetylsalicylic acid reduces collagen contraction,
remodelling and myofibroblast proliferation in subconjunctival tissue mimetic. Presented at ARVO;
2018 May 1; Honolulu, Hawaii
Denstedt, J., Armstrong, J.J., Trelford, C. and Hutnik, C. The Effects of Indomethacin and
Dexamethasone on Tenon’s Capsule Tissue Mimetics: avoidance of fibrotic outcomes. Presented at
ARVO; 2018 April 29; Honolulu, Hawaii
Armstrong, J. J., Denstedt, J. and Hutnik, C. M. L. Acetylsalicylic acid reduces collagen contraction,
remodelling and myofibroblast proliferation in subconjunctival tissue mimetic. Presented at the
Department of Pathology and Laboratory Medicine Research Day, Schulich School of Medicine;
April 13; London, On
Hutnik, C. M. L., Michaelov, Evan, Armstrong, J.J., Kansal, Vinay and Denstedt, James. Evaluation of
Micro-invasive Glaucoma Surgery Devices: A Systematic Review and Meta-analysis. Presented at
the American Glaucoma Society Annual Meeting; March 1-3; New York, NY
Armstrong, J.J., Welk, B., Reid, J.N.S., Kansal, V. and Hutnik, C.M.L. Risk Factors for Secondary
Surgical Intervention after Glaucoma Filtration Surgery: a population-based study. Presented at the
American Glaucoma Society Annual Meeting; March 1-3; New York, NY
Denstedt, J., Armstrong, J.J., Trelford, C. and Hutnik, C. The Effects of Indomethacin and
Dexamethasone on Tenon’s Capsule Tissue Mimetics: avoidance of fibrotic outcomes. Presented at
the American Glaucoma Society Annual Meeting; March 1-3; New York, NY
2017

Michaelov, E., Armstrong. J.J., Nguyen, M., Instrum, B., Lam, T., Denstedt, J. and Hutnik, C.M.L.
Assessing the Methodological Quality of Glaucoma Clinical Practice Guidelines and their
Recommendations on Microinvasive Glaucoma Surgery: a Systematic Review and AGREE II
Assessment. Presented at the American Academy of Ophthalmology Annual Meeting; November
11-14; New Orleans
*Awarded best poster
Kansal, V., Armstrong, J.J., Pintwala, R. and Hutnik, C.M.L. Optical Coherence Tomography for
Glaucoma Diagnosis: An Evidence Based Meta-Analysis. Presented at the American Academy of
Ophthalmology Annual Meeting; November 11-14; New Orleans
Armstrong, J. J., Dang, B., Liu, H., Tellios, V., Tellios, N., Cejic, N. Cronk, A. and Hutnik, C. Biomodulation of Primary Human Tenon's Capsule Fibroblasts Using a Novel Application of Coated
Magnesium. Presented at the Canadian Ophthalmological Society Annual Meeting & Exhibition;
June 15-18; Montreal, Quebec
Armstrong, J. J. and Hutnik, C.M.L. Effect of Glaucomatous Aqueous Humor Cytokines on Tenon’s
Capsule Fibroblast Populated Collagen Lattices. Presented at The Department of Pathology and
Laboratory Medicine Research Day; March 30; London, Ontario
Armstrong, J. J., Wasiuta, T., Kiatos, E., Malvankar, M. and Hutnik, C.M.L. The Effects of
Phacoemulsification on Intra-Ocular Pressure and Topical Medication Use in Patients with
Glaucoma: A Systematic Review and Meta-Analysis of Three Year Data. Presented at the London
Health Research Day; March 28, 2017; London, Ontario
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Trelford, C., Armstrong, J. J., Hutnik, C.M.L. The Validation of a 3D Bioartificial Tissue of the Tenon's
Capsule. Presented at the London Health Research Day; March 28, 2017; London, Ontario
Michaelov, E., Armstrong, J. J., Nguyen, M. and Hutnik, C.M.L. The quality of ophthalmology clinical
practice guidelines and a review of recommendations for micro-invasive glaucoma surgical
procedures: an AGREE II appraisal. Presented at the London Health Research Day; March 28, 2017;
London, Ontario
Kiatos, E., Armstrong, J. J., Hutnik, C.M.L., Tsioros, S. M., Malvankar-Mehta, M. S. and Hodge, W. G.
The Value of Corneoscleral Rim Cultures in Keratoplasty: A Systematic Review and CostEffectiveness Analysis. Presented at the London Health Research Day; March 28, 2017; London,
Ontario
Trelford, C., Armstrong, J. J., Hutnik, C.M.L. The Validation of a 3D Bioartificial Tissue of the Tenon's
Capsule. Presented at The Department of Pathology and Laboratory Medicine Research Day; March
30; London, Ontario
Armstrong, J. J., Wasiuta, T., Kiatos, E., Malvankar, M. and Hutnik, C.M.L. The Effects of
Phacoemulsification on Intra-Ocular Pressure and Topical Medication Use in Patients with
Glaucoma: A Systematic Review and Meta-Analysis of Three-Year Data. Presented at the Canadian
Society for Epidemiology and Biostatistics: 2017 Biennial Conference; May 30 – June 2; Banff,
Alberta
2016

Armstrong J. J., Diaz, A. P., O’Gorman, D., B. Dupuytren’s disease: toward an in vitro model of
fibroproliferative disease. Poster presented at: Canadian National Medical Students Research
Symposium; 2016 June 8; Winnipeg, MB
Armstrong J. J., Diaz, A. P., O’Gorman, D., B. Dupuytren’s disease: toward an in vitro model of
fibroproliferative disease. Poster presented at: Canadian Connective Tissue Conference; 2016 June
3; Hamilton, On

2013

Armstrong, J. J., Dragunas, A. J., Dickey, J. P. Early or late kick: a biomechanical comparison of two
breaststroke underwater swimming techniques. Poster presented at: University of Western
Ontario, in partial fulfillment of requirements for biology 4970G; 2013 April 10; London, On.
*Awarded a mark of 95%

Training/Safety Policy Documents
2018

Armstrong, J.J. Safe Work Practices / Standard Operating Procedure for Persons Working with
Varicella Zoster or Herpes Simplex Virus in vitro. Prepared for: Lawson Health Research Institute,
London, On, Canada.

Student Supervision (co-supervision under Dr. Cindy Hutnik)
2019

A. Budure (MD3), J. Denstedt (MD3), M. Fung (MD2), E. Li (HBSc), G. Ge (MD4), E. Boyd (MD2), D.
Rabinovitch (HBSc), A. Vinokurtseva (MD1), M. Wai (HBSc), C. Christian (High School Co-op)

2018

A. Budure (MD3), J. Denstedt (MD3), R. McInnis (MD2), M. Fung (MD2), E. Li (HBSc), G. Ge (MD4), E.
Boyd (MD2), D. Rabinovitch (HBSc), A. Vinokurtseva (MD1), M. Wai (HBSc)

2017

A. Budure (MD2), J. Dube (HBSc), J. Denstedt (MD2), E. Michaelov (MD4), M. Nguyen (HBSc), S.
Tsioros (HBSc), T. Lam (MD2), R. McInnis (MD1), M. Fung (MD1), E. Boyd (MD1)

2016

V. Kansal (MD4), J. Denstedt (MD1), E. Michaelov (MD3), C. Trelford (HBSc),

Ethics Applications
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2019

Boyd, E., Armstrong J. J., Denstedt, J. and Hutnik, C. A national multi-center randomized controlled
trial evaluating efficacy of dexamethasone versus [NSAID] for wound modulation after
trabeculectomy.
Armstrong J. J., Belrose, J., Hutnik, C. Incidence of perioperative hypertension and management
strategies employed for patients undergoing cataract surgery.

2017

Armstrong J. J., Denstedt, J., Hutnik, C. Growth factors in the aqueous humor and subsequent
trabeculectomy failure
Armstrong J. J., Belrose, J., Hutnik, C. Incidence of perioperative hypertension and management
strategies employed for patients undergoing cataract surgery.

Research Awards/Accolades
2018

Ivey Eye Institute Best Presentation by a Graduate Student. Awarded to the best presentation at
research day as judged by the panel. Value: $1000
Canadian Glaucoma Society Best Paper Award – Medical Student Category 2018. Awarded to the
best paper published by a Canadian medical student within the topic of Glaucoma. Value: $500
*Second Author
Canadian Ophthalmological Society Paper Presentation Award 2018. Awarded for excellence in
ophthalmic research. Value: $2,000.

2016

Dr. Glen S. Wither Award for Research. Awarded for outstanding participation and research
excellence in the Schulich Summer Research Training program. Value: $600.
Research featured by The US Agency for Healthcare Research and Quality’s Effective Healthcare
Program’s Scientific Resource Center (SRC) newsletter.
Research featured by The British Dupuytren’s Society.
www.dupuytrens-society.org.uk/ongoing-research/
Top Oral Presentation. Novel Therapies: Biological Repair and Tissue Regeneration.
Canadian Bone and Joint Conference 2016. Value: $200.

Supervisors/Mentors
Dr. Cindy Hutnik, MD, PhD, Ivey Eye Institute, Departments of Ophthalmology and Pathology,
Schulich School of Medicine
Dr. David O’Gorman, PhD, Roth|MacFarlane Hand and Upper Limb Center, Departments of Surgery
and Biochemistry, Schulich School of Medicine
Dr. Blayne Welk, MD, MSc, Departments of Surgery and Epidemiology & Biostatistics, Schulich
School of Medicine
Dr. Jim Lewis, MD, PhD, Director of Clinical Research Training, Schulich School of Medicine

Other Research Experience
Judge

Pathology & Toxicology 4980E – Judge for honors thesis poster presentations, Schulich School of
Medicine. March 27, 2017.
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Reviewer

Osteoporosis International (3), Toxicology in Vitro (2), International Journal of Molecular Sciences
(1), Canadian Journal of Ophthalmology (1), BMJ Open (1),

Lab Manager

Import/export/customs for human, animal and cell culture derived specimens: infectious and noninfectious.

Business / Industry Involvement
2018/19

Appili Therapeutics. Partnership encompassing mentorship and guidance to attain venture capital
funding and build drug development pipeline for downstream applications of patented
intervention.
Aequus Pharma. Consultation and development relating to novel ophthalmic applications for
repurposed drugs. Work done on anti-fibrotic/anti-inflammatory surgical adjuvants. Preparation of
pre-clinical development plan for a chitosan based thermosensitive injectable gel, loaded with an
anti-inflammatory/anti-fibrotic agent, as an adjuvant for glaucoma filtration surgery.

2017

Alcon Canada. Expert opinion and intellectual contribution to wound healing as it relates to the
Cypass glaucoma stent.

2016

Allergan Canada. Expert opinion and intellectual contribution to wound healing instructional
presentation relating to the XEN glaucoma stent.

Medical Electives
2016

Ophthalmology (300hrs research)
Dr. Cindy Hutnik, St. Joseph’s Hospital, London, Ontario
Meds 5010 Non-Credit Pre-Clerkship Summer Research Elective

2015

Plastic Surgery (100hrs Surgery/Clinic)
Dr. Brian Evans, University Hospital, London, Ontario
Meds 5010 Non-Credit Pre-Clerkship Summer Clinical Elective

Medical Observerships
2016

2015

Ophthalmology (8hrs)
Dr. Devesh Varma, Prism Eye Institute, Credit Valley Hospital, Mississauga, Ontario
Ophthalmology (32hrs)
Dr. David Tingey, St. Joseph’s Hospital, London, Ontario
Plastic Surgery (12hrs)
Dr. Brian Evans, University Hospital, London, Ontario
Oral and Maxillofacial Surgery (12hrs)
Dr. Joe Armstrong, University Hospital, London, Ontario
Plastic Surgery (8hrs)
Dr. Bing Gan, St. Joseph’s Health Care, London, Ontario
Plastic Surgery (32hrs)
Dr. Damir Matic, Victoria Hospital, London, Ontario
Neurosurgery (9hrs)
Dr. Stephen Lownie, University Hospital, London, Ontario
Oral and Maxillofacial Surgery (8hrs)
Dr. Joe Armstrong, University Hospital, London, Ontario
Emergency Medicine (12hrs)
Dr. Denis Atoe, Blenheim, Ontario
Family Medicine (8hrs)
Dr. Martha Clendenning, Blenheim, Ontario
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2014

Orthopedic Surgery (35hrs)
Dr. Robert Litchfield, University Hospital, London, Ontario
Emergency Medicine (6hrs)
Dr. Behzad Hassani, University Hospital, London, Ontario
Radiology (6hrs)
Dr. Mark Landis, Victoria Hospital, London, Ontario

Employment Experience
2016-Present

Graduate Research Assistant. Deps. of Ophthalmology and Pathology, Schulich School of Medicine
Private Tutor. Grade 11/12 physics.

2015-2016

Security. Belfort Nightclub.

2013-2014

Personal Trainer. Goodlife Fitness. #1 performing level 2 trainer – city wide, London, On

2013-2016

Security. Gatsby Soundhouse and Bar. Broke up 5 physical altercations without the use of force.

2011-2014

Exam Proctor. London Public Library.

Leadership and Community Involvement
2017-2018

Polymerase Spiral Reaction Technology Group, founding member. Coordinate weekly meetings for
all Lawson affiliated labs currently working on diagnostic applications for novel PSR technology.
SMART committee, founding member. MD/PhD students mentoring MD students who wish to
undertake research endeavors
MD Curriculum Development - Research Integration Experience: Pilot Project. Helped develop a
pilot project to integrate MD students into health research labs, fostering inter-professional
cooperation and the early development of critical research skills in medical students. Medical
school-wide implementation schedule for 2019.

2015-2016

Oral Symposium Chair, Canadian National Medical Student Research Symposium.
Schulich Summer Research Training Program Committee, Student Representative.
Mentor, Altitude: Healthcare Mentorship.
Surgery Interest Group Executive, Schulich School of Medicine.
Inter-professional Summer Surgery School, Chair of Organizing Committee, Schulich School of
Medicine.

2003-2014

Emergency Department Volunteer, London Health Sciences Center, University Hospital.
Athlete, London Aquatic Club.
Reading Tutor, London Public Library.
Team Captain (twice elected), Western Mustangs Swimming Team.

2008-2013

Athlete, Western Mustangs Swimming.

2011-2012

Athletes Representative, Swim Ontario Fundraising Committee.
Team Canada Member (Swimming), Pan American Games, Guadalajara, Mexico.
Team Canada Member (Swimming), Nations Cup, Montreal, Quebec.

2002-2015

London Aquatic Club, Athlete

Other Awards
Academic
2011-2013

CIS Academic All Canadian
Qualify for CIS championships and achieve an average greater than 80%.
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2011-2013
2008

Deans Honor List
Obtain an average greater than 80%.
Western University Scholarship of Excellence
Given to students entering university with an average of 90% or more.

Athletic
2013
2013
2010-2013
2009-2013
2012
2011
2009

Western Mustangs Purple Blanket Award
Selected by Committee: Western athlete with greatest athletic and academic achievement.
OUA Graduating Athlete Award of Distinction
Selected by Committee.
OUA All-Star (5 time)
Given to athletes who receive silver or better in one or more events.
OUA Medalist (18 times) and CIS Medalist (3 times)
Western Mustangs Swimming Team.
Canada Games Aquatic Center Hall of Fame Inductee
Chosen by Committee.
Western Mustangs Bronze W Award
Given to athletes who qualify for their sports’ OUA team three years in a row.
Western Mustangs Rookie of the Year
Top ranked swimmer in first year of varsity eligibility.

Volunteer
2014
2011

Ontario Volunteer Service Award
Nomination then Chosen by Committee.
Volunteer of Distinction, London Public Library.
Chosen by Committee.

Extracurricular Activities
Memberships

CMA, since Aug 2014
OMA, since Aug 2014
Canadian Connective Tissue Society, since June 2016
Clinician Investigator Trainee Association of Canada, since June 2016
Canadian Society for Clinical Investigation, since June 2016

Sports

Ballroom Dancing – Fred Astaire Studios, Intermural Softball – Schulich Medicine Team, Intermural
Inner Tube Water Polo – Schulich Medicine Team, Schulich Inter-Class Hockey League, Schulich
Meds Golf League, Schulich Weightlifting Club

Clubs

Medical Skills Club, Microsurgery Interest Club, Neurology and Neurosurgery Interest Group,
Oncology Interest Group, Ophthalmology Interest Group, Point and Shoot Billiards Club, Point of
Care Ultrasound Interest Group, Radiology Interest Group, Sports and Rehabilitative Medicine
Interest Group, Surgery Interest Group, Surgically Oriented Anatomy Prosectors (SOAP), Western
Emergency Medicine Interest Group

Academic Affiliations
2014-2021
2016-2019
2016-2019
2016-2019
2016-2019

Student, Department of Undergraduate Medical Education, Schulich School of Medicine
Student, Department of Pathology and Laboratory Medicine, Schulich School of Medicine
Student, Department of Ophthalmology, Schulich School of Medicine
Student, Ivey Eye Institute, St. Joseph’s Healthcare, London, On
Student, Institute for Clinical and Evaluative Sciences (ICES Western), LHSC, London, On
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